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Abstract 
Background: Up to 60% of women and children living in low- and middle-income 
countries (LMICs) are anaemic. Food fortification and iron supplementation are the 
most common measures employed to combat anaemia. However, these are not 
effective treatments for anaemias caused by non-nutritional factors. Genome-wide 
association studies (GWAS) mainly in Europeans and Asians have identified single 
nucleotide polymorphisms (SNPs) within the hepcidin and iron regulatory genes that 
are associated with the risk of anaemia. Several of these SNPs are in 
the TMPRSS6 gene, which encodes matriptase-2, a protein that regulates the 
expression of hepcidin. This thesis examined the impact of SNPs in the iron regulatory 
genes previously reported in non-African populations, on the risk of anaemia and on 
impaired oral iron absorption in Africans.  
Methods: First, the literature was searched for genetic variants identified in the 
hepcidin and iron regulatory genes, that are associated with low iron status. Second, 
we investigated the effects of common TMPRSS6 and transferrin (TF) SNPs on iron 
status in a cohort of healthy individuals from rural Gambia (n=1315). Third, a recall-
by-genotype (RbG) study was conducted to investigate the impact of carrying single 
or multiple alleles at the common TMPRSS6 SNPs on oral iron absorption in healthy 
individuals from rural Gambia.  
Results:  TMPRSS6 rs855791, rs4820268 and rs2235321, and TF rs3811647 are the 
most common SNPs that associated with low iron status. We did not find effects of 
any of the TMPRSS6 SNPs on the risk of anaemia. However, we found 
that TMPRSS6 rs2235321 was associated with serum hepcidin concentration, with a 
more substantial effect on individuals with low haemoglobin or ferritin. 
Also, TF rs3811647 had a significant influence on transferrin and its binding capacity, 
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with a single allele effect of 8-12%. In the RbG study, we did not find any effect of the 
three TMPRSS6 SNPs on oral iron absorption. However, we found that each of 
the TMPRSS6 SNPs affects hepcidin, with carriers of major alleles having higher 
hepcidin compared to minor allele carriers. Also, we found that heterozygotes at both 
rs2235321 and rs855791 did not alter their hepcidin concentration after an oral iron 
dose, whereas, individuals in all the other genotype groups did. 
Conclusions: This thesis confirms the previously observed association between 
the TF rs3811647 and transferrin in other Africans and Europeans replicates in West 
Africans. However, we could not demonstrate that the previous associations 
between TMPRSS6 gene variants and iron status, exist in West Africans. This lack of 
replication might be due to the high genetic diversity that exists in African populations. 
We identified an effect of TMPRSS6 rs2235321 on serum hepcidin concentration. In 
the RbG study, the three TMPRSS6 SNPs studied influenced serum hepcidin levels 
but not oral iron absorption in healthy individuals. This finding suggests that there 
might be an alternate pathway of iron regulation independent of hepcidin at the 
enterocytes. These findings highlight the need to conduct more research on genetic 
determinants of iron status in African populations. Investigating more genetic markers 
and in different populations may provide a clearer insight into the role of genetic risk 
factors on iron deficiency and anaemia in African populations. Identifying the role of 
genetic risk factors of iron status may pave the way for the formulation of population-
specific anaemia control measures. 
 
Key terms: Anaemia; Iron deficiency; SNPs; TMPRSS6; TF; Hepcidin, Hepcidin 
regulatory genes; African populations; iron absorption. 
 
Page 8 of 264 
 
Table of Contents 
Declaration ............................................................................................................................ 2 
Dedication ............................................................................................................................. 3 
Acknowledgement .............................................................................................................. 4 
Abstract ................................................................................................................................. 6 
Table of Figures ................................................................................................................. 10 
Abbreviations ..................................................................................................................... 11 
Chapter 1: ............................................................................................................................ 14 
Candidate’s contribution and thesis structure ................................................................. 14 
1.1. Candidate’s contribution ............................................................................. 15 
1.2. Thesis scope and composition ...................................................................... 16 
1.3. Supervisory team ................................................................................................. 19 
1.4. Funding ................................................................................................................. 19 
1.5. References .......................................................................................................... 19 
Chapter 2: ............................................................................................................................ 21 
General Introduction ........................................................................................................... 21 
2.1. Background and Rationale .................................................................................. 22 
2.2. Epidemiology and impact of anaemia .............................................................. 22 
2.3. Aetiology of anaemia ........................................................................................ 25 
2.3.1. Anaemia definition criteria ...................................................................... 27 
2.4. Anaemia control strategies ............................................................................. 28 
2.5. The need for better intervention methods ........................................................ 29 
2.6.1. Hepcidin regulatory pathways ............................................................... 32 
2.6.2. Transmembrane protease serine 6 (TMPRSS6) regulation of 
hepcidin ....................................................................................................................... 37 
2.7. Anaemia in the context of Gambia ................................................................ 38 
2.8. The need to investigate the genetic influences of anaemia ................... 41 
2.9. Importance of the MRCG Keneba Biobank ................................................. 43 
2.10. Aims and Objectives ..................................................................................... 44 
2.11. References ...................................................................................................... 45 
Chapter 3: ............................................................................................................................ 60 
Differences in allele frequencies of genetic variants associated with iron imbalance 
among global populations .................................................................................................. 60 
Chapter 4: .......................................................................................................................... 146 
Association between common TMPRSS6 and TF gene variants with hepcidin and 
iron status in healthy rural Gambians ............................................................................. 146 
Page 9 of 264 
 
4.1. Abstract .................................................................................................................. 150 
4.2. Introduction ........................................................................................................... 152 
4.3. Subjects and Methods ........................................................................................ 153 
Genotyping ................................................................................................................... 155 
Genotype combinations and allele risk scores ................................................... 155 
Statistical analysis ...................................................................................................... 156 
Ethics .............................................................................................................................. 157 
4.4. Results ................................................................................................................... 157 
4.5. Discussion ............................................................................................................. 160 
4.6. NOTES .................................................................................................................... 164 
4.7. References ............................................................................................................ 166 
4.9. Figure legends ...................................................................................................... 170 
4.10. Figures ................................................................................................................. 172 
4.11. Supplemental Data ............................................................................................ 176 
Chapter 5: .......................................................................................................................... 181 
A recall-by-genotype study on polymorphisms in the TMPRSS6 gene and oral iron 
absorption: a study protocol ............................................................................................. 181 
Chapter 6: .......................................................................................................................... 191 
Common variants in the transmembrane protease serine 6 (TMPRSS6) gene alters 
hepcidin but not plasma iron in response to oral iron in healthy Gambian adults: a 
recall-by-genotype study .................................................................................................. 191 
Author Affiliations ........................................................................................................... 194 
Funding .............................................................................................................................. 194 
6.1. Abstract .................................................................................................................. 195 
6.2. Introduction ........................................................................................................... 197 
6.3. Materials and Methods ....................................................................................... 198 
6.4. Results ................................................................................................................... 202 
6.5. Discussion ............................................................................................................. 204 
6.6. NOTES .................................................................................................................... 208 
6.7. References ............................................................................................................ 209 
6.8. Tables ..................................................................................................................... 214 
6.9. Figure Legends .................................................................................................... 217 
6.10. Figures ................................................................................................................. 219 
6.11. Supplemental information ............................................................................... 224 
6.12. A summary of the pilot study ......................................................................... 230 
Chapter 7: .......................................................................................................................... 236 
Page 10 of 264 
 
General discussion and conclusions .............................................................................. 236 
7.1. General discussion ............................................................................................. 237 
7.2. Main findings ........................................................................................................ 237 
7.3. Discussion of main findings ............................................................................. 238 
7.4. Limitations implications .................................................................................... 241 
7.5. Public health implications and recommendations ..................................... 242 
7.6. Potential future studies ...................................................................................... 243 
7.6.1 Specific immediate future research ............................................................... 244 
7.7. Conclusions .......................................................................................................... 245 
7.8. References ............................................................................................................ 247 
Chapter 8: .......................................................................................................................... 251 
Appendices ......................................................................................................................... 251 
 
Table of Figures  
Figure 1. Global estimates of anaemia prevalence. ................................................. 24 
Figure 2. Hepcidin regulation of systemic iron distribution. ...................................... 32 
Figure 3. The molecular pathways governing hepcidin regulation of hepcidin 
transcription. ...................................................................................................... 35 
Figure 4. A map of Africa showing the location of the Gambia 104. .......................... 39 























Anaemia of inflammation 
Analysis of variance 
Allele risk score 
Body mass index 




Bone morphogenetic protein receptor 
C-reactive protein 
Department for International Development 
DMT1 Divalent metal transporter 1 
DNA Deoxyribonucleic acid 
EDTA Ethelenediametelenetatraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
ERK 
eQTL 
Extracellular signal-regulated kinase 
Expression quantitative trait loci 
G6PD Glucose-6-phosphatase dehydrogenase 
GAM The Gambia 
GiA Genes-in-Action 
GWAS Genome-wide association study 
HAMP Hepatic antimicrobial peptide 
Hb Haemoglobin 
HBA Haemoglobin subunit alpha 





HCP1  Haem carrier protein 1 
HFE 
HH 





Human genetic epidemiology 
Human Hereditary & Health in Africa 
Page 12 of 264 
 
ID Iron deficiency 
IDA Iron deficiency anaemia 
IRIDA Iron-refractory iron deficiency anaemia 
IL6 Interleukin 6 
IL6R Interleukin 6 receptor 
JAK Janus associated kinase 
KWDSS 
LMIC 
Kiang West Demographic Surveillance System 
Low- and middle-income Countries 
LSHTM London School of Hygiene & Tropical Medicine 






Mitogen-associated activated protein kinase 
Mean corpuscular haemoglobin 
Mean corpuscular haemoglobin concentration 
Mean corpuscular volume 




Medical Research Council The Gambia Unit 
National Health and Nutrition Education Survey 
Polymerase chain reaction 
pSMAD phosphorylated SMAD 




Red cell distribution width 




Scientific coordination committee 
Standard error 




Solute carrier family 11 member 2 
Solute carrier family 40 member 1 
SMAD Sons of mothers against decapentaplegic 
SNP Single nucleotide polymorphism 
SSA Sub-Saharan Africa 
STAT Signal transducer and activator transcription 
Page 13 of 264 
 
TF Transferrin 
TFR1 Transferrin receptor 1 
TFR2 Transferrin receptor 2 
TIBC  Total iron binding capacity 
TMPRSS6 Transmembrane protease serine 6 
TSAT Transferrin saturation 
UIBC Unsaturated iron binding capacity 
WHO 
WABR 
World Health Organisation 
West Africa BioResource 


















Chapter 1:  
Candidate’s contribution 


























Page 15 of 264 
 
1.1. Candidate’s contribution 
Prior to starting my PhD, I have been working with the MRC International Nutrition 
Group, which later became the Nutrition Theme at the MRC Unit The Gambia, for eight 
years. I started as a laboratory technician and I rose to a Scientific Officer responsible 
for performing hepcidin assay optimisation and validation. Over this period, I have 
been involved in several research projects investigating the influences of iron and 
hepcidin on various diseases. As a result, I developed strong interest in iron research. 
This is why when this PhD opportunity was presented to me by Prof Andrew Prentice 
and Dr Branwen Hennig (my initial supervisor) I saw it as a perfect opportunity for 
developing my career in this cross-cutting field involving nutrition and genetics.  
When I started the PhD, I did an extensive literature review on the topic and I made 
significant changes to the initial study design. These changes include introducing 
additional candidate genetic variants, optimising the study design and the idea of 
investigating the cumulative effect of SNPs on iron status. 
With the departure of my initial supervisor and coming of the new supervisory team 
(Dr Susana Campino and Dr Carla Cerami) at the early stage of my PhD, I had to learn 
with them to ensure that they were familiar with my PhD topic and plans.  
I spearheaded the selection of the candidate gene variants for the main study, wrote 
the study design and protocol, and presented the amended protocol at the MRCG 
Scientific Coordinating Committee (SCC), submitted the ethics application to the 
London School of Hygiene & Tropical Medicine via the online ethics portal (LEO 
online) for ethics approval. I responded to the ethics questions with the support of my 
supervisors, and resubmitted amended versions. Furthermore, I wrote the study 
information sheets and all the standard operating procedure. 
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I mobilised the study team (one nurse, 2 fieldworkers, one laboratory technician and 
one data manager) in consultation with the respective section heads. Also, I managed 
the purchasing of the study consumables and managed all the study supplies. I 
planned and conducted the pilot study (September 2016 to January 2017). I worked 
with the data manager to develop the study database. I selected the candidate SNPs 
and identified the potential participants from the genotyped cohort. I coordinated all 
the participant recruitment, follow-ups, study visits and all the study procedures. 
I supervised sample collection, processing and storage. Also, I performed the hepcidin 
analysis using an enzyme-linked immunosorbent assay (ELISA). I supervised iron 
biomarkers’ analysis which was done by a member of the Keneba Laboratory platform 
Team. I supervised data recording in the study forms and verified all forms before 
handing over to the data management team for entry into the study database. 
I curated all the study data and performed all the analysis and presented the results 
to my supervisory team for review. I wrote all the manuscripts, managed co-authors’ 
comments and reviews, and incorporated them in the final manuscripts, and managed 
journal submissions. I ensured that all the authors approved the final manuscripts 
before submission for publication. 
 
1.2. Thesis scope and composition 
The purpose of this thesis was to investigate the genetic determinants of anaemia and 
their effects on the response to oral iron supplementation in Africans. Anaemia is a 
global health problem, and women and children living in low- and middle-come 
countries are the most vulnerable 1. High burden of anaemia remains in these settings 
despite decades of implementing anaemia control measures. Current control 
measures have been mainly targeted at alleviating anaemia caused by nutritional iron 
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deficiency 2,3. However, only about half of anaemia cases are attributed to nutritional 
iron deficiency, and this varies across populations and geographical regions 4,5. The 
aetiology of anaemia is complex, and the role of genetic risk factors has not been 
thoroughly investigated, particularly in West African populations, where the burden of 
anaemia is among the highest. 
The discovery of hepcidin brought in a new understanding of iron biology and 
metabolism 6. Subsequently, genome-wide association studies, mainly on European 
and Asian populations, identified several genetic variants that are associated with 
impaired iron status and the risk of anaemia 7–10. The studies constituting this thesis 
were designed to investigate whether genetic variants in the hepcidin and iron 
regulatory genes predispose healthy Africans to anaemia and whether such variants 
would impede the response to oral iron supplementation. This work was made 
possible by the existence of the Keneba Biobank at the MRCG at LSHTM, which 
comprises of individuals with genotype and phenotype data. This resource enabled 
the recall of participants for subsequent detailed investigations based on their 
previously available genotype data. This thesis consists of chapters with published 
papers incorporated into chapters and papers not published are yet presented in the 
format they were submitted for publication.  
 
The thesis structure is as follows: 
Chapter 1: Candidate’s contribution and thesis structure 
 
Chapter 2: This chapter explains the background and rationale for conducting the 
PhD.  
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Chapter 3: This chapter is a review paper on the genetic determinants of iron 
imbalance among global populations. It also presents results of analysis of genetic 
data from the 1000genomes project and the Keneba Biobank population. It describes 
differences in allele frequencies and linkage disequilibrium and investigates signatures 
of selection across global populations. This was done to enable the selection of 
candidate gene SNPs for the subsequent studies. This is presented in a paper titled: 
Differences in the frequency of genetic variants associated with iron imbalance among 
global populations, that has been published in PLOS ONE 
(https://dx.plos.org/10.1371/journal.pone.0235141).  
 
Chapter 4: This chapter is a research paper investigating the effects of common 
TMPRSS6 and TF genes’ SNPs on iron status in healthy individuals of all ages, titled: 
Association of common TMPRSS6 and TF gene SNPs with hepcidin and iron status 
in healthy rural Gambians. This paper describes the effects of carrying single or 
multiple risk alleles at the common TMPRSS6  and TF SNPs on the risk of anaemia. 
This paper is has been submitted to Nature Scientific Reports. 
 
Chapter 5: This chapter is the published protocol paper. This paper described the 
background of the recall-by-genotype study. In this paper we presented the study 
design, study location, ethical permissions, informed consent and confidentiality, 
sample size estimation and the statistical analyses methods would be applied. The 
paper is published in F1000 Research (https://f1000research.com/articles/8-701/v1).  
Chapter 6: This chapter describes the results of the recall-by-genotype study. This 
results have been written in a paper titled: Common variants in the transmembrane 
protease serine 6 (TMPRSS6) gene alter hepcidin but not oral iron absorption in 
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healthy Gambian adults: a recall-by-genotype study, and submitted to Current 
Development in Nutrition. 
Chapter 7: This chapter presents the summary discussion and conclusions including 
limitations of the thesis. Furthermore, the public health implications and future 
research needs are discussed.  
 
Chapter 8: Appendices: This chapter consists of documentation of the study and 
photos taken during the PhD. 
 
1.3. Supervisory team 
My supervisors for this PhD are Dr Susana Campino, ITD Faculty, LSHTM and  Dr 
Carla Cerami, Nutrition Theme, MRCG at LSHTM. 
The Advisory committee members are: Prof Andrew Prentice and Dr Robert Butcher.  
1.4. Funding  
This PhD is funded by the UK Medical Research Council (MRC) and the UK 
Department for International Development (DFID), under the MRC/DFID Concordat 
agreement to the MRC International Nutrition Group (MRC-ING), grant MC-A760-
5QX00. 
1.5. References 
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30, 247–308 (2016). 
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2.1. Background and Rationale 
Iron is an essential micronutrient required for most physiological processes in both 
humans 1 and microorganisms 2. In humans, the primary requirement for iron is 
erythropoiesis, which consumes 60-70% of body iron 3. Iron is also required for DNA 
synthesis, electron transport, cell proliferation and the maintenance of effective 
immune system 2,4. Thus, reduced or inadequate iron availability in the body results in 
impaired physiological function 5.  
Microorganisms also need iron for growth and proliferation 6. Therefore, excess body 
iron favours pathogens as they utilise iron to grow and proliferate 2. Also, excess iron 
in the body results in the generation of reactive oxygen species which can cause organ 
damage 7. In contrast, a deficit in iron supply results in iron deficiency and anaemia, 
which is also detrimental to health and wellbeing.  
In order to avoid the consequences of either excess or deficit, the human body evolved 
to maintain an optimum balance 7. However, despite effective iron regulatory 
mechanisms, inevitably, iron imbalance occurs. Among the two iron imbalances, 
anaemia (deficit in the supply of iron) is the most common nutrient disorder worldwide 
8.  
2.2. Epidemiology and impact of anaemia 
Anaemia remains a global health concern that is responsible for approximately 8% of 
all non-fatal health loss from disease  9. In 2013, anaemia was estimated to affect 1.9 
billion people worldwide 9,10. Low- and middle-income countries (LMICs) carry 89% of 
the global anaemia burden 9. In sub-Saharan Africa, up to 60% of women of 
reproductive age are anaemic (Figure 1A), and the same is true for children under 
five years of age in this setting 9. In Western and Central Africa, the prevalence of 
anaemia in the general population reached 50% (Figure 1B). In the Gambia, a recent 
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national nutritional status survey identified that 50.4% and 59.0% of pre-school 
children have anaemia and iron deficiency, respectively 11. Also, in non-pregnant 
woman of reproductive age, 50.9% and 41.4% are anaemic and iron deficient, 
respectively 11. This indicates a high burden of anaemia in the Gambia, particularly in 
population groups that are most vulnerable to the effects of anaemia. 
Despite being amenable to cheap and widely available medicinal products (iron 
preparations), the overall disease burden of anaemia is higher than cardiovascular 
diseases, asthma and diabetes combined, resulting in 61.5 million yearly lost in 
disability (YLD) 9. Also, the Global Burden of Disease Study 2016 estimated that iron 
deficiency anaemia (IDA) is the primary cause of YLD in women and it accounts for 
one-in-five leading causes of the YLD burden 9. Anaemia has devastating 
consequences, particularly in young children, as it results in impaired cognitive 
function, which in turn impacts educational attainment 12,13. During pregnancy, 
anaemia can lead to adverse outcomes in both the mothers and newborns. Also, 
anaemia can lead to impaired physical activity in adults, which affects working capacity 
and economic productivity 14. In the elderly, anaemia leads to reduced cognition 13,15 
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(A) Global prevalence of anaemia in pregnant women (15-49 years), 2011 
 
(B) Global prevalence of anaemia in all ages, 2013 
Figure 1. Global estimates of anaemia prevalence. 
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2.3. Aetiology of anaemia 
The aetiology of anaemia is complex and multifactoral. One of the significant causes 
of anaemia is nutritional iron deficiency, which has been commonly attributed to 
approximately 50% of cases 9,19. However, this varies across populations. For 
example, Petry and colleagues reported that in settings where the prevalence of 
anaemia is higher than 40%, only 25% of cases are attributable to iron deficiency 20. 
This suggests that about 75% of anaemias in such settings may be due to reasons 
that are not purely nutritional iron deficiency. This information is essential in the fight 
against anaemia as most of the anaemia control programmes are tailored towards 
alleviating nutritional deficiency anaemia 21. Other important causes of anemia are 
micronutrient deficiencies, particularly iron, vitamin A, folate, and vitamin B12 
deficiencies. Given the different factors that influence anaemia, adjusting for these 
factors in different settings and populations are crucial to determine the true 
prevalence of anaemia. For example, in high inflammation burden settings, adjusting 
for biomarkers of inflammation would be useful when assessing anaemia.  
Iron deficiency anaemia (IDA) usually results from a single or a combination of three 
main factors:  (a) inadequate daily iron intake and increased demand, particularly at 
certain stages of life, including pregnancy and childhood; (b) chronic blood loss (e.g. 
menstruation, ulcers or parasitic infections); and (c) impaired iron absorption and 
utilization (e.g. which could be caused by genetic factors) 9,22.  
Inadequate iron intake is one of the most common causes of IDA in SSA, particularly 
in young children and women of reproductive age 23,24. This is due to the consumption 
of diets that are low in iron content or low bioavailable haem iron 24. Meat is a major 
source of dietary iron; however, meat consumption is generally low in many African 
societies due to high cost 25. Also, the consumption of foods that inhibit iron absorption 
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such as tea reduces the iron absorption 25. Although consumption of iron absorption 
enhancers such as vitamin C promotes effective absorption, most African plant-based 
foods such as cereals and legumes contain phytates that inhibit iron absorption 25,26. 
Also, most beverages contain iron-binding phenolics that limit iron absorption 25. 
Therefore, in settings where the availability of iron-rich diet is low, increase demand 
for iron in children and women of reproductive age may increase to prevalence of 
anaemia in these groups.   
In children, increase demand for iron occur due to rapid growth spurt, and thus, 
inadequate supply of dietary iron to compensate for this need my result in iron 
deficiency 27. Similarly, women of reproductive age have an increasing demand for 
iron due to regular blood loss and childbirth 14. In settings where dietary in iron intake 
is inadequate, women of reproductive may have a higher predisposition to iron 
deficiency anaemia 28,29. Also, chronic blood loss can occur due to ulcers and parasitic 
infections. Children are most vulnerable to parasitic infection such as soil-transmitted 
helminths 28. Furthermore, acute and chronic infections/inflammations such as malaria 
29, tuberculosis, HIV and cancers may increase the risk of anaemia and iron deficiency 
anaemia 9. Furthermore, respiratory infections in children impair iron absorption due 
to increase in hepcidin levels 30.  
Furthermore, genetic risk factors such as haemoglobinopathies (sickle cell and 
thalassaemias) are known to reduce Hb levels 31. Also, genetic defects in the DMT1 
or the transmembrane protease serine 6 (TMPRSS6) (the gene that encodes 
matriptase 2) genes are associated with impaired iron absorption 32,33. DMT1 plays a 
crucial role in iron absorption as it transfers dietary iron into the duodenal enterocytes 
34. Similarly, the TMPRSS6 gene is vital in iron absorption as it acts by suppressing 
hepcidin, thereby allowing effective iron absorption 33. Therefore, genetic variations 
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that lead to a loss-of-function of the genes that regulate iron absorption may 
predispose to low iron status. 
Although the influence of nutritional deficiencies and inflammation/infection on 
anaemia has been widely investigated, the role of genetic risk factors has not received 
adequate attention, particularly in West Africa. Given the high burden of anaemia in 
Sub-Saharan Africa (SSA) and diverse genetic background of African populations 
35,36, it is crucial to assess the impact of genetic risk factors on anaemia. This may aid 
in identifying better anaemia control measures. 
 
2.3.1. Anaemia definition criteria 
The haemoglobin (Hb) threshold is used to define anaemia. At the population level, 
measurement of Hb is the easiest and most reliable indication of anaemia 37. The 
WHO set 12.0g/dL and 11.0g/dL as the threshold for defining anaemia in non-pregnant 
and pregnant women respectively 38. However, these Hb cut-offs have been a subject 
of controversy, due to the argument that the thresholds may not be applicable 
universally 39. This is attributed to the different population characteristics such as race, 
ethnicity and geographical location. For example, African-Americans have been found 
to have lower Hb levels compared to their White counterparts and these differences 
remained even after controlling for racial differences 40,41. This demonstrates that 
applying the WHO criteria may increase the prevalence of anaemia in African-
Americans. Similarly, people living in higher altitudes usually have higher Hb 42, 
therefore, applying the WHO threshold may lead to a lower prevalence of anaemia in 
such settings 38.  
In sub-Saharan Africa, the presence of infectious diseases may also influence 
adaptation to low iron status 43. For example, iron deficiency is considered to be a 
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protection against malaria 44, whereas, malaria is said to increases the risk of iron 
deficiency 45. This has led to the hypothesis that the anaemia burden can be reduced 
by eliminating malaria 46. This demonstrates the need to consider setting and 
population characteristics when determining anaemia prevalence using universal 
thresholds. Thus, it has been proposed to adjust for population characteristics when 
defining anaemia at the populations level 47, to avoid over-or under-estimation of 
anaemia prevalence in a given population. 
 
2.4. Anaemia control strategies 
Iron supplementation is the routine anaemia treatment and prevention approach 48. 
This measure is implemented alone or alongside food fortification programmes 
targeted at vulnerable populations 21,48. Oral iron supplementation is generally 
effective in anaemias caused by nutritional iron deficiency. Thus, the WHO 
recommends daily or intermitted iron supplementation in pregnant women and 
children under five years of age 49–51. This policy guidline is advanced based of the 
evidence that intermittent iron supplementation has been associated with minimal side 
effects 52. A comprehensive review by Penas-Rozas and colleagues found that both 
intermittent and daily iron supplementation has similar outcomes in both mothers and 
infants 52. Despite decades of rolling out these strategies, the burden of anaemia 
remained high in low- and middle-income countries (LMICs), with Western Africa and 
East Asia carrying the highest burden 53. Thus, reducing the burden of anaemia in the 
most affected populations remains a priority for governments and international 
organisations 54.  
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Therefore, in a quest to reduce the anaemia burden in the vulnerable groups, in 2012, 
the World Health Assembly resolved to take action to reduce by half the 2012 anaemia 
prevalence among women of reproductive age, by the year 2025 55. According to the 
World Health Organisation (WHO), one of the strategies to achieve this goal is to 
improve identification, measurement and understanding of anaemia among women of 
reproductive age 48,55. Consequently, the WHO recommended the implementation of 
evidence-based, setting and population-specific strategies, while taking into account 
the aetiology and prevalence of anaemia 56. However, implementing this tailored 
preventive and treatment strategies requires a clear understanding of the risk factors 
and significant drivers of anaemia. This is particularly critical in populations where the 
prevalence of anaemia remained high. Thus, it is crucial to gain a deeper 
understanding of the genetic determinants of anaemia particularly in settings 
characterised by a high burden of anaemia and disproportionately high genetic 
diversity, such as in African populations. 
 
2.5. The need for better intervention methods 
Anaemia continues to be a recalcitrant global health problem that has gained 
significant attention due to its consequences on human health and wellbeing 18. The 
fight against anaemia is intense in LMICs because of the sustained high burden 57.  
The most recent study on the global burden of anaemia 9 and related studies 37,58–60 
reported high disparities in the prevalence of anaemia between different geographical 
locations and population. Also, there are within-country disparities among different 
populations. For example, in the US, the National Health and Nutrition Examination 
Surveys (NHANES) identified considerable differences in anaemia burden between 
racial groups, with black women having more anaemia compared to white women 60. 
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The search for better iron intervention strategies necessitates a deeper understanding 
of the drivers of anaemia. The ambitious target commissioned by World Health 
Assembly to reduce the 2012 anaemia burden in women of reproductive age by half 
by 2025 61, brought the identification of the underlying genetic determinants of 
anaemia to the forefront. Identification of the genetic determinants of an ineffective 
response to iron supplementation and those that predispose individuals or populations 
to anaemia may help in developing population-specific or personalised interventions. 
The discovery of hepcidin, the hormone that centrally regulates iron metabolism, 
brought new insights into the understanding of iron homeostasis 62–64. Additionally, the 
recent explosion in genome-wide association studies (GWASs) enabled the discovery 
of numerous single nucleotide polymorphisms (SNPs) within the hepcidin-iron axis 
that are associated with impaired iron status 65–67. However, most of the studies on the 
effects of SNPs within the hepcidin regulatory genes have been conducted in non-
African populations.  
There have been calls to increase human genetic research in the African continent 
68,69. The high genetic diversity among Africans motivated the interest to study genetics 
determinants of diseases affecting Africans. Results from human genetic studies 
conducted in Europeans are not readily transferrable to African populations for 
multiple reasons: 1) Europeans only carry a subset of the global human genetic 
diversity 69; 2) There is variation between populations in their biological adaptations to 
infectious diseases 68; 3) There are differences in allele frequencies of genetic variants 
and differences in linkage disequilibrium of alleles across global populations 36. Thus, 
it is crucial to conduct genetic studies in African populations to determine the effects 
of common genetic variants on anaemia in Africans. 
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2.6. The role of hepcidin in iron homeostasis 
The discovery of hepcidin as the master regulator of iron metabolism brought new 
insights into how body iron is regulated 70. Hepcidin is a liver-synthesised 25-amino 
acid hormone,  which is encoded by the HAMP (hepcidin antimicrobial peptide) gene 
71,72. Hepcidin acts by binding to ferroportin, the mammalian cellular iron transporter, 
thereby inducing ferroportin’s internalisation and degradation 73. This action of 
hepcidin regulates plasma iron levels by restricting iron transport from the gut and 
mobilisation from storage sites (stores and reticuloendothelial iron release) 8 (Figure 
2).  Hepcidin deficiency leads to maximal levels of hight functional ferroportin, resulting 
in increased iron absorption, release and transport in the blood 74. Conversely, 
hepcidin excess leads to decreased ferroportin availability, which results in diminished 
iron absorption 4,75 Figure 2.  Hepcidin is synthesised in response to increased iron 
stores, high plasma iron concentration and inflammation 1. Reduced extracellular iron, 
hypoxia and increased erythropoiesis, leads to diminished hepcidin transcription 
(Figure 2). Conversely, elevated hepcidin levels prevent dietary iron absorption and 
recycling from macrophages, and mobilisation from hepatocytes, leading to reduced 
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Figure 2. Hepcidin regulation of systemic iron distribution. 
Adapted from Ganz and Nemeth 2012 8. 
The three major signals that influences hepcidin activity: Extracellular and intracellular iron, 
inflammation and erythropoiesis 8. Hepcidin is elevated in response to inflammation, increased 
iron stores and high extracellular iron levels 1. Conversely, increase erythropoietic drive lead 
to reduced hepcidin levels to allow increase iron mobilisation from the storage sites (liver and 
spleen), and absorption from the gut 76,77.   
 
2.6.1. Hepcidin regulatory pathways 
Hepcidin regulation of iron metabolism is mediated via three main molecular 
pathways, through the interconnection of genes and proteins  78. The Janus associated 
kinase (JAK)/ signal transducer and activator of transcription 3 (STAT3) and bone 
morphogenetic protein (BMP)/ sons of mothers against decapentaplegic (SMAD) 
signalling pathways promote hepcidin synthesis 78. In contrast, the hemochromatosis 
protein (HFE) – transferrin receptor 2 (TfR2) pathway suppresses hepcidin synthesis 
in response to elevate extracellular iron 79. The JAK/STAT3 is activated in response 
to inflammatory stimuli, which induces interleukin 6 (IL6) production 80.  Increase 
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inflammation results in elevated IL6 which binds to its receptor (IL6R) thereby 
activating JAK1 79. Consequently, activated JAK1 causes the phosphorylation of 
STAT3 which moves to the nucleus to activate hepcidin production (Figure 3A).  
 
The BMP/SMAD pathway is activated in response to increasing hepatic iron stores. 
Increased hepatic cellular iron induces BMP6 expression, which then interacts with 
BMPR and HJV, forming a complex 81. The BMP6/BMPR interaction activates the 
SMAD pathway (Figure 3B). The SMAD pathway involves phosphorylation of 
regulatory SMAD1, 5 and 8 (PSMADs). The phosphorylated SMADs (pSMADs) 
complexed with SMAD4, and subsequent translocation of this complex to the nucleus 
results in the activation of hepcidin gene expression (Figure 3B). Furthermore, within 
the BMP/SMAD pathway, transmembrane protease serine 6 (TMPRSS6) (also 
referred to as matriptase 2) cleaves HJV to form a soluble HJV (sHJV), which inhibits 
BMP-induced hepcidin expression, as HJV is required for BMP/BMPR complex 
formation 81. Thus, TMPRSS6 acts as a negative regulator of hepcidin through its 
interaction with HJV within the BMP/SMAD pathway. TMPRSS6 exerts its action in 
response to extracellular iron (Figure 3B). During increased iron stores, TMPRSS6 
activity is reduced, allowing the BMP/SMAD pathway to continue which promotes 
hepcidin synthesis. Consequently, hepcidin elevation curtails iron absorption and 
release from storage sites 74. Inversely, when extracellular iron levels are reduced, 
TMPRSS6 activity is increased to displace HJV, which in turn interferes with the 
BMP/SMAD pathway to suppress hepcidin transcription (Figure 3B). This action of 
TMPRSS6 on hepcidin promotes iron absorption from the enterocytes and release 
from storage sites 82.  
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The HFE/TfR2 pathway is activated when transferrin saturation increases and Tf-Fe2+ 
displaces HFE from TfR1 83. HFE then interacts with TfR2 to form the HFE/TfR2 
complex 83. Consequently, this complex activates hepcidin transcription via the 
HJV/BMP/SMAD and or extracellular signal-regulated kinase (ERK) – mitogen-
associated protein kinase (MAPK) signalling pathways through a mechanism which is 
yet to be fully understood (Figure 3C) 84. 
Hepcidin induction during iron overload reduces circulating plasma iron by restricting 
absorption and release of stored iron 74,76. Similarly, hepcidin elevation during 
infection/inflammation promotes the reduction of iron availability to invading 
pathogens, a mechanism known as bacteriostatic hypoferremic response to 
infection/inflammation 8. This mechanism is referred to as an evolutionary innate 
immune response to prevent worsening of infection 8. Therefore, impaired hepcidin 
regulation has a vital role in modulating iron imbalance. 
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Figure 3. The molecular pathways governing hepcidin regulation of hepcidin 
transcription.  
Adapted and modified from Ganz and Nemeth, 2015 79.  
Three main molecular pathways have been described to be involved in modulating hepcidin 
transcription: JAK/STAT3, BMP/SMAD and HFE/TfR2 signalling pathways 84. In the 
inflammatory pathway (A), IL6 is induced in response to inflammatory stimuli, thereby 
activating the JAK/STAT3 pathway, which then triggers hepcidin production 84. Similarly, in 
the BMP/SMAD pathway (B) increased hepatic cellular iron induces BMP6 expression, which 
then interacts with BMPR and HJV, forming a complex. TMPRSS6 and furin cleave HJV to 
form a soluble HJV (sHJV), which inhibits BMP-induced hepcidin expression, as HJV is 
required for BMP/BMPR complex formation 84. The BMP/BMPR activates the SMAD pathway. 
The SMAD pathway involves phosphorylation of SMAD1, 5 and 8 (pSMADs). The formation 
of pSMADs/SMAD4 complex and subsequent translocation of this complex to the nucleus 
results in the activation of hepcidin gene expression 85,86. (C) The HFE/TfR2 pathway is 
activated when transferrin saturation increases and Tf-Fe2+ displaces HFE from TfR1. HFE 
then interacts with TfR2 to form the HFE/TfR2 complex 83. Consequently, this complex 
activates hepcidin transcription via the HJV/BMP/SMAD and or ERK/MAPK signalling 
pathways through a mechanism which is yet to be fully understood 84.  
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IL6, interleukin-6; IL6R, IL6 receptor; JAK, Janus associated kinase; STAT, signal transducer 
and activator of transcription; BMP, bone morphogenetic protein; BMPR, BMP receptor; 
TMPRSS6, transmembrane protease serine 6; HJV, hemojuvelin; SMAD, sons of mothers 
against decapentaplegic; pSMAD, phosphorylated SMAD; TfR, transferrin receptor; HFE, 




The hepcidin-iron relationship has been implicated in numerous iron-related 
pathologies, which are attributed to dysregulation of the hepcidin-iron axis 6. Hepcidin 
excess is associated with anaemia due to inhibited iron absorption and decreased 
release from storage compartments 87. Conversely, hepcidin suppression leads to 
haemochromatosis, characterised by the accumulation of excess iron in vital organs 
4. Haemochromatosis arises from decreased hepcidin synthesis, which promotes 
excess intestinal iron absorption, recycling and mobilisation of iron from old red cells 
and macrophages, thereby increasing extracellular iron 83.  
 
Different stimuli promote either increase or decrease in hepcidin expression (Figure 
3). Each of the two extremes can result in iron-related pathologies 88. Altered hepcidin 
expression is associated with iron pathologies. Among the two principal iron 
pathologies considered to be mediated by impairment of the hepcidin regulatory 
genes, anaemia is the most common in sub-Saharan Africa (SSA) 10,22. In iron 
deficiency anaemia (IDA), hepcidin is generally low, whereas, in anaemia of chronic 
disease (ACD) or inflammation, hepcidin is either normal or elevated 89. These has led 
to the proposal that hepcidin levels can be used as a specific diagnostic marker to 
distinguish between IDA and ACD 90–92.  
In addition to being a potential diagnostic marker, manipulation of hepcidin has been 
proposed to be a treatment of iron-related pathologies 93. For example, hepcidin 
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antagonists have the potential to treat anaemias due to inappropriately elevated 
hepcidin 94. Conversely, hepcidin agonists are proposed for use in treating diseases 
of loading anaemias 89. Research into the usability of hepcidin as treatment of iron 
pathologies are currently under at various stages 93.  
 
2.6.2. Transmembrane protease serine 6 (TMPRSS6) regulation of hepcidin 
The role of TMPRSS6 (matriptase-2), a type 2 serine protease in regulating iron 
homeostasis was first discovered in mice which lacked this protease  95,96. The mice 
presented with anaemia due to elevated levels of hepcidin and impaired intestinal iron 
absorption 95. Further in vitro studies demonstrated that TMPRSS6 exerts its function 
by suppressing BMP6 stimulation of hepcidin transcription through cell surface 
proteolytic cleavage of the HJV, the BMP6 co-receptor 97. Subsequently, human 
studies elucidated the role of TMPRSS6 in modulating iron homeostasis through its 
interaction with hepcidin 81. Impaired TMPRSS6 function has been associated with 
iron deficiency and several single nucleotide polymorphisms (SNP) in the TMPRSS6 
gene has been associated with iron-refractory iron deficiency (IRIDA) 98,33,99. 
The TMPRSS6 gene has 18 exons 66,96, and rs855791, rs2235321 and rs4820268 are 
the most commonly reported SNPs. The TMPRSS6 rs8557891 is a non-synonymous 
SNPs on exon 17, which is caused by a G to A change leading to amino acid change 
from alanine to valine at the catalytic domain 66,96. TMPRSS6 rs855791 has been 
found to modulate hepcidin transcription in vitro 100. TMPRSS6 rs2235321 and 
rs4820268 are synonymous SNPs located on exon 13 and 17, respectively  33. How 
these two synonymous SNPs affect TMPRSS6 activity is unknown. Although non-
coding variants and synonymous SNPs were previously not known to influence 
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phenotype, recent findings demonstrate that such variants may influence splicing or 
slow down the translation, and RNA transcription and regulation 101,102. Therefore, 
given the role of TMPRSS6 in hepcidin regulation of iron homeostasis and its 
association with iron deficiency and impaired iron absorption, it is important to 
investigate the impact of the SNPs in this gene and those in other genes in the hepcidin 
regulatory pathway, in modulating low iron status in Africans. 
2.7. Anaemia in the context of Gambia 
The Gambia is situated at the coast of West Africa, and it is surrounded on three sides 
by Senegal, except on the Atlantic Ocean (Figure 4). The country has a population of 
2.2 million as of October 2018, with a growth rate at 3.2% per year 103. More than half 
of the population (approximately 63.6%) is below 25 years age and 52% of the 
population is between 15 and 59 years old 103. 
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Figure 4. A map of Africa showing the location of the Gambia 104. 
 
The Gambia is classified as a low-income and food-deficit country 105, with tourism 
and agriculture as the principal foreign exchange-earners 106. The predominant staple 
foods are rice and millet. Rice is regularly eaten in the urban areas, whereas millet is 
the main dish in most rural communities 105. These foods are complemented with other 
cereals such as maize, sorhgum and Digitaria exilis (locally called Findi or Fonio) 105. 
In urban areas, the typical lunch dish is rice, whilst bread is mainly consumed for 
dinner and breakfast 107. All the main dishes are served with sauces made with oil or 
peanut butter paste and either fish or meat and other vegetables 105. Meat 
consumption is generally low, and fish is the primary source of protein 108. Recently, 
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there has been a massive increase in imported chicken, and this is increasingly 
consumed instead of fish or meat  105.  
The Gambia is among the countries with the highest anaemia prevalence 58. In 2012, 
a  National Health Survey was conducted, which reported that more than 60% and 
73% women of reproductive age and children under five years old, are anaemic 
respectively 108. Also, a recent National Micronutrient Survey (MNS) reported that 50% 
of children under five years of age and non-pregnant women of reproductive age were 
anaemic 11. From the MNS study, the prevalence of iron deficiency was 59% and 41% 
pre-school children and non-pregnant women of reproductive age respectively were 
iron deficient 11. Although the prevalence of anaemia appears to decline, it remains a 
significant public health concern. 
Due to the high anaemia prevalence, particularly among the most vulnerable 
populations, there have been various control programmes in place 108. The anaemia 
control programmes include routine and intermittent iron supplementation for pregnant 
women and children 108. Also, food fortification programmes are implemented, and 
children are regularly dewormed to prevent worm infestation 108. The flour is the 
common staples that is fortified with vitamins 109, but new biofortified crops have been 
introduced in the country targeting rural communities 110. These biofortified crops 
include vitamin A rich sweet potato and maize, and iron rich beans 111 and pearl millet 
112. 
Despite, decades of implementing anaemia control strategies particularly iron 
supplementation, the prevalence of anaemia remains high, particularly among the 
vulnerable groups (women of reproductive age and pre-school children). Therefore, it 
is crucial to investigate the underlying causes of anaemia in The Gambia and in similar 
settings to improve future iron intervention strategies. 
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2.8. The need to investigate the genetic influences of anaemia 
The discovery of hepcidin and its related regulatory proteins renewed the interest in 
understanding the genetic influences of iron related pathologies 4,78,113. Dysregulation 
of the TMPRSS6 genes is one of the most commonly studied genetic determinants of 
anaemia, due to its association with iron-refractory iron deficiency anaemia (IRIDA)  
66,114,115. IRIDA has been described mainly in non-African populations 33,66,116. 
However, given the high prevalence of anaemia in Africans, it is relevant to investigate 
the influence of these known genetic variants associated with anaemia in African 
populations.  
Also, apart from TMPRSS6, defects in other iron regulatory genes such as SCL11A2, 
SLC40A1 and transferrin (TF) have been linked to impaired iron status 4,117. SLC11A2 
encodes the divalent metal transporter 1 (DMT1) protein which is involved in iron 
transport across the duodenum in the duodenal enterocytes 32,118. In mice models, 
impairment of SLC11A2 has been associated with microcytic anaemia due to impaired 
iron absorption 119,120. Subsequently, human studies revealed the association between 
SLC11A2 variants and microcytic anaemia 32,121. Similarly, defects in SLC40A1 (the 
gene that encodes ferroportin) is associated with increased hepatic iron accumulation, 
accompanied by microcytic anaemia in Africans 122,123. This happens due the inability 
of hepcidin to downregulate ferroportin, which leads to inappropriate iron transport 88. 
Also, defects in the transferrin gene (TF) has been associated with 
hypotranferrinaemia, which leads to iron-loading 124. Therefore, it is possible that 
genetic variants in genes involved in iron regulation could cause a range of degrees 
of iron deficiency and anaemia.  
The majority of the early studies on genetic influences of iron status were conducted 
in European populations 125–127. Most of these studies focused on identifying the 
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genetic influences of iron overload syndromes 128,129, including studies on hereditary 
hemochromatosis (HH). HH is a rare disorder that mainly affects populations of 
European ancestry and primarily caused by a rare genetic defect in the HFE gene 130. 
Recently, there has been an increased interest in understanding the genetic influences 
of low iron status. Several studies have observed associations between genetic 
variants and iron status biomarkers 131–133.  Consistently, studies have implicated 
TMPRSS6 (the gene that encodes matriptase-2) as one of the genes that modulate 
iron status 100,134,135. Numerous SNPs in the TMPRSS6 gene have been linked to 
abnormal iron biomarkers and haematological traits, including serum iron 
concentrations, transferrin saturation, haemoglobin, erythrocyte count and mean 
corpuscular volume 82,136–139.  
Despite the growing interest in understanding genetic influences of anaemia and low 
iron status, there is a scarcity of data in this regard on Africans populations. This is 
particularly essential given that African populations have disproportionately high 
genetic diversity. Furthermore, it is particularly incredible to conduct genetic studies of 
anaemia and iron deficiency in African populations to examine whether the genetic 
effects observed in Europeans and Asian are replicable. Also, given the environmental 
factors that favour anaemia in Africans, including diet with low bioavailable iron, 
infectious diseases (e.g. malaria), it is necessary to determine the impact of host 
genetic factors in modulating iron status. Understanding the genetic determinants of 
anaemia and iron deficiency in African populations may help to improve future iron 
intervention strategies.  
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2.9. Importance of the MRCG Keneba Biobank 
The Keneba Biobank at MRCG at LSHTM is a collection of biological samples and 
phenotype data from the residents of the Kiang West district, located in the Lower 
River Region of The Gambia 140, Figure 5.  This district has a population of 
approximately 16,000 people distributed among 36 villages. The Kiang West 
Demographic Surveillance System (KWDSS) at the MRCG Keneba was established 
in 2004. Since then, the KWDSS has been monitoring and recording migration and 
vital statistics (e.g. birth, deaths) for the entire population of this district.   
The Biobank was established in 2012, and it utilises the KWDSS to recruit study 
participants. The Keneba Biobank has already recruited 11,5000 individuals. From 
these, 3116 individuals have been genotyped using the Illumina Human Exome array, 
providing data on 80K SNPs. The KWDSS, in conjunction with the Keneba Biobank, 
offers a unique platform for studies involving the whole of the rural population of Kiang 




Figure 5. Map of the Gambia and Kiang West showing the study location. 
 Adapted and modified from Hennig et al. 2017 104,140. 
Page 44 of 264 
 
2.10. Aims and Objectives 
 
The aim of this PhD was to investigate the role of genetic variants in the human 
hepcidin and iron regulatory genes on the risk anaemia and impaired response to oral 
supplementation in Africans. 
The objectives of this PhD are: 
a) To identify the genetic variants within the iron and hepcidin regulatory genes 
that influence iron status in global populations. 
b) To investigate the effects of common genetic variants in the iron regulatory 
genes on iron status in health rural Gambians. 
c) To examine the impact of TMPRSS6 SNPs on oral iron absorption in healthy 
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Chapter 3:  
Differences in allele 
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variants associated with 








This chapter presents the results of narative review paper and the assessment of the 
differences in allele frequencies of single nucleotide polymorphisms (SNP) associated 
with iron imbalance across global populations.  This research paper has been 
published in PLOS ONE. https://dx.plos.org/10.1371/journal.pone.0235141 
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Abstract  
Iron deficiency anaemia is a major health problem affecting approximately 1.2 billion 
people worldwide. Young children, women of reproductive age and pregnant 
women living in sub-Saharan Africa are the most vulnerable. It is estimated that iron 
deficiency accounts for half of anaemia cases. Apart from nutritional deficiency, 
infection, inflammation and genetic factors are the major drivers of anaemia. However, 
the role of genetic risk factors has not been thoroughly investigated. This is particularly 
relevant in African populations, as they carry high genetic diversity and have a high 
prevalence of anaemia. Multiple genetic variations in iron regulatory genes have been 
linked to impaired iron status. Here we conducted a literature review to identify genetic 
variants associated with iron imbalance among global populations. We compare their 
allele frequencies and risk scores and we investigated population-specific selection 
among populations of varying geographic origin using data from the Keneba Biobank 
representing individuals in rural Gambia and the 1000 Genomes Project. We identified 
a significant lack of data on the genetic determinants of iron status in sub-Saharan 
Africa. Most of the studies on genetic determinants of iron status have been conducted 
in Europeans. Also, we identified population differences in allele frequencies in 
candidate putative genetic risk factors. Given the disproportionately high genetic 
diversity in African populations coupled with their high prevalence of iron deficiency, 
there is need to investigate the genetic influences of low iron status in Sub-Saharan 
Africa. The resulting insights may inform the future implementation of iron intervention 
strategies. 
 
Key words: Anaemia, Iron deficiency, iron, Genetic variants, iron imbalances, African 
populations.  
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Introduction 
Iron deficiency anaemia (IDA) is a major health problem affecting approximately 1.2 
billion people worldwide [1]. It was estimated to account for the 7th leading cause of 
disability worldwide in 2017 [2]. IDA is regarded as the dominant cause of anaemia, 
accounting for approximately 60% of the global anaemia burden[3]. Pre-school 
children and women of childbearing age in low- and middle-income countries are the 
most vulnerable [3,4], particularly those living in sub-Saharan Africa, where anaemia 
prevalence in the general population exceeds 40% [3]. This high prevalence of IDA 
persists despite the existence of aggressive iron supplementation programmes for 
vulnerable populations (women of childbearing age and children) [5–7]. 
 
Although iron supplementation can be effective in nutritional IDA, it is ineffective in 
non-nutritional IDA, particularly those caused by genetic factors [8]. Therefore, the 
identification of the major drivers of IDA in sub-Saharan Africa is required to inform 
new strategies. The discovery of hepcidin and other proteins involved in iron regulation 
have led to the identification of genetic factors associated with altered iron 
homeostasis [9–11]. Several genetic variants within the iron regulatory genes have 
been associated with imbalances in iron homeostasis, which could lead either to iron 
deficiency or overload [12–16]. Genetic variants leading to excess body iron occur 
mainly in the haemochromatosis (HFE) gene but are also seen in hepcidin (hepcidin 
antimicrobial peptide (Hamp)), transferrin receptor 2 (TFR2), solute carrier family 40 
member 1 (SLC40A1), haemojuvelin (HJV) and transferrin (TF) genes [9–11]. These 
loci have important functions in the iron homeostasis pathways. For example, hepcidin 
regulates iron absorption and release [17]. Genetic polymorphisms in genes involved 
in the hepcidin suppressive pathway such as TMPRSS6 (transmembrane protease 
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serine 6), have been associated with low iron status [18–20] and a condition described 
as iron-refractory iron deficiency anaemia (IRIDA) [18–21]. Individuals with IRIDA 
have a hereditary form of anaemia that does not respond to oral iron supplementation 
[22,23].  Although IRIDA is quite rare, it may be at the extreme end of a broad 
continuum of disease, since TMPRSS6 genetic variants can lead to different degrees 
of iron deficiency and anaemia [18–20]. In addition, SNPs in the TF gene, also 
important in iron transport to cells, have also been reported to affect iron status and 
lead to low iron status [24–26]. Furthermore, SNPs in the divalent metal transporter 1 
(DMT1), the duodenal apical iron transporter encoded by the SLC11A2 gene have 
been associated with an unusual syndrome characterized by microcytic anaemia and 
a paradoxical iron overload [27,28]. 
 
A genome-wide association study (GWAS) investigating genetic determinants of 
relevant haematological traits and iron status have identified variants in TF and HFE, 
which explain approximately 40% of variation in serum transferrin levels [26].  Also, 
GWASs have identified genetic variants in TMPRSS6  associated with alterations of 
serum iron status, erythrocyte volume [29], and haemoglobin levels [20]. African 
populations have been greatly under-represented in such studies. A GWAS using an 
African population cohort replicated only the association of two SNPs in TMPRSS6 
with lowered haemoglobin concentration, and one SNP in TF with increased ferritin 
concentrations [30]. Differences in the frequencies of risk alleles and linkage 
disequilibrium patterns might explain the limited replication of association results 
between European, Asian and African populations. Hence, there is a need to 
investigate population-specific genetic variants that may affect iron status.  
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Here, we conducted a review of the literature to identify genetic variants that have 
been associated with iron imbalances, with a special focus on SNPs in TMPRSS6, 
HAMP, TF, TFR2, SLC40A1 and HFE genes. We investigated the geographical 
distribution of studies and assessed the differences in allele frequency of these 
polymorphisms and their linkage disequilibrium patterns across global populations. 
We use genetic data from our Keneba Biobank in rural Gambia and from the 1000 
Genomes Project.  We also explored the possibility of natural selection acting on these 
genes and any resulting population-specific selection, as measured through large 
differences in allele frequencies between geographic regions. As part of this, we 
sought to summarize the geographical distribution of genetic determinants of iron 
status. The resulting insights may assist in designing future genetic association 
studies that are geared towards identifying population-specific genetic risk factors 




Selection of SNPs 
A literature search was conducted using the Human Genetic Epidemiology (HuGE) 
navigator, a database of published population-based human genetic epidemiology 
studies. This review was complemented using the PubMed site with search terms: 
“anaemia”, “iron”, “iron overload”, “iron deficiency anaemia”, “iron imbalance”, 
“hepcidin”, “genome-wide association study”, “GWAS”, “haematology traits”, and 
“haemochromatosis”. The search was conducted on articles published between 01 
January 1999 to 31 October 2018. The assessment process included examining titles 
and abstracts of studies and excluding duplicates. Articles were included if they were: 
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(1) original research papers conducted in humans; (2) tested for an association 
between at least one SNP in the genes commonly linked to dysregulated iron status 
(TMPRSS6, HAMP, TF, TFR2, SLC40A1 and HFE) or iron status measures. These 
include iron status biomarkers (serum iron, transferrin, ferritin, soluble transferrin 
receptor, transferrin saturation, total iron binding capacity, unsaturated iron binding 
capacity and hepcidin) alone or in combination with haematology traits (haemoglobin, 
red blood cells, hematocrit, mean corpuscular haemoglobin and mean corpuscular 
hemoglobin concentration). Animal studies, case reports, commentaries and articles 
not written in English were excluded.  Rare variants reported in a single individual or 
family were discarded. Information on genomic and gene location, allele ancestry, 
minor allele variant and the predicted consequence of each SNP were obtained from 
the Ensembl dataset (release 98) [31] and the dbSNP nucleotide variation database 
[32].  
 
Genotype data and statistical analysis  
We obtained genotype data from the Keneba at MRCG at LSHTM [33] (n=3,116 
healthy Gambian individuals) and from the 1000 Genomes project [n=2,504; 26 
populations categorised into African (AFR, n=661), European (EUR, n=503), 
American (AMR, n=347), East Asian (EAS, n=504) and South Asian (SAS, n=489)] 
[34]. Genotyping of the Keneba Biobank populations was performed using the Infinium 
240K Human Exome Beadchip (v1.0 and v1.1). Genotype calling was performed using 
data-driven clustering (Genome Studio, Illumina, CA, USA).  
 
We assessed the differences in allele frequencies for SNPs with genotype calls in both 
the Keneba Gambian and the pan-African populations in the 1000 Genomes Project. 
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Linkage disequilibrium (LD) measures (D’ and r2) were calculated using the R package 
Genetics [35].  The correlation between minor allele frequencies across populations 
was calculated using the Pearson's correlation coefficient in the R package corrplot. 
We calculated the allele risk score for each individual by aggregating the number of 
risk alleles an individual carried. To do this, from each SNP, the risk allele was 
assigned 1 and alternate allele assigned 0. For the genotype of each SNP, an 
individual was given either 0 (wildtype), 1 (heterozygote) or 2 (homozygote for the risk 
allele). Using this information, we determined the allele risk scores across populations 
for both low and high iron SNPs. For 23 SNPs it was not possible to identify the 
associated alleles (e.g. just a “A/T” label) or classify the direction of association (e.g. 
absence of regression coefficients). Also, for some SNPs (TF rs3811658 and 
rs1880669, and TMPRSS6 rs2072860 and rs2111833) (S1 Table) we found 
contradictory information about their association with iron biomarkers between 
studies. They were all excluded from risk allele analysis. Statistic differences in the 
distribution of risk alleles between populations were calculated using a Wilcoxon rank 
sum test in the R statistical package [36]. To allow for multiple comparisons, a 
Bonferroni correction was applied.  
 
The minor allele frequency (MAF), observed and expected heterozygosities and 
measures of population differentiation (global and pairwise FST to assess differences 
in allele frequencies) were calculated from the genotype data for all iron-associated 
SNPs using a combination of the R packages Adegenet [37], Hierfstat [38] and Pegas 
[39]. Weir & Cockerham FST values were calculated and range from 0 to 1, where a 
zero value implies that the two populations are interbreeding, and a value of one 
means that the two populations do not share any genetic diversity. Population Branch 
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Statistic (PBS) values were calculated using the FST data from the comparison of three 
populations (AFR-EUR, AFR-SAS, EUR-SAS) according to methods described 
elsewhere [40]. To evaluate the significance of the observed FST and PBS values, the 
results were compared with the empirical distribution of genome-wide SNPs reported 
by others using individuals from several geographical locations and including data 
from the HapMap and HGDP [41–45]. 
 
Statistical differences between MAFs were analysed using the two-proportion Z-Test 
in R.  The integrated Haplotype Score (iHS) [46,47]  statistic was investigated using 
Haplotter (http://haplotter.uchicago.edu/)[48] and HGDP selection browsers 




The Keneba Biobank Project received ethical approval from the MRCG at LSHTM 
Scientific Coordinating Committee and the MRCG at LSHTM/ Gambia Government 
Joints Ethics Committee (SCC1185). Written informed consent was obtained from 
each participant.  
 
Results 
Genetic variants associated with iron imbalances 
A total of 64 studies were selected that contained data on the effects of genetic 
polymorphisms on the variations in iron or haematological parameters (S1 Table). The 
majority of the studies (59/64) were conducted in Europe, Asia and the USA (Fig 1, 
S2 Table). Only five studies were conducted in Africa, two in Rwanda [49,50], one in 
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Zimbabwe [51], one in South Africa [52] and one meta-analysis across Kenya, 
Tanzania and South Africa [30]. Across the 64 studies, 50 SNPs were identified in six 
genes (TMPRSS6, HAMP, TF, TFR2, SLC40A1 and HFE) (S1 Table). More than half 
of these SNPs were found to be associated with variation in iron or in other 
haematological parameters in more than one country (29 SNPs, 58%). Of these 29 
SNPs, 79.3% were reported in more than one ethnic group (S2 Table). Nine SNPs lead 
to a missense mutation causing an amino acid change, four SNPs had synonymous 
variants, and the remaining SNPs are in intronic (n=32), regulatory or intergenic 
regions (n=5).   
 
 
Figure 1. Geographical locations of the sixty-four studies that reported genetic 
variants associated with iron imbalance. Nine studies involved multi-ethnic 
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The highest number of SNPs were identified in the TMPRSS6 gene region (n=23), 
where the majority were associated with IRIDA, iron deficiency or indicators of low iron 
status (S1 Table). The most commonly reported TMPRSS6 SNP was rs855791, 
followed by rs4820268, rs2235321 and rs2235324, all associated with biomarkers of 
low iron status. These SNPs have been mainly reported in non-African populations. 
Three TMPRSS6 SNPs (rs5756504, rs5756506 and rs1421312) were also associated 
with biomarkers indicating elevated iron status (S1 Table).  
 
The TF gene had the second highest number of SNPs related to either low or high iron 
status (n=18). The most common of these (rs3811647) was reported by ten studies 
(S1 Table). This variant has been mainly associated with elevated transferrin and total 
iron binding capacity levels [26,53,54]. For the SLC40A1 gene, three SNPs were 
selected that led to alterations in iron status measures and severity of 
haemochromatosis [50,51,55–57].  One SNP was identified in HAMP (rs10421768) 
[30,55,58–60] and one in TFR2 (rs7385804) (6,7,33,34,37,38), both of which were 
found to be associated with increases in haemoglobin and alterations serum in ferritin 
concentrations [30,55,56,58,61–63].  For the HFE gene, we found four SNPs that have 
been associated with alterations in haemoglobin and/or an increase in the genetic risk 
of hereditary haemochromatosis [13,14,19,20,24,26,29,56,62,64–74]. The most 
commonly reported HFE variant is rs1800562 (C282Y)  [13,19,24,26,29,71,72], which 
has been widely associated with the severe form of hereditary haemochromatosis in 
European descents.  
Global geographic distribution of allele frequencies  
We investigated the allele frequencies of the 50 SNPs across data from the Keneba 
Biobank at the MRCG at LSHTM in The Gambia (n= 3,116) and the 1000 Genome 
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project (n= 2,504) [34]. The 1000 Genomes project includes data from African (AFR, 
n=661; including from The Gambia), European (EUR, n=503), American (AMR, 
n=347), East Asian (EAS, n=504) and South Asian (SAS, n=487) populations. Only 
thirteen of the 50 SNPs in the TF, TMPRSS6, HFE and SLC40A1 genes, were 
available in the Keneba Biobank, because not all the SNPs were on the Exome chip 
that was used for genotyping this population. When we compared the allele 
frequencies of the SNPs with data from The Gambians in the Keneba Biobank with 
the pan-African populations in the 1000 Genomes project, we observed minimal 
differences (Fig 2). 
 
 
Figure 2. Minor Allele frequencies (MAF) of 13 SNPs across African populations.  
Comparing MAF between the two Gambian datasets, Yoruba (YRI) from Nigeria and 
overall African populations included in the 1000 Genomes Project. The minor alleles 
were defined by the 1000 Genomes Project. 
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For the majority of SNPs, the MAFs in the African populations were very different to 
other worldwide populations (Fig 3 and Fig 4). The greatest allele frequency 
differences were observed in rs1439816 in SLC40A1, and in several SNPs in 
TMPRSS6 (including rs855791 and rs855788).  The intronic variant rs1439816 in the 
SLC40A1 gene has a MAF of ~20% in the non-African populations but reaches >73% 
frequency in Africa (S1 Table). The missense variant A736V (TMPRSS6 rs855791) is 
the most reported SNP associated with iron deficiency and has a MAF of ~50% across 
all non-African populations, but in Africa it only reaches 10% (7% in the MRCG Keneba 
Biobank population) (Fig 4). The intronic variant rs855788 in TMPRSS6 has a MAF of 
~30% across non-African populations, contrasting with a frequency in excess of 86% 
in the African populations (Fig 4). 
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Figure 3. Correlation of minor allele frequencies between different geographic 
regions. Correlation coefficients were obtained by pairwise comparisons of each of 
the 50 SNPs identified across two populations. They are coloured according to the 
value using a gradient from white (representing 0 for no correlation) to dark blue (1 for 
perfect correlation). The minor allele variant was defined by the 1000 Genomes 
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Figure 4. The differences in minor allele frequencies of SNPs in the six genes investigated, across different geographic regions. The 
comparisons were made between Africans and other global populations (A) Africa vs. Europe; (B) Africa vs. South Asia; (C) Africa 
vs. East Asia; (D) Africa vs. America. The thick grey lines indicated borders between SNPs in different genes: HAMP, SLC40A1, 
TMPRSS6, TF, HFE and TFR2. The minor alleles were defined according to the 1000 Genomes Project database [34]. AFR, African; 
EUR, European; AMR, American; EAS, East Asian; SAS, South Asian. 
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From the selected SNPs, several in African (n=10 SNPs) and East Asian (n=11 SNPs) 
populations have fixed ancestral alleles or low MAF (<5%) (Fig 4). These SNPs 
include four missense variants, with the lowest overall MAF or with fixed ancestral 
alleles in several populations (associated with low iron: TMPRSS6 rs78174698 and 
TF rs1799899; associated with increased serum ferritin: SLC40A1 rs11568350; 
associated with haemochromatosis: HFE rs1800562). The TMPRSS6 rs78174698 
(P555S) MAF is low overall (<2%) across most populations, except in South Asia 
where the minor allele is >10%.  The minor allele for rs1799899 (G277S) is rare in 
Africa and East Asia (<0.2%), and only reaches >4% MAF in European, American and 
South Asian populations. For SLC40A1 rs11568350 (Q248H), the minor allele reaches 
5% in Africans, including in both The Gambian populations in the two datasets 
analysed. In the other global populations, the ancestral allele is almost fixed. The 
variant A allele of rs1800562 (C282Y) has the highest frequency in European 
populations (4.3% and 5.3% in Caucasians from Europe in the 1000 Genome Project 
and in the HapMap CEU population, which have ancestry from Northern and Western 
Europe, respectively). The frequency of this variant is extremely low in Africans (0.2% 
in the 1000 Genomes project) and it was not detected (MAF=0) in the Keneba Biobank 
population.  
We also investigated the population-specific linkage disequilibrium (LD) patterns 
between SNPs in the candidate genes. There were blocks of high LD in the non-
African population, and the overall levels of LD were lower in the African populations 
(Fig 5, Fig S1), including in The Gambia. In contrast, the SNPs in the TF gene still 
showed a pattern of high LD in the African populations. 
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Figure 5. Linkage disequilibrium (LD) plots in SNPs in HAMP, SLC40A1, TMPRSS6, 
TF, HFE and TFR2 genes. LD plot showing r2 values in SNPS associated with iron 
imbalances in: (A) African populations, (B) European populations and (C) Gambian 
population in the Keneba Biobank.  
 
Distribution and frequency of iron imbalance risk alleles 
To investigate if any population had an over- or under-representation of risk alleles 
leading to iron imbalances, we first classified the alleles as protective or susceptible 
based on previous associations with low or high iron status or related biomarkers (S1 
Table). A total of 23 SNPs were included in the risk allele analysis (see Methods for 
exclusion criteria). Eleven SNPs had alleles that were clearly associated with low iron, 
iron deficiency anaemia and/or IRIDA (SNPs in TMPRSS6 (rs855791, rs2235321, 
C 
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rs2235324, rs4820268, rs2413450, rs228916, rs228918 and rs228921) and TF 
(rs3811647, rs1799899 and rs8177253) (S1 Table). 
   
The South and East Asian populations had the highest number of low iron risk alleles, 
whereas, Africans had the lowest and were significantly different from the other 
populations (Fig 6A, P < 0.0001). The American and European populations had similar 
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Figure 6. Distribution of the number of low iron risk alleles across global populations. 
(A) Distribution of the number of low iron risk alleles in eleven SNPs associated with 
low iron status across five populations. (B) Distribution of the number of low iron risk 
alleles in six SNPs with genotype data in the MRC Keneba Biobank population.  
Designation of the allele (risk or not) was determined by their previously published 
information as presented in S1 and S2 Tables. AFR, African; EUR, European; AMR, 
American; EAS, East Asian; SAS, South Asian. 
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Out of the eleven SNPs we found to be associated with low iron, it was only possible 
to compare six using the Keneba Biobank data, as data on the remaining SNPs were 
not available. The number of low iron risk alleles of the Gambians in the Keneba 
Biobank and the overall Africans in the 1000 Genomes were similar (Fig 6B). 
However, the low iron risk alleles in the Gambian and overall African populations were 
significantly lower compared to the other populations (P < 2x10-16) (Fig 6B).   
 
Twelve SNPs were clearly associated with high iron or related biomarker (SNPs in 
HAMP, TMPRSS6, TF, SLC40A1, TRF2 and close to HFE) with their risk alleles 
indicated (S1 Table).  Three out of these twelve high iron associated SNPs were in or 
close to the HFE gene (rs1799945, rs1800562 and rs198846). These three SNPs were 
associated with haemochromatosis. Since haemochromatosis is predominantly 
common in those of European descent and rare in other populations, we analysed 
these SNPs separately. The European populations have the highest number of high 
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Figure 7. Distribution of the number of risk alleles for haemochromatosis among 
global populations. Designation of the risk allele was determined by previously 
published information as presented in S1 and S2 Tables. AFR, African; EUR, 
European; AMR, American; EAS, East Asian; SAS, South Asian. 
 
Data for two of the SNPs (rs1799945 and rs1800562) were available for the Keneba 
Biobank population, but the frequency of risk alleles was low (1% and 0%, 
respectively). Therefore, we could not compare the frequencies of risk alleles of these 
SNPs between the Keneba Biobank population and the 1000 Genomes project 
populations. Furthermore, we compared the frequencies of the high iron risk alleles of 
the remaining nine SNPs associated with elevated iron status in other genes. The 
African population in the 1000 Genomes Project had a significantly lower number of 
high iron risk alleles than the other populations (P <0.0001) (Fig 8A). The distributions 
between the other populations were similar. From these nine SNPs, genotype data for 
three SNPs (TMPRSS6 rs5756506, TF rs1799852 and SLC40A1 rs11568350 
(Q248H) were available for the Gambians in the Keneba Biobank. When we compare 
the frequencies of the high iron risk alleles at these three SNPs across populations 
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(Fig 8A), Gambians in the Keneba Biobank and pan-African populations have the 
lowest number of combined risk alleles for high iron (Fig 8B). 
 
Figure 8. Distribution of the number of high iron risk alleles across global populations. 
(A) Distribution of the number of high iron risk alleles across five populations. (B) 
Distribution of the number of high iron risk alleles in three SNPs in the MRC Keneba 
Biobank (Gambian) and other populations.  Designation of the allele (risk or not) was 
determined by their previously published information as presented in S1 and S2 
Tables. AFR, African; EUR, European; AMR, American; EAS, East Asian; SAS, South 
Asian. 
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Global population differentiation  
We calculated the global and pairwise fixation index (FST) across the 5 populations to 
assess population divergence for all iron-associated SNPs. The overall FST across the 
populations was 0.076. The pairwise FST between the continental groups shows that 
African versus non-African populations had the greatest allele frequency differentiation 
(FST >0.09; Table 1). 
 







AFR, African; EUR, European; AMR, American; EAS, East Asian; SAS, South Asian; 
FST, fixation index. 
 
We then investigated the individual SNPs driving the differentiation between African 
and other populations (Fig 9). The variants with the highest FST (>0.3) and highest 
allele frequency differences were rs1439816 in SLC40A1 and rs855791, rs855788 
and rs5756506 in TMPRSS6 (Fig 9). The average FST values for the set of SNPs in 
each population was less than 0.065. The highest FST values we observed lay within 
the top 5% of the distribution of empirical global FST values described by others (95% 
percentile FST > 0.28) [43–45].
  EUR EAS AMR SAS 
EAS 0.0317       
AMR 0.0248 0.0232     
SAS 0.0263 0.0154 0.0130   
AFR 0.0992 0.1465 0.1507 0.1425 
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Figure 9. Pairwise FST values for iron related SNPs between African and non-African populations. This figure illustrates the 
comparison of FST scores between African and other global populations. AFR, African; AMR, American; EUR, European; EAS, East 
Asian; SAS, South Asian, FST, fixation index. 
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We also calculated the Population Branch Statistic (PBS) values, an FST-based test 
involving the comparison of three populations, to investigate if the differentiation 
between populations could be driven by positive selection [40]. We used African, 
European and South Asian populations and observed that the PBS analysis reaffirms 
the FST results. In particular, the highest PBS values were present in: SLC40A1 
(rs1439816: AFR=0.27, EUR=0.05, SAS=0.0) and TMPRSS6 (rs855791: AFR=0.16, 
EUR=0.0, SAS=0.07; rs855788: AFR=0.29, EUR=0, SAS=0.04; rs5756506: 
AFR=0.25, EUR=0.0, SAS=0.07) (S3 Table). These values are above the top five-
percentile threshold of genome-wide PBS values  (PBS> 0.156) described by others 
[41,42].  
 
Finally, we investigated if any signals of recent positive selection could be detected in 
these genes by using the Integrated Haplotype Score (iHS) values from the 
Haplotter and HGDP selection browsers. The iHS statistic is based on the LD 
surrounding a positively selected allele compared with the LD around the alternative 
variant in the same position [46].  A positive iHS score (iHS > 2) means that the 
haplotypes on the ancestral allele background are longer than those with the derived 
allele [46]. A negative iHS score (iHS < -2) means that the haplotypes on the derived 
allele background are longer and are under selection. No clear evidence of selection 
was shown in the genomic regions containing HAMP, TMPRSS6, TF and TRF2 
(iHS<1). However, values of iHS scores close to 2 were found for the regions 
containing SLC40A1 (e.g. rs1439816: iHS =1.8 (East Asian-Hapmap ASN), iHS=2 
(European HapMap CEU) and HFE (e.g. rs198846: iHS=1.8 ASN), suggesting a high 
frequency of longer haplotypes with the ancestral allele. Other studies have suggested 
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In this study we identified a significant lack of data on the genetic influences of iron 
status in African populations. This finding highlights a critical gap since African 
populations have high genetic diversity, and information from other populations may 
not be transferable to Africans [76,77]. African-specific studies on the genetic 
influences of iron status will help increase our understanding of the role played by 
genetic risk factors in the prevalence of anaemia in sub-Saharan Africa.  
 
We used genotype data of populations from the Keneba Biobank at MRCG at LSHTM, 
The Gambia [33] and the 1000 Genome project [34] to describe the minor allele 
frequencies and differences in risk alleles in SNPs associated with iron imbalances or 
iron biomarkers. The allele frequencies of the available SNPs from the Gambian 
participants in the Keneba Biobank population were very similar to the Gambian 
population in the 1000 Genomes project. Both the Keneba Biobank population and 
1000 Genomes Project included Gambians from the same ethnic group the Mandinka 
[33,34], which is the largest ethnic group in The Gambia. However, several 
other ethnic groups live in The Gambia, including Fula and Wolof ethic groups [78]. 
Variability in disease risk and nutrition status between the Fula and the Mandinka 
ethnic groups has been reported [79]. This finding is consistent with the inter-
population genetic variability within African populations, which may also influence 
differences in disease susceptibility. Thus, future work could investigate the genetic 
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diversity in the genes related to iron imbalances in non-Mandinka ethnic groups in The 
Gambia to determine their possible effect on impaired iron status.  
 
Substantial differences in minor allele frequencies were observed when comparing the 
African versus non-African populations. The major differences occur in SNPs in 
SLC40A1 and TMPRSS6 genes.  SLC40A1 encodes ferroportin, a transmembrane 
transport protein which is the only known mammalian iron exporter [80]. The SLC40A1 
Q248H variant (rs11568350) is rare globally except in populations of African ancestry 
populations, where it reaches frequencies of ~5% [34]. The Q248H variant is 
associated with increased serum ferritin, decreased hepcidin concentrations and the 
risk of iron-loading in African populations [57,81]. Also, SLC40A1 Q248H is associated 
with modest protection against anaemia and iron deficiency in African children [51,82].   
We found significant differences in allelic frequencies for variants in the 
TMPRSS6 gene which encodes for Matriptase-2, a type II transmembrane serine 
protease that negatively regulates hepcidin synthesis  [23,83]. Impaired matriptase-2 
activity leads to inappropriately raised hepcidin levels [84,85], which results in 
restricted iron absorption and release from storage sites [17]. Several SNPs in 
TMPRSS6 had allele frequencies that are significantly different between African and 
non-African populations. These variants include rs855791, which has a low MAF 
(<10%) in African populations and reaches more than 35% in other populations. 
TMPRSS6 rs855791 is associated with iron deficiency anaemia and IRIDA, with 
elevated hepcidin, reduced iron and reduced haemoglobin indices [20,21,84,86,87].  
Differences in allele frequencies between continents have been described in many 
other genetic markers across the genome using data from the 1000 Genomes project 
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[88,89] Therefore, the observed large allele frequency differences in SNPs associated 
with iron differences could be the result of demographic differences.  
 
To understand if the differences in the observed allele frequencies could lead to 
differences in over- or under-representation of risk alleles leading to iron imbalances, 
we explored the frequencies of the combined risk alleles across the genes. We found 
that African populations, including the Gambian population from the Keneba Biobank, 
had a significantly lower number of alleles associated with the risk of anaemia or low 
iron. Similarly, we observed a lower number of risk alleles associated with high iron, 
or iron overload in Africans. This observation is likely because most of the studies 
were conducted in non-African populations. However, it is also possible that these 
differences are due to natural selection processes to balance the environmental risk 
factors to which African populations are exposed. For example, malnutrition and 
infections (e.g. helminths and malaria parasites) can lead to anaemia or limit iron 
overload which can increase susceptibility to certain infections (e.g bacterial). It is 
possible that the allele frequency differences between populations we described have 
occurred through founder effects as humans migrated out of Africa rather than through 
selective pressure. Possible signals of selection have only been observed for one SNP 
in SLC40A1 and three SNPS in TMPRSS6, which have the highest FST and PBS 
values in Africa.  
 
Our study has limitations. These include the potential for bias in the SNPs selection 
from the literature as there is an overrepresentation of studies related to genetics of 
iron imbalances in European and Asian populations.  Also, it was difficult to ascertain 
the risk allele for several variants either because they were not described by the 
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original study and/or the different studies used different genotyping platforms. In 
addition, although some risk alleles have been confirmed in more than one ethnic 
group (46% of the SNPs), for other SNPs it is possible that the alleles have different 
effects across populations and this could affect the risk allele analysis. Overall, our 
study highlights a major gap in genetic studies in Africa and the need to perform 
genetic studies in African populations.  
 
We also observed a lower linkage disequilibrium between SNPs in African 
populations. For example, the TMPRSS6 rs4820268 is in strong LD with TMPRSS6 
rs855791 in Europeans [90], but we found that these two SNPs are in weak LD in the 
Keneba Biobank population. This should be taken into account when performing 
association studies and selecting tag SNPs. In this setting, it may be easier to fine-
scale map “causal” variants, but more difficult to identify the novel putative loci in a 
GWAS. Also, as iron imbalances can be due to multiple factors, it is critical to 
complement genetic studies with detailed meta-data collection, including detailed 
nutritional status, iron biomarkers, and clinical histories. Alternatively the effects of the 
variants can be studied prospectively using recall-by-genotype methods [91] that can 
also interrogate the dynamic responses to, for instance, the administration of iron 
supplements. Follow-up GWAS and candidate gene studies will be important to 
understand the genetic underpinning the geographic variation in the prevalence of iron 
imbalances disorders.  
 
In conclusion, this study identified a substantial disparity in allele frequencies of 
genetic variants associated with iron, between Africans and other populations.  We 
also, identified the scarcity of data on the genetic influences of iron status in Africa. 
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Given the high burden of iron deficiency in sub-Saharan Africa, particularly in child-
bearing women and children, comprehensive mapping of the genetic influences on 
iron status may help lay the foundation for future studies and assist in developing 
future iron intervention strategies.  
 
Supporting information 
 The 1000 Genomes data is publicly available (www.internationalgenome.org). The 
Keneba Biobank genotyping data for the 13 SNPs used in this study is available in 
Table S4. 
 
Supporting information captions 
Fig S1: Linkage disequilibrium (LD) plots in SNPs in HAMP, SLC40A1, 
TMPRSS6, TF, HFE and TFR2 genes. LD plot showing D prime values in SNPs 
associated with iron imbalances in (A) African populations, (B) European populations 
and (C) Gambian population in the Keneba Biobank. 
 
S1 Table: Details of the fifty SNPs identified in the six genes that are associated 
with iron imbalance  
 
S2 Table: Details of populations where each SNP was reported and the 
associated phenotypes 
 
S3 Table: Population Branch Statistic (PBS) values involving the comparison of 
three populations. 
 
S4 Table: Genotyping data for 13 SNPs for the Gambian population in the 
Keneba Biobank 
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Minor Allele Frequency References 
             1000 Genomes HapMap Keneba 
Biobank  
  





GWD EUR EAS SAS AMR YRI CEU     
rs10421768 HAMP intron variant G A A High 0.16 0.19 0.26 0.24 0.03 0.20 0.14 0.21 0.13 NA (1–4) 
rs1799945 HFE missense 
variant (aa: 
H/D) 
G C G High 0.07 0.01 0.00 0.17 0.03 0.07 0.12 0.01 0.13 0.01  (5–17) 
rs1800562 HFE Missense 
variant 
(C282Y) 
A G A High 0.01 0.00 0.00 0.04 0.00 0.00 0.02 0.00 0.05 0  (13,15,16,18–
20) 
rs198846 close to 
HFE 
Intron variant A G A High 0.11 0.12 0.05 0.18 0.02 0.07 0.14 0.21 0.16 NA  (21,22) 
rs129128 close to 
HFE 
Intron variant C T C High 0.07 0.01 0.00 0.16 0.03 0.09 0.11 0.01 0.14 NA  (23) 





C T T Modera
tes HH2 
0.14 0.21 0.18 0.16 0.04 0.19 0.08 0.18 0.15 NA  (5) 
rs1439816 SLC40A1 intron variant C G G Modera
tes HH2 






A C A High 0.01 0.05 0.06 0.00 0.00 0.00 0.00 0.05 0.00 0.05  (24–26) 




A C  NA Low 0.49 0.41 0.38 0.37 0.61 0.56 0.47 0.40 0.34 NA  (18) 
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Minor Allele Frequency Referenc
es 
             1000 Genomes HapMap Keneba 
Biobank  
  




GWD EUR EAS SAS AMR YRI CEU     
rs1867504 TF Intron variant A G A High 0.42 0.22 0.24 0.49 0.50 0.52 0.43 0.48 0.23 NA  (2) 
rs9872999 TF Intron variant C T NA High 0.33 0.35 0.39 0.47 0.26 0.25 0.30 NA NA NA  (12) 
rs8177179 TF Intron variant G A A Moderates 
HH2 
0.34 0.36 0.40 0.47 0.26 0.26 0.30 0.28 0.42 NA  (5) 
rs1799852 TF Synonymous 
variant 
(L247L) 
A G A High 0.14 0.05 0.10 0.14 0.22 0.19 0.14 0.06 0.06 0.07 (2,13,18,
20,27) 






A G A Conflict3 0.03 0.00 0.00 0.07 0.00 0.05 0.04 0.00 0.04 NA (28,29) 
rs3811658 TF Intron variant T C T Conflict3 0.32 0.12 0.10 0.35 0.43 0.41 0.39 0.01 0.37 NA  (2,27,30) 
rs8177248 TF  intron variant T C  NA Low 0.31 0.08 0.07 0.35 0.43 0.41 0.39 0.04 0.36 NA  (30) 
rs8177253 TF intron variant T C T Low 0.35 0.22 0.15 0.35 0.43 0.41 0.40 0.22 0.36 NA  (12) 
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Minor Allele Frequency References 
          
 
 1000 Genomes HapMap Keneba 
Biobank  
  






GWD EUR EAS SAS AMR YRI CEU     
rs1880669 TF intron 
variant 
T C NA Conflict3 0.50 0.65 0.66 0.39 0.50 0.44 0.44 0.70 0.39 NA  (27,30,31) 
rs3811647 TF intron 
variant 
A G A Low 0.34 0.19 0.15 0.35 0.42 0.41 0.39 0.17 0.36 0.14  (6,12,13,18,27,
32–36) 
rs1358024 TF intron 
variant 
T C NA Low 0.19 0.01 0.00 0.19 0.39 0.27 0.17 0.00 0.18 NA  (18,27,30,33) 
rs1525892 TF intron 
variant 
A G A Conflict3 0.36 0.26 0.23 0.35 0.47 0.41 0.40 0.37 0.23 NA  (2,30,33) 
rs1049296 TF Missense 
variant 
(S589P) 
T C NA High 
 
0.16 0.06 0.02 0.14 0.26 0.23 0.12 0.07 0.16 0.01  (27) 
rs7638018 TF intron 
variant 
G A NA Low 0.33 0.15 0.14 0.35 0.42 0.41 0.40 0.15 0.36 NA  (30) 
rs1830084 TF 3 prime 
UTR variant 
T A Uncertain 
risk 
allele4 
Low 0.32 0.11 0.08 0.34 0.46 0.40 0.40 0.13 0.35 NA  (12,30) 
rs7385804 TFR2 Intron 
variant 




A G A Low 0.36 0.41 0.44 0.42 0.41 0.26 0.21 0.38 0.39 0.44  (38–40) 
rs855791 TMPRSS6 Missense 
variant 
(A736V) 
A G A Low 0.40 0.10 0.10 0.39 0.57 0.54 0.49 0.12 0.41 0.07  (5,8,10,15–
17,21,22,32,36,
39,41–59) 
rs78174698 TMPRSS6 missense 
variant 
(P555S) 























Minor Allele Frequency References 
          
 
 1000 Genomes HapMap Keneba 
Biobank  
  








EAS SAS AMR YRI CEU 
 
  
rs5756504 TMPRSS6 Intron variant T C T High 0.43 0.67 0.65 0.40 0.42 0.26 0.24 0.71 0.33 NA  (22,56,57,60) 
rs5756506 TMPRSS6 Intron variant C G C High 0.47 0.83 0.82 0.40 0.43 0.26 0.26 0.85 0.35 0.84  (27,37,47) 
rs4820268 TMPRSS6 Missense 
variant 
(D521E) 
G A G Low 0.46 0.28 0.27 0.42 0.56 0.57 0.53 0.21 0.48 0.27  (2,6,21,22,32,3
9,42,47,57,61,6
2) 
rs2413450 TMPRSS6 Intron variant T C T Low 0.42 0.12 0.12 0.41 0.56 0.56 0.52 0.12 0.48 0.17  (2,47,53,63) 
rs2072860 TMPRSS6 Intron variant G A NA Conflict3 0.46 0.28 0.27 0.42 0.57 0.57 0.53 NA NA NA  (12,43) 
rs9610643 TMPRSS6 Intron variant A G NA Low 0.38 0.60 0.59 0.33 0.40 0.23 0.22 NA NA NA   (43) 
rs855788 TMPRSS6 intron variant A G NA High 0.49 0.90 0.86 0.44 0.30 0.35 0.27 0.95 0.31 NA  (57) 
rs2543519 TMPRSS6 Intron variant G A NA Low 0.25 0.40 0.43 0.21 0.17 0.25 0.14 0.36 0.21 NA  (39,43) 
rs2111833 TMPRSS6 Synonymous 
variant (S>S) 
T C T Conflict3 0.31 0.38 0.31 0.39 0.31 0.24 0.20 0.42 0.34 NA (4) (30) 
rs2235324 TMPRSS6 Missense 
variant 
(K253E) 
G A G Low 0.39 0.40 0.43 0.43 0.40 0.37 0.33 0.43 0.35 0.45  (38–
40,47,51,57) 
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Minor Allele Frequency References 
             1000 Genomes HapMap Keneba 
Biobank 
  




GWD EUR EAS SAS AMR YRI CEU     
rs1421312 TMPRSS6 intron variant G A  NA High 0.47 0.60 0.58 0.42 0.40 0.50 0.35 0.62 0.47 NA  (30,57) 
rs5756512 TMPRSS6 intron variant T C  NA Low 0.33 0.28 0.26 0.42 0.33 0.36 0.23 NA NA NA  (43) 
rs2160906 TMPRSS6 Intron variant A G  NA Low 0.13 0.06 0.05 0.19 0.18 0.14 0.12 0.05 0.20 NA  (36) 
rs732756 TMPRSS6 Intron variant C T  NA Low 0.14 0.08 0.08 0.19 0.18 0.14 0.12 0.06 0.20 NA  (43) 
rs228904 TMPRSS6 Intron variant G A  NA High 0.14 0.08 0.08 0.19 0.18 0.14 0.12 0.06 0.20 NA  (57) 
rs11704654 TMPRSS6 Synonymous 
variant 
(P33P) 
T C  NA Low 0.15 0.15 0.14 0.19 0.13 0.16 0.11 0.16 0.25 NA  (39,42) 
rs5756516 TMPRSS6 Intron variant T C  NA Low 0.32 0.30 0.27 0.42 0.33 0.20 0.35 0.31 0.43 NA   (43) 
rs228916 TMPRSS6 5 prime UTR 
variant 







G A G Low 0.41 0.40 0.40 0.41 0.43 0.48 0.31 NA 0.40 NA (21,35)  





A G G  Low 0.41 0.40 0.40 0.41 0.43 0.49 0.31 0.34 0.47 NA  (2,21) 
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1 The documented effect of each SNP on iron status, based on its influence on iron biomarkers. High: Indicates SNPs that have been associated 
with elevated iron status as shown by at least iron biomarker signifying elevated iron status. Low indicates SNPs associated with decreased iron 
status, determined by at least one biomarker signifying low iron. 
2 The only information available about this SNPs is that they modulate hemochromatosis. 
3 We found contradictory information about the effects of these SNPs on iron status. Different papers reported direction of effects of these SNPs 
on iron status. 
NA indicates SNPs that we could not establish the risk allele because it was not stated by the respective studies that reported the SNPs. In the 
Keneba Biobank, NA indicates SNPs whose genotype data was not present in the Biobank population.  
4Indicates a SNP in which the effect of the risk allele has not been clearly described in the paper it was reported. 
5The phenotype associated with the risk allele  
 
AFR, Africans; AMR, Americans; CEU, Utah residents with Northern and Western European ancestry from the CEPH collection; EAS, East 
Asians; EUR, Europeans; GWD, Gambians from Western Division; HAMP, hepcidin antimicrobial peptide; Hb, haemoglobin; HCT, haematocrit; 
HFE, High fe; HH, hereditary hemochromatosis; IDA, iron deficiency anaemia; MCH, mean corpuscular haemoglobin; NA, not available; SAS, 
South Asians; SI, serum iron; SLC40A1, solute carrier family 40 member 1; SNP, single nucleotide polymorphism; sTfR, soluble transferrin 
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Table S2. Details of populations where each SNP was reported and the associated phenotypes  
 






Study/ first author Location/ Population/ 
Ethnicity1 
Associated trait2 Reference3 
rs10421768 HAMP G A A Javaheri-Kermani et al., 
2014 
Iran Associated with elevated 
serum iron and low hepcidin 
levels 
(3) 
rs10421768 HAMP G A A Andreani et al., 2009 Italy Associated with elevated 
liver iron concentration and 
raised serum ferritin levels 
(1) 





rs10421768 HAMP G A A Gichohi-Wainaina et al., 
2016 
Kenyans, Tanzanians, S. 
Africans and African-
Americans 
Significant increased in Hb in 
Kenyans only 
(2) 





SLC40A1 A C A Masaisa et al., 2012 Rwanda Associated with low hepcidin 





SLC40A1 A C A Kasvosve et al., 2018 Zimbabwe Associated with elevated 





SLC40A1 A C A Rivers et al., 2007 African-Americans Associated with elevated 
serum ferritin in men 
(26) 
rs11704654 TMPRSS6 T C NA Delbini et al., 2010 Italy Associated with iron 
deficiency 
(39) 
rs11704654 TMPRSS6 T C NA Kloss-Brandstatter et al., 
2012 
Netherlands Associated with increased 
serum iron and ferritin 
(42) 
rs12493168 TF G A  NA Constantine et al., 2009 European ancestry Elevated serum transferritin (27) 
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Study/ first author Location/ Population/ 
Ethnicity1 
Associated trait2 Reference3 
rs129128 HFE C T C Li et al., 2015 USA Elevated serum iron (12) 
rs1358024 TF T C NA Constantine et al., 2009 European ancestry Elevated serum 
transferritin 
(27) 
rs1358024 TF T C NA Benyamin et al., 2009 Aurtralians Affects serum transferrin 
concentrations, but 
direction of effect was not 
stated 
(18) 
rs1405023 TF C T  NA Constantine et al., 2009 European ancestry Reduced serum transferrin 
levels 
(27) 
rs1421312 TMPRSS6 G A  NA McLaren et al., 2012 Whites, African-Americans, 
Hispanics and Asians (US 
& Canada) 
Increased serum iron and 
TSAT, and decreased 
sTfR in Whites 
(30) 
rs1421312 TMPRSS6 G A  NA Tanaka et al., 2010 Italy and USA Significantly associated 
with reduced iron status 
(57) 
rs1439816 SLC40A1 C G G Radio et al., 2016 Italy Moderates hereditary 
hemochromatosis 
(4) 
rs1525892 TF A G A Gichohi-Wainaina et al., 
2016 







rs1525892 TF A G A McLaren et al., 2012 Whites, African-Americans, 
Hispanics and Asians (US 
& Canada) 
Elevated TIBC in all the 
populations 
(30) 
rs1799852 TF A G A Gichohi-Wainaina et al., 
2016 
South Africa The A allele is associated 
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Study/ first author Location/ Population/ 
Ethnicity1 
Associated trait2 Reference3 
rs1799852 TF A G A Benyamin, et al., 2009 Australian of European 
ancestry 
Decreased transferrin, increased 
serum iron, ferritin and TSAT 
(18) 
rs1799852 TF A G A Blanco-Rojo et al., 2011 Spain Reduced serum transferrin 
levels 
(13) 





TF A G A Sarria et al., 2007 Spain No significant differences in iron 









HFE G C G Pichler et al., 2011 Italy and USA Reduced serum iron (6) 
rs1799945 
(H63D) 
HFE G C G Athiyarath et al., 2015 India The G allele was significantly 
associated with adequate 















HFE G C G De Falco et al., 2018 Italy associated with elevated Hb, 





HFE G C G Mast et al., 2012 Multicenter: USA Increased iron stores (9) 
rs1799945 
(H63D) 
HFE G C G Sørensen et al., 2015 Denmark The C alleles are associated 
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Study/ first author Location/ Population/ 
Ethnicity1 
Associated trait2 Reference3 
rs1799945 
(H63D) 
HFE G C G Whitfield et al., 2000 Australia Associated with high iron stores (11) 
rs1799945 
(H63D) 
HFE G C G Benyamin et al., 2014 European ancestry Reduced serum iron, TSAT and 




HFE G C G Li et al., 2015 USA Elevated serum iron (12) 
rs1799945 
(H63D) 
HFE G C G Pichler et al., 2013 European Ancestry 
populations 
Increased iron stores (17) 
rs1799945 
(H63D) 





HFE G C G Garewal et al., 2005 India No effect on iron status (7) 
rs1799945 
(H63D) 
HFE G C G Beutler et al., 2003 European ancestry Elevated Hb, TSAT, ferritin and 




HFE G C G Jackson et al., 2001 UK: Wales Elevated serum ferritin, TSAT and 




HFE A G A Benyamin, et al., 2009 Australian of European 
ancestry 
Increased serum iron, ferritin and 




HFE A G A Kullo et al., 2010 USA Elevated MCH (22) 
rs1800562 
(C282Y) 
HFE A G A Blanco-Rojo et al., 2011 Spain Reduced serum transferrin levels (13) 
rs1800562 
(C282Y) 
HFE A G A Galesloot et al., 2013 Netherlands Significantly associated with 




HFE A G A Benyamin et al., 2009 Aurtralians Reduced transferrin, raised serum 
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Study/ first author Location/ Population/ 
Ethnicity1 
Associated trait2 Reference3 
rs1800562 
(C282Y) 
HFE A G A Seiki et al., 2018 Japanese Elevated MCV, Hb (60) 
rs1800562 
(C282Y) 
HFE A G A Gordeuk et al., 2017 Multi-ethnic: USA and 
Canada 





HFE A G A De Falco et al., 2018 Italians Carriage of C282Y was higher in 





HFE A G A Sørensen et al., 2015 Denmark The G allele is associated with 




HFE A G A Whitfield et al., 2000 Australians Associated with high iron stores (11) 
rs1800562 
(C282Y) 
HFE A G A Benyamin et al., 2014 European ancestry Elevated iron, TSAT and ferritin, 




HFE A G A Li et al., 2015 USA Elevated ferritin and low TIBC (12) 
rs1800562 
(C282Y) 
HFE A G A Pichler et al., 2013 European Ancestry 
population 
Increased iron stores (17) 
rs1800562 
(C282Y) 





HFE A G A Koller et al., 2016 European-American 
(USA) 
Associated with TIBC (34) 
rs1800562 
(C282Y) 





HFE A G A McLaren et al., 2011 GWAS on Americans of 
European ancestry 
Decreased TIBC and UIBC (33) 
rs1800562 
(C282Y) 
HFE A G A Beutler et al., 2003 European ancestry Elevated Hb, TSAT, ferritin and 
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Study/ first author Location/ Population/ 
Ethnicity1 
Associated trait2 Reference3 
rs1800562 
(C282Y) 
HFE A G A Jackson et al., 2001 UK: Wales Elevated serum ferritin, TSAT 
and Hb, and reduced UIBC; 
compound heterozygotes of 
H63D and C282Y has has 
high iron stores 
(64) 
rs1830084 TF T A A Benyamin, et al., 2009 Australian of European 
ancestry 
increased transferrin (18) 
rs1830084 TF T A T Li et al., 2015 USA Elevated TIBC (12) 
rs1867504 TF A G A Gichohi-Wainaina et al., 
2016 
Kenyans, Tanzanians, S. 
Africans and African-
Americans 
Elevated ferritin levels (2) 
rs1880669 TF T C NA McLaren et al., 2012 Whites, African-
Americans, Hispanics and 
Asians (US & Canada) 




T C NA 
Constantine et al., 2009 European ancestry Reduced serum transferrin 
levels 
(27) 
rs1880669  TF 
T C 
A Piao et al., 2017 Chinese adolescents A allele is associated with 
highet sTfR 
(31) 
rs198846 HFE A G A Kullo et al., 2010 USA Elevated MCV and MCH (22) 
rs198846 HFE A G A Chambers et al.,  2009 European and Indian 
Ancestry 
The major allele (G) are 
associated with lower Hb 
concentration 
(21) 
rs2072860 TMPRSS6 G A NA Bhathia et al., 2017 India Associated with IRIDA (43) 
rs2072860 TMPRSS6 G A A Li et al., 2015 USA Elevated serum iron (12) 
rs2111833 TMPRSS6 T C T McLaren et al., 2012 Whites, African-
Americans, Hispanics and 
Asians (US & Canada) 
Increased serum iron and 







Table S2 Continued 






Study/ first author Location/ Population/ 
Ethnicity1 
Associated trait2 Reference3 
rs2111833 TMPRSS6 T C T Radio et al., 2016 Italy No significant differences in iron 
biomarkers between genotypes 
(4) 
rs2160906 TMPRSS6 A G NA Tanaka et al., 2010 Italy and USA Significantly associated with reduced 
iron status 
(57) 
rs2235321 TMPRSS6 A G A Lee et al., 2012 White Americans Decreased TSAT (38) 
rs2235321 TMPRSS6 A G A Delbini et al., 2010 Italy Associated with iron deficiency (39) 
rs2235321 TMPRSS6 A G A Poggiali et al., 2015 Italy Associated with iron deficiecy (40) 
rs2235324 TMPRSS6 G A G Lee et al., 2012 White Americans Elevated TSAT (38) 
rs2235324 TMPRSS6 G A G Beutler et al., 2010 Caucasians Associated with iron deficiency (51) 
rs2235324 TMPRSS6 G A NA Delbini et al., 2010 Italy Associated with iron deficiency (39) 
rs2235324 TMPRSS6 G A NA Tanaka et al., 2010 Italy and USA Significantly associated with reduced 
iron status 
(57) 
rs2235324 TMPRSS6 G A NA Poggiali et al., 2015 Italy Associated with iron deficiecy (40) 
rs2280673 TF A C NA Benyamin, et al., 2009 Australian of European 
decent 
Elevated transferrin, decrease TSAT 
and ferritin 
(18) 
rs228904 TMPRSS6 G A NA Tanaka et al., 2010 Italy and USA Significantly associated with elevated 
iron status 
(57) 
rs228916 TMPRSS6 C T T Benyamin et al., 2014 European ancestry Reduced serum iron (5) 
rs228918 TMPRSS6 A G C Chambers et al.,  2009 European and Indian 
Ancestry 
Associated with decreased Hb 
levels, increased sTfR and low 
serum iron 
(21) 
rs228918 TMPRSS6 A G G  Gichohi-Wainaina et al., 
2016 
Kenyans, Tanzanians, S. 
Africans and African-
Americans 
Reduced Hb (2) 
rs228921 TMPRSS6 G A G Chambers et al.,  2009 European and Indian 
Ancestry 
Associated with low iron status (21) 
rs228921 TMPRSS6 G A G Gichohi-Wainaina et al., 
2015 
South Africa Higher sTfR and lower serum iron 
levels in combination with rs228918 
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Study/ first author Location/ Population/ 
Ethnicity1 
Associated trait2 Reference3 
rs2413450 TMPRSS6 T C T Batar et al., 2018 Turkish Associated with elevated TIBC (47) 
rs2413450 TMPRSS6 
T C 
A Gichohi-Wainaina et al., 
2016 
Kenyans, Tanzanians, S. 
Africans and African-
Americans 
Reduced Hb (2) 
rs2413450 TMPRSS6 T C T Guo et al., 2016 Estonian Elevated MCH (63) 
rs2413450 TMPRSS6 T C T Ganesh et al, 2009 European ancestry Reduced MCV, MCH and HCT (53) 
rs2543519 TMPRSS6 G A NA Bhathia et al., 2017 India Associated with IRIDA (43) 
rs2543519 TMPRSS6 G A NA Delbini et al., 2010 Italians Associated with iron deficiency (39) 
rs3811647 TF 
A G A 
Benyamin, et al., 2009 Australian of European 
dancestry 
Increased transferrin (18) 
rs3811647 TF A G A Pichler et al., 2011 Italy and USA Elevated transferrin concentration (6) 
rs3811647 TF 
A G A 
Blanco-Rojo et al., 2011 Spain Elevated serum transferritin (13) 
rs3811647 TF 
A G A 
Constantine et al., 2009 European ancestry Elevated serum transferritin (27) 
rs3811647 TF 
A G A 
An et al., 2012 Han Chinese Reduced Hb, increased transferrin 
and TIBC 
(32) 
rs3811647 TF A G A Benyamin et al., 2009 Aurtralians Raised serum iron and transferrin (18) 
rs3811647 TF A G A Gichohi-Wainaina et al., 
2015 
South Africa Heterozygotes are associated with 
lower sTfR and higher iron stores; 
homozygotes of both extremes 
have similar levels of sTfR and 
body iron stores 
(35) 
rs3811647 TF A G A Li et al., 2015 USA Elevated TIBC (12) 
rs3811647 TF 
A G A 
Koller et al., 2016 European-American 
(USA) 
Associated with TIBC serum iron (34) 
rs3811647  TF 
A G A 
McLaren et al., 2011 Americans of European 
ancentry 
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Study/ first author Location/ Population/ 
Ethnicity1 
Associated trait2 Reference3 
rs3811658 TF T C NA McLaren et al., 2012 Whites, African-Americans, 
Hispanics and Asians (US & 
Canada) 





T Gichohi-Wainaina et al., 
2016 
Kenyans, Tanzanians, S. 
Africans and African-
Americans 
Increased Hb (2) 
rs3811658 TF 
T C 
NA Constantine et al., 2009 European ancestry Increased transferrin (27) 
rs4820268 TMPRSS6 G A G Benyamin, et al., 2009 Australian of European 
ancestry 
Decreased serum iron and 
TSAT 
(18) 
rs4820268 TMPRSS6 G A G Pichler et al., 2011 Italy and USA Decreased serum iron, Hb, 
MCV, MCH and ferritin; 
increased TF, sTfR and 
sTfR/ferritin index 
(6) 
rs4820268 TMPRSS6 G A G Kullo et al., 2010 USA Associated with reduced MCH 
and MCHC 
(22) 
rs4820268 TMPRSS6 G A G Constantine et al., 2009 European ancestry Lower TSAT and serum iron (27) 
rs4820268 TMPRSS6 G A NA Chambers et al.,  2009 European and Indian 
Ancestry 
Associated with decreased Hb 
levels, increased sTfR and low 
serum iron  
(21) 
rs4820268 TMPRSS6 G A NA Delbini et al., 2010 Italians Associated with iron deficiency (39) 
rs4820268 TMPRSS6 G A NA Tanaka et al., 2010 Italy and USA The C allele is significantly 
associated with increased 
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Study/ first author Location/ Population/ 
Ethnicity1 
Associated trait2 Reference3 
rs4820268 TMPRSS6 G A G An et al., 2012 Han Chinese Low Hb, serum iron, TSAT. 
Associated with the risk of IDA 
(32) 
rs4820268 TMPRSS6 G A NA Ji et al., 2018 Australia Associated with reduced ferritin 
levels 
(62) 
rs4820268 TMPRSS6 G A NA Poggiali et al., 2015 Italy Associated with iron deficiecy (40) 
rs4820268 TMPRSS6 G A NA Gan et al., 2012 Chinese Associated with low Hb and 
ferritin 
(46) 
rs4820268 TMPRSS6 G A A Li et al., 2015 USA Elevated serum iron and TSAT (12) 
rs4820268 TMPRSS6 G A G Piao et al., 2017 Chinese adolescents G alleles associated with lower 
serum ferritin 
(31) 
rs4820268 TMPRSS6 G A G Gichohi-Wainaina et al., 
2016 
Kenyans, Tanzanians, S. 
Africans and African-
Americans 
Reduced Hb (2) 
rs5756504 TMPRSS6 T C T Kullo et al., 2010 USA Elevated MCH (22) 
rs5756504 TMPRSS6 
T C 
NA Tanaka et al., 2010 Italy and USA The T allele Asscoiated with 





T Seiki et al., 2018 Japanese Associated with elevated MCV, 









NA Constantine et al., 2009 European ancestry increase serum iron and TSAT (27) 
rs5756506 TMPRSS6 C G C Seiki et al., 2018 Japanese Elevated MCH, Hb (60) 
rs5756506 TMPRSS6 
C G 
NA Batar et al., 2018 Turkey Associated with elevated Hb 
and HCT 
(47) 
rs5756512 TMPRSS6 T C  NA Bhathia et al., 2017 India Associated with IRIDA (43) 
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Study/ first author Location/ Population/ 
Ethnicity1 
Associated trait2 Reference3 
rs732756 TMPRSS6 C T  NA Bhathia et al., 2017 India Associated with IRIDA  (43) 
rs7385804 TFR2 C A C Pichler et al., 2011 Italy and USA Increased serum iron  (6) 
rs7385804 TFR2 C A C Benyamin et al., 2014 European ancestry Elevated iron, TSAT and ferritin, 
and reduced tranferrin 
 (5) 
rs7385804 TFR2 C A C Soranzo et al., 2009 Europeans and South 
Asians 
Elevated RBC  (37) 
rs7385804 TFR2 C A C An et al., 2012 Han Chinese Lower TSAT and serum iron  (32) 
rs7385804 TFR2 C A C Gichohi-Wainaina et al., 
2016 
Kenyans, Tanzanians, S. 
Africans and African-
Americans 
Increased ferritin in Kenyans  (2) 
rs744653 SLC40A1 C T T Benyamin et al., 2014 European ancestry Moderated HH via elevated 
transferrin and reduced TSAT, and 
ferritin levels 
 (5) 
rs7638018 TF G A NA McLaren et al., 2012 Whites, African-
Americans, Hispanics and 
Asians (US & Canada) 
Increased TIBC in all the 
populations 
 (30) 
rs78174698 TMPRSS6 A G NA Bhathia et al., 2017 India Associated with IRIDA   (43) 
rs8177179 TF G A A Benyamin et al., 2014 European ancestry Reduced transferrin  (5) 
rs8177248 TF T C  NA McLaren et al., 2012 Whites, African-
Americans, Hispanics and 
Asians (US & Canada) 
increased TIBC in all the 
populations 
 (30) 
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Study/ first author Location/ Population/ 
Ethnicity1 
Associated trait2 Reference3 
rs855788 TMPRSS6 
A G NA 
Tanaka et al., 2010 Italy and USA Significantly associated with 
elevated iron status 
(57) 
rs855791 TMPRSS6 A G A Lee et al., 2012 White Americans No significant assciation with 
outcome variables 
(38) 
rs855791 TMPRSS6 A G T Pei et al., 2014 Taiwan Associated with IDA; C alleles 
protective against IDA 
(50) 
rs855791 TMPRSS6 A G A Athiyarath et al., 2015 India Significantly associated with 
higher levels of serum iron 
(10) 
rs855791 TMPRSS6 A G A Kullo et al., 2010 USA Significantly associated with 
decreased MCV, MCH and 
MCHC 
(22) 
rs855791 TMPRSS6 A G A Valenti et al., 2012 Italians Lower MCV, ferritin and 
elevated hepcidin 
(58) 
rs855791 TMPRSS6 A G A Beutler et al., 2010 European ancestry Associated with iron deficiency (51) 
rs855791 TMPRSS6 A G A Pelusi et al., 2013 Italy Associated with elevated 
hepcidin; low MCV 
(52) 
rs855791 TMPRSS6 A G A Chambers et al.,  2009 European and Indian 
Ancestry 
Associated with decreased Hb 
levels, increased sTfR and low 
serum iron   
(21) 
rs855791 TMPRSS6 A G NA Bhathia et al., 2017 India Associated with IRIDA (43) 
rs855791 TMPRSS6 A G NA Delbini et al., 2010 Italy Associated with iron deficiency (39) 
rs855791 TMPRSS6 A G NA Tanaka et al., 2010 Italy and USA The A allele is significantly 
associated with increased serum 
iron and Hb, MCV, reduced 
RDW 
(57) 
rs855791 TMPRSS6 A G NA Galesloot et al., 2013 Netherlands Significantly associated with 






Table S2 continued 






Study/ first author Location/ Population/ 
Ethnicity1 
Associated trait2 Reference3 
rs855791 TMPRSS6 A G A An et al., 2012 Han Chinese Low Hb, serum iron, TSAT. 
Associated with the risk of IDA 
(32) 
rs855791 TMPRSS6 A G A Benyamin et al., 2009 Aurtralians Reduced serum iron, TSAT, ferritin, 
Hb and MCV, and raised transferrin 
(18) 
rs855791 TMPRSS6 A G A van der Harst et al., 
2012 
Europeans and South 
Asians 
Elevated MCH (54) 
rs855791 TMPRSS6 A G NA Kamatani et al., 2010 Japanese The G alleles are associated with 
elevated MCV, MCH and MCHC 
(56) 
rs855791 TMPRSS6 A G NA Batar et al., 2018 Turkey Associated with increased RBC 
count 
(47) 
rs855791 TMPRSS6 A G NA Poggiali et al., 2015 Italy Associated with low Hb, MCV and 
MCH 
(40) 
rs855791 TMPRSS6 A G NA Gan et al., 2012 Chinese Associated with low Hb and ferritin (46) 
rs855791 TMPRSS6 A G A Nai et al., 2011 USA Associated with elevated hepcidin, 
hepcidin/TSAT ratio, 
hepcidin/ferritin ratio, and low 
TSAT and serum iron 
(48) 
rs855791 TMPRSS6 A G A Cheng et al., 2014 Australia G alleles associated with higher 
serum iron and lower hepcidin at 
baseline 
(59) 
rs855791 TMPRSS6 A G NA De Falco et al., 2018 Italy Significanty associated with IDA (16) 
rs855791 TMPRSS6 A G T Sorensen et al., 2015 Denmark The T allele is associated with 
lower iron stores in men 
(8) 
rs855791 TMPRSS6 A G A Benyamin et al., 2014 European ancestry Reduced serum iron, TSAT and 
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Study/ first author Location/ Population/ 
Ethnicity1 
Associated trait2 Reference3 
rs855791 TMPRSS6 A G A Pichler et al., 2013 European Ancestry 
populations 
Protective against iron 
overload 
(17) 
rs855791 TMPRSS6 A G A Traglia et al., 2011 Italians Non-statistical significant 
increase in hepcidin/ferritin 
ratio and non-significant 
decrease in hepcidin and 
ferritin 
(45) 
rs855791 TMPRSS6 A G A Danquah et al., 2014 Rwanda Non-significantly associated 
with low Hb  
(49) 
rs855791 TMPRSS6 A G A Bedard et al., 2018 UK Associated with reduced iron 
stores 
(55) 
rs9610643 TMPRSS6 A G NA Bhathia et al., 2017 India Associated with IRIDA (43) 
rs9872999 TF C T NA Li et al., 2015 USA Reduced TIBC (12) 
 
 
Hb, haemoglobin; HCT, haematocrit; HFE, High fe; HH, hereditary hemochromatosis; IDA, iron deficiency anaemia; MCH, mean corpuscular haemoglobin; NA, not available; 
SAS, South Asians; SI, serum iron; SLC40A1, solute carrier family 40 member 1; SNP, single nucleotide polymorphism; sTfR, soluble transferrin receptor 
NA indicates SNPs that we could not establish the risk allele because it was not stated by the respective studies that reported the SNPs. 
 
1The population or the study location where the study that reported each SNP was conducted. 
2The phenotype that was reported  
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Table S3: Population Branch Statistic (PBS) values involving the comparison of 
three populations. 
 
            
  SNP PBS-AFR PBS-EUR PBS-SAS   
  rs10421768 0.001 0.003 0.000   
  rs744653 0.001 0.003 0.000   
  rs11568350 0.021 0.000 0.000   
  rs1439816 0.266 0.051 0.000   
  rs2235321 0.000 0.003 0.027   
  rs855791 0.163 0.000 0.071   
  rs78174698 0.000 0.011 0.051   
  rs5756504 0.109 0.000 0.060   
  rs5756506 0.249 0.000 0.078   
  rs4820268 0.045 0.000 0.043   
  rs2413450 0.116 0.000 0.057   
  rs2072860 0.098 0.000 0.035   
  rs9610643 0.098 0.000 0.035   
  rs855788 0.286 0.000 0.042   
  rs2543519 0.031 0.009 0.000   
  rs2111833 0.000 0.002 0.025   
  rs2235324 0.000 0.001 0.002   
  rs1421312 0.017 0.013 0.000   
  rs5756512 0.011 0.010 0.000   
  rs2160906 0.026 0.013 0.000   
  rs732756 0.017 0.012 0.000   
  rs228904 0.016 0.012 0.000   
  rs11704654 0.001 0.002 0.000   
  rs5756516 0.000 0.030 0.027   
  rs228916 0.027 0.006 0.000   
  rs228918 0.001 0.000 0.006   
  rs228921 0.001 0.000 0.006   
  rs1867504 0.089 0.000 0.009   
  rs9872999 0.000 0.029 0.026   
  rs8177179 0.000 0.024 0.022   
  rs12493168 0.047 0.019 0.000   
  rs1799852 0.034 0.000 0.017   
  rs1799899 0.033 0.005 0.000   
  rs3811658 0.093 0.000 0.021   
  rs8177248 0.130 0.000 0.024   
  rs8177253 0.032 0.000 0.014   
  rs1405023 0.040 0.000 0.013   




  rs3811647 0.042 0.000 0.014   
  rs1358024 0.125 0.000 0.033   
  rs1525892 0.014 0.000 0.010   
  rs1049296 0.032 0.000 0.028   
  rs7638018 0.071 0.000 0.019   
  rs1830084 0.093 0.000 0.019   
  rs2280673 0.000 0.010 0.027   
  rs1799945 0.043 0.043 0.000   
  rs1800562 0.001 0.020 0.000   
  rs198846 0.000 0.013 0.012   
  rs129128 0.052 0.026 0.000   
  rs7385804 0.000 0.003 0.000   
  Average 0.053 0.008 0.017   
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4.1. Abstract  
Background: Genome-wide association studies in Europeans and Asians have 
identified numerous variants in the transmembrane protease serine 6 (TMPRSS6) and 
transferrin (TF) genes that are associated with changes in iron status.  
Aims: We sought to investigate the effects of common TMPRSS6 and TF gene SNPs 
on iron status indicators in a cohort of healthy Africans from rural Gambia.  
Methods: We measured iron biomarkers and haematology traits on individuals 
participating in the Keneba Biobank with genotype data on TMPRSS6 (rs2235321, 
rs855791, rs4820268, rs2235324, rs2413450 and rs5756506) and TF (rs3811647 and 
rs1799852), n=1316. After controlling for inflammation, age and sex, we analysed the 
effects of carrying either single or multiple iron-lowering alleles on iron status.  
Results: TMPRSS6 rs2235321 was significantly associated with plasma hepcidin 
concentrations (AA genotypes having lower hepcidin levels; F ratio 3.7, P=0.014) with 
greater impact in individuals with low haemoglobin or ferritin. No 
other TMPRSS6 variant affected influenced plasma hepcidin levels. None of 
the TMPRSS6 variants nor a TMPRSS6 allele risk score affected other iron 
biomarkers or haematological traits. TF rs3811647 AA carriers had 21% higher 
transferrin (F ratio 16.0, P<0.0001), 24% higher unsaturated iron-binding capacity (F 
ratio 12.8, P<0.0001) and 25% lower transferrin saturation (TSAT) (F ratio 4.3, 
P<0.0001) compared to GG carriers. There was no association between 
either TF SNP and any haematological traits or iron biomarkers. 
Conclusions: We identified an association between TMPRSS6 rs2235321 and 
plasma hepcidin levels and replicated the previous findings on the effects of 
TF rs3811647 on transferrin and iron binding capacity. However, the effects are subtle 




including polymorphisms frequent in Africa populations, are needed to identify markers 
for genetically stratified approaches to prevention or treatment of iron deficiency 
anaemia. 
























The discovery of hepcidin and the molecular mechanisms modulating its function in 
iron metabolism have brought new insights into how iron is regulated in the human 
body 1,2. Subsequently, several genome-wide studies (GWASs) have revealed single 
nucleotide polymorphism (SNPs) in genes involved in hepcidin regulatory pathways, 
that are associated with impaired iron status 3–5. The most common SNPs associated 
with low iron status are in the TMPRSS6 gene, encoding the matriptase-2 protein 6–8. 
TMPRSS6 suppresses hepcidin synthesis, and its impaired function has been 
associated with inappropriately high hepcidin, which restricts iron absorption by the 
duodenum and iron mobilisation from storage 6,9,10. Impaired TMPRSS6 activity has 
been implicated in the development of iron-refractory iron deficiency anaemia (IRIDA) 
8.  
So far, more than 50 SNPs within the TMPRSS6 gene have been reported to be 
associated with impaired iron status. The most commonly reported SNPs are 
rs855791 and rs4820268 and rs2235321 3,4,11–14. However, most studies linking 
TMPRSS6 SNPs and low iron status were conducted in Europeans and Asians. 
Genetic variations in the TMPRSS6 gene has been linked to variations in iron status 
indicators in different populations across the world, including in India 12, Turkey 15 and 
Australia 16. 
Also, SNPs in the transferrin (TF) gene have been associated with altered iron status 
17–19. The most common TF SNP associated with the risk of iron deficiency is 
rs3811647 17,20–22. This SNP is associated with low iron status in different populations 
globally, including in African populations 23. However, little information exists on the 





Despite efforts to identify genetic risk factors for anaemia, very few such studies have 
been reported from sub-Saharan Africa. Exceptions are one study on the effects of 
TMPRSS6, TF, and  tumour necrosis factor (TNF)- alpha on iron status in Black 
South African Women 23 and a similar study on the effects of TF and TMPRSS6 SNPs 
on haematological phenotypes in four African ancestry cohorts (Kenyans, Tanzanians, 
South Africans and African Americans) 24.  To the best of our knowledge, no study has 
been done in West Africa to assess the effects of genetic variants in hepcidin and iron 
regulatory genes on low iron status. This is particularly important given that West 
Africa is one of the regions with the highest prevalence of anaemia 25. In this study, 
we investigated the association between common SNPs in the TMPRSS6 and TF 
genes, and iron indicators in healthy individuals from the rural Gambia.  
 
4.3. Subjects and Methods 
Study populations and sample collection 
This study utilised a cohort of healthy individuals, enrolled in the Keneba Biobank at 
MRCG@LSHTM 26. Based on the availability of genotype data, we studied 1316 
individuals aged 1 to 87 years (54.2% females). Each participant was interviewed and 
had a basic health examination, and those with significant health conditions excluded. 
After an overnight fast, a venous blood sample was collected in EDTA and lithium 
heparin tubes. DNA was extracted from cell pellets using standard procedures and 
stored at -70oC. Plasma samples from lithium heparin anticoagulant were stored at -








Full blood count (FBC) was performed within 4 hours of sample collection using a 
Medonic M-Series automated haematology analyser (Boule Medical, Sweden) and 
results analysed for haemoglobin (Hb), mean corpuscular volume (MCV), mean 
corpuscular haemoglobin (MCH), mean corpuscular Hb concentration (MCHC), red 
cell distribution width (RDW), red blood cell number (RBC) and haematocrit (Hct). 
 
Biomarker measurements 
Iron biomarkers [serum iron, transferrin, ferritin, unsaturated iron-binding capacity 
(UIBC), soluble transferrin receptor (sTfR) and the inflammation marker C-reactive 
protein (CRP)] were measured using an automated biochemistry analyser (COBAS 
Integra 400 Plus; Roche Diagnostics). For all the biochemistry analysis, a single 500µl 
plasma aliquot was used to measure all the iron parameters. The analyser was 
calibrated using commercial calibrators for each parameter. Also, to ensure quality 
and reliable results, commercially available standards were analysed alongside the 
samples. Haemolysed samples are excluded from the analysis.  Plasma total iron-
binding capacity (TIBC) and transferrin saturation (TSAT) were calculated from UIBC 
and plasma iron (TIBC =  plasma iron + UIBC) and TSAT= [plasma iron/TIBC] X 100).  
 
Hepcidin quantification 
Plasma hepcidin was quantified using a competitive ELISA (Bachem Hepcidin-25 
[human], EIA kit; Peninsula Laboratories International), with a detection range of 
0.049–25 ng/mL, as previously described 27. Hepcidin was measured in duplicates and 
the mean of the two reads was calculated. Samples with a coefficient of variation (CV) 




using a MultiskanTM FC Microplate Photometer (Thermofisher Scientific). 
Concentrations were interpolated from a 4-parameter curve fitted from a 2-fold, 10-
point serial dilution made from a manufacturer-provided standard peptide. The 
concentrations were calculated using the SkanIt Software (Thermofisher Scientific). 
Samples outside the standard curve were re-analyzed at a higher dilution, and the 
final concentration was calculated based on the dilution factor. 
 
Genotyping 
This study population was genotyped using the Illumina Infinium 240K Human Exome 
Beadchip (v1.0 and v1.1), as previously described 28, in which 848 SNPs were 
genotyped. Genotype calling was performed using data-driven clustering (Genome 
Studio, Illumina, CA, USA). The TMPRSS6 rs2235321, rs855791, rs4820268, 
rs2235324, rs2413450 and rs5756506, and TF rs3811647 and rs1799852 were 
selected for inclusion in this study based on their previously published association with 
iron status.  
Genotype combinations and allele risk scores 
For both the TMPRSS6 and TF SNPs, we generated genotype combinations and allele 
risk scores (ARS) by summing up the genotypes and the number of risk alleles 
respectively, from all the SNPs an individual carried. Risk alleles were defined as the 
alleles that are previously reported to be associated with low iron at each SNP. For 
each SNP, genotypes were assigned 0,1 or 2, with risk alleles assigned 1 and the 
alternate allele assigned 0. Thus, homozygous for the risk allele scored 2 and 
homozygous for non-risk alleles were scored 0, Table S1 (TMPRSS6 SNPs) and 




A total of 94 genotype combinations from the six TMPRSS6 SNPs were found in our 
population (Table S3). We investigated the effects of individual TMPRSS6 and TF 
SNPs on all the iron biomarkers and haematology phenotypes. In addition, based on 
the functional role of TMPRSS6 on hepcidin regulation, and its effects on iron status, 
we investigated the effects of TMPRSS6 ARS on hepcidin. Similarly, we assessed the 
effects of TF SNPs’ genotype combinations and TF ARS on transferrin level.  
 
Statistical analysis 
The effects of genetic variants (genotypes of single SNPs or combinations of multiple 
SNPs) on iron biomarkers were determined by linear modelling with iron and 
haematological traits as response variables and genotype as dependent variables. 
Age, sex, inflammation (CRP) were added as covariates where indicated. We tested 
the effects each SNP individually and in combinations on iron biomarkers. Hepcidin, 
ferritin and CRP were log transformed. We added log ferritin as a covariate when 
analysing the effects of genotype on plasma hepcidin because TMPRSS6 modulates 
the interaction between iron status and hepcidin gene expression. Furthermore, we 
stratified the study population based on haemoglobin and ferritin levels and 
determined the effects of genotype on each sub-population. For each sub-population, 
we used analysis of variance (ANOVA) to determine the effects of individual SNPs on 
iron biomarkers. Bonferroni correction was applied to account for multiple testing. The 
statistical analyses were conducted using R statistical software 29 and DataDesk 






The study was approved by the MRCG@LSHTM / Gambia Government Ethics 
Committee (SCC1185). A written informed consent was obtained from each study 
participant.  
4.4. Results 
Baseline characteristics of the study population are presented in Table 1. Due mostly 
to out-migration of males there was a slight sex bias (54.2% were female). There were 
significant differences between the sexes in age, RBC count and RBC indices, serum 
iron and transferrin.  
Table 2. Demographic characteristics of the study population 
Variables All (n=1316)  Males (n=595) Female (n=721) P-value 
Age, median 
(range) 
9 (1, 87) 11.5 (1, 79) 19.7 (1, 87) 0.000 
Gender, M/F (%)  45.8/54.2  - - -  
Hb (g/dl) 11.6 (6.5, 16.0) 11.6 (8.2, 16.0) 11.6 (6.5, 15.3) 0.056 
RBC (x10^12) 4.20 (2.41, 5.62) 4.30 (2.90, 5.61) 4.21 (2.41, 5.65) 0.000 
MCV (fl) 78.9 (51.3, 103.2) 78.2 (51.3, 103.2) 79.6 (52.7, 97.9) 0.000 
Haematocrit (%) 33.0 (20.1, 48.10) 32.9 (24.3, 48.1) 33.1 (20.1, 44.9) 0.374 
RDW (%) 14.6 (12.7, 27.4) 14.6 (12.8, 24.0) 14.5 (12.7, 27.4) 0.320 
MCH (pg) 27.6 (16.2, 34.9) 27.4 (16.2, 34.2) 27.9 (17.3, 34.9) 0.005 
MCHC (g/dl) 34.9 (28.9, 37.2) 35.1 (29.9, 37.2) 34.8 (28.9, 37.1) 0.024 
Serum iron 
(umol/l) 
12.15 (0.60, 52.40) 11.85 (1.7, 28.9) 12.50 (0.6, 52.4) 0.005 
Hepcidin (ng/ml) 8.86 (0.11, 103.78) 8.70 (0.17, 94.64) 9.00 (0.11, 103.78) 0.780 
TSAT (%) 20.73 (2.84, 75.72) 20.07 (2.84, 57.51) 21.42 (4.31, 75.72) 0.114 
Transferrin (g/l) 2.75 (0.01, 4.77) 2.74 (0.00, 4.21) 2.77 (0.00, 4.77) 0.009 
TIBC (umol/l) 60.4 (1.4, 129.3) 60.0 (20.5, 129.3) 60.8 (1.4, 123.0) 0.028 
UIBC (umol/l) 47.3 (0.8, 120.8) 47.3 (11.8, 120.8) 47.2 (0.8, 113.4) 0.642 
Ferritin (ug/l) 26.9 (0.10 (166.8) 27.7 (0.2, 161.7) 25.3 (0.1, 166.8) 0.063 




CRP (mg/l) 1.19 (0.0, 40.26) 1.11 (0.00, 40.26) 1.23 (0.00, 32.24) 0.083 
Data are presented in median (ranges), except gender.  
CRP, C-reactive protein; Hb, haemoglobin; MCV. Mean corpuscular volume; MCH, mean 
corpuscular haemoglobin; MCHC, mean corpuscular Hb concentration; RDW, red cell 
distribution width; RBC, red blood cells; ; sTfR, soluble transferrin receptor; TIBC, total iron-




All the SNPs investigated were in Hardy-Weinberg Equilibrium. Also, all were in low 
linkage disequilibrium (LD) in this study population, except rs4820268 and rs2413450 
which have r2=0.7 (Figure 1). Among the SNPs we investigated, TMPRSS6 
rs2235324 had the highest minor allele frequency (MAF) in our study population 
(45%), and TMPRSS6 rs855791 and TF rs1799852 had the lowest MAF (7% each) 28. 
There was no detectable influence of sex on any associations, so sex was discarded 
from the models. None of the TMPRSS6 SNPs studied showed any association with 
any of the iron status markers (ferritin, serum iron, transferrin, TSAT, sTfR, TIBC or 
UIBC) or haematological variables (Hb, MCV, MCH, MCHC, RDW, RBC or Hct) or 
with CRP. However, hepcidin levels varied significantly by rs2235321 genotype 
(Figure 2A) with lower hepcidin in the AA homozygotes, 19% than GG carriers (F ratio 
3.70, P=0.014). Note that Bonferroni correction for having analysed 6 SNPs would 
render the rs2235321 of marginal significance. These trends were stronger in subjects 
with lower Hb (Figure 2B) and lower ferritin levels (Figures 2C). The other SNPs had 
no detectable influence on hepcidin. 
Despite the lack of significant association with 5 of the 6 SNPs, we investigated 
whether allele risk score (ARS) was a significant predictor of hepcidin by using 
published data on the direction of association to allocate a score of 0, 1 or 2 to allele 










The two TF SNPs were also tested in combination and individually. Rs1799852 
showed no association with any outcomes. However, rs3811647 was strongly 
associated with transferrin levels (Figure 4A) with or without the inclusion of sex and 
age as co-variables (F ratio 16.0, P<0.0001). There was an apparent allele dose effect 
with AA homozygotes having 21% higher transferrin than GG. TIBC (partially 
computed from transferrin) was similarly affected with a 16% higher value for the AA 
genotype (F ratio 14.0, P<0.0001). UIBC, which is directly measured rather than 
computed, showed the same pattern (Figure 4B) with 24% higher values in individuals 
carrying AA (F ratio 12.8, P<0.0001). Serum iron was not significantly associated with 
the rs3811647 genotype. So, on account of the raised TIBC and transferrin, TSAT was 
lower in the AA group (by 25%, with a single allele effect of 12.5%) (F ratio 4.3, 
P<0.0001) (Figure 4C). The transferrin, UIBC and TSAT associations were robust 
when we separated the subjects into above and below the median ferritin value 
(Figures 4A, B & C). None of the other iron markers was affected nor was there any 









Based upon prior GWAS studies, pathway analysis, availability on the Illumina Exome 
Array, and having a high minor allele frequency in our Gambian population we studied 
the effect of six candidate SNPs in TMPRSS6 and two in TF on multiple indices of iron 
and haematological status in 1316 individuals from 1 to 87 years age, from the Keneba 
Biobank at the MRCG @ LSHTM, in the Gambia. We found weak evidence that one 
TMPRSS6 SNP (rs2235321) had lower hepcidin levels in the variant (AA) 
homozygotes with an indication of an allele dose effect. One TF variant (rs3811647) 
showed increased serum transferrin levels, TIBC and UIBC levels in the AA 
homozygotes and lower levels of TSAT. 
In this population, none of the other variants was significantly associated with any of 
the iron, haematological, hepcidin or inflammation markers. Applying an allele risk 
score approach to the 6 TMPRSS6 variants also yielded no detectable association 
with any outcomes. 
In a separate recall-by-genotype (RbG) study within adults in this same populations, 
we have assessed fasting hepcidin levels together with iron absorption and changes 
in plasma hepcidin at two and five hours after an oral dose of 130 mg elemental iron 
as ferrous sulphate (Jallow et al., in preparation). We recruited individuals 
homozygous for the variant forms of rs2235321 (n=35) and rs4820268 (n=29) from a 
panel of 1695 pre-genotyped individuals and compared them to individuals that are 
wildtype for all of the three variants (n=39). There were no individuals homozygous for 
the variant allele of rs855791, so we compared heterozygotes (n=28) against the 
reference group. As in the current study, carriers of the rs2235321 GG genotype had 
higher fasting hepcidin than AA (GG vs AA, 9.50 vs 6.60ng/ml, p = 0.035). But contrary 




3.27ng/mL, p=0.002) and a difference between heterozygotes and wildtype for 
rs855791 (GG vs AG, 9.50 vs 4.96ng/mL, p=0.015). These differences are likely 
because subjects in the reference group of our recall-by-genotype study were selected 
as being wildtype at all three SNPs. 
Most previous research on the effects of our candidate SNPs were conducted in non-
African populations, and there is no prior data on West Africans. The associations we 
observed differ from results obtained in other populations. TMPRSS6 rs855791 is a 
non-synonymous SNP that has been widely reported to influence iron parameters and 
to be associated with the risk of IDA in Europeans 14,19 and Asians 12,30. We found no 
such associations.  
The TMPRSS6 rs2235321 is a synonymous variant which has been reported to 
associate with benign microcytic anaemia 31. We did not find any other reported 
associations. Our data confirm a null effect on hepcidin even in a population with high 
levels of anaemia and low iron status. A meta-analysis of GWAS on the genetic 
determinants of hepcidin did not identify any TMPRSS6 SNP that is significantly 
associated with hepcidin concentration 13. It is important to notice that our candidate 
gene approach demonstrated a relatively small effect of TMPRSS6 rs2235321 on 
hepcidin (single allele effect of 9.5%), and this needs to be considered when designing 
GWAS.  
TF rs3811647 is an intron variant on the transferrin gene with extensive prior evidence 
for functional effects. In discovery and replication GWAS analyses of cohorts from Italy 
and the USA, Pichler et al. 32 confirmed the association between rs3811647 and 
transferrin levels. In a subsequent GWAS analysis, Mclaren et al. 19 showed that TF 
rs3811647 is associated with elevated serum TIBC. Also, Blanco-Rojo et al. 21 




Previously, Benyamin et al. showed that three variants in TF (rs3811647, rs1799852 
and rs2280673) plus the HFE C282Y mutation explained ∼40% of genetic variation in 
serum transferrin (p = 7.8 × 10−25) 17. Our data are suggestive of an allele dose-
response relationship with a single allele effect of 9.5% for transferrin levels (higher 
with the A variant) and a reverse effect of about 12.5% for TSAT. 
Other investigators have reported associations between the TF rs1799852 and iron 
status. In a study of female black South Africans, Gichohi and colleagues reported 
that heterozygotes at TF rs1799852 (AG) had lower iron status (low serum ferritin and 
body iron, and higher sTfR concentrations) than the homozygotes (AA) 23. This 
suggested that rs1799852 AA might be protective against low iron status. Similarly, 
Benyamin and colleagues reported that the TF rs1799852 was associated with lower 
transferrin concentration and the risk of haemochromatosis 33. Furthermore, Blanco-
Rojo and colleagues 18 reported that the TF rs1799852 A allele was associated with 
low serum transferrin concentration, and it compensated for the effect of rs3811647 A 
allele on the risk of IDA. The authors further suggested that carrying TF rs3811467 G 
allele simultaneously with rs1799852 A allele and HFE C282Y and H63D might be 
protective against low iron status as they increase the susceptibility to iron overload 
18. In the present study, we could not include the HFE C282Y and H63D variants, 
because their MAF in Gambians is extremely low (0.4% and 0% respectively) 34. Our 
failure to replicate the prior findings for rs1799852 may be ascribed to the fact that we 
had only nine individuals homozygous for the A allele. However, in contrast to the 
South African data 23 , we also found no evidence for differences in any of the iron 
markers between rs1799852 GG (n=854) and AG (n=117). 
This study has strengths and weaknesses. We used highly standardised laboratory 




hepcidin and CRP. The sample size was large in the context of candidate gene 
studies, and we spanned the age range 1-87y (with appropriate adjustment for age 
and sex in the analyses). The population generally has marginal iron status and high 
levels of anaemia which might better expose underlying genetic effects. We were 
limited to the six TMPRSS6 and two TF SNPs available on the exome chip. By 
definition, these SNPs had been curated onto the chip because of prior evidence of 
functionality. A limitation is that for some of the SNPs (notably rs1799852 discussed 
above) we had very few individuals homozygous for the variant allele.  
In conducting this study, our initial objective was to explore whether common genetic 
variants in iron regulatory pathways might have a significant influence on the risk of 
iron deficiency and iron-deficiency anaemia in African populations. The objective was 
to provide evidence to inform actionable therapeutic or preventive approaches based 
on genetic screening. Despite selecting the variants with some strong prior evidence 
of functionality, our data indicate that such a stratified medicine approach would not 
be warranted at least in African population. Even where we observed associations 
(effects of TMPRSS6 rs2235321 on plasma hepcidin, and TF rs3811647 on iron 
transporting capacity and TSAT), the single allele effect sizes approximated 10%, and 
there were few people homozygous for the variant allele. Furthermore, there may be 
inherent compensatory mechanisms because none of the variants had any effect on 
other markers of iron or haematological status. In summary, the overall population 
attributable risk conferred by these known genetic factors is negligible. As these 
variants were mainly studied in European and Asian populations, it is possible that 
other genetic variants in these genes will be more informative for iron studies in African 
populations, and this needs to be addressed to develop genetically stratified 
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4.9. Figure legends 
Fig 1 Linkage disequilibrium analysis between SNPs investigated in this study 
Fig 2 Influence of TMPRSS6 rs2235321 on plasma hepcidin levels 
A. All data (GG n=416, GA n=586, AA n=262). ANOVA P for trend = 0.004. 
B. Sample divided into high and low Hb (<11.5g/dL). High Hb (GG n=245, GA 
n=344, AA n=162). ANOVA P for trend = 0.02. Low Hb (GG n=171, GA 
n=242, AA n=100). ANOVA P for trend = 0.0002. 
C. Sample divided above and below median ferritin (<26ng/ml). High ferritin 
(GG n=247, GA n=313, AA n=155). ANOVA P for trend = 0.0004. Low ferritin 
(GG n=169, GA n=273, AA n=107). ANOVA P for trend = NS. 
 
Fig 3 Influence of TMPRSS6 allele risk score on plasma hepcidin 
 Error bars = standard errors (SE) 
 
Fig 4 Influence of TF rs3811647 and rs1799852 on plasma iron binding capacity 
and TSAT 
A. Transferrin rs3811647 All data (GG n=720, GA n=215, AA n=24). ANOVA 
P for trend <0.0001. Sample divided above and below median ferritin 
(<26.9ng/ml). High ferritin (GG n=360, GA n=108, AA n=15). ANOVA P for 
trend <0.0001. Low ferritin (GG n=360, GA n=107, AA n=11). ANOVA P for 
trend = <0.0001. rs1799852 All data (GG n=839, GA n=116, AA n=4). 
ANOVA P for trend = NS. 
B. UIBC rs3811647 All data (GG n=985, GA n=301, AA n=28). ANOVA P for 
trend <0.0001. Sample divided above and below median ferritin (<26ng/ml). 




Low ferritin (GG n=511, GA n=154, AA n=12). ANOVA P for trend < 0.0001. 
rs1799852 All data (GG n=1139, GA n=116, AA n=9). ANOVA P for trend = 
NS. 
C. TSAT rs3811647 All data (GG n=720, GA n=215, AA n=24). ANOVA P for 
trend < 0.0001. Sample divided above and below median ferritin (<26ng/ml). 
High ferritin (GG n=360, GA n=108, AA n=15). ANOVA P for trend < 0.0001. 
Low ferritin (GG n=360, GA n=107, AA n=11). ANOVA P for trend < 0.0001. 
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4.11. Supplemental Data 
Association of common TMPRSS6 and TF gene variants with hepcidin and iron status 
in healthy rural Gambians. 
 
Momodou W. Jallow, Susana Campino, Andrew M. Prentice and Carla Cerami 
 
Supplemental information  
 
Supplemental Table S1. Allele configuration of the allele risk score from the 6 TMPRSS6 
SNPs 
SNP rs2235321 rs855791 rs4820268 rs2235324 rs2413450 rs5756506 Total 
Risk 
score 
major/minor G/A G/A A/G A/G G/A G/C  
Risk allele* A A A G G C  




A/A (2) A/A (2) A/A (2) G/G (2) G/G (2) C/C (2) 12 
normal group G/G (2) G/G (0) G/G (0) A/A (0) A/A (0) G/G (0) 0 
 
ARS, allele risk score 
 
* Allele linked to low iron status from the previously-published studies 




Supplemental Table S2. Details of the allele configuration for the allele risk score from the 2 
TF SNPs 
SNP rs1799852 rs3811647 Genotype combination ARS N 
major/minor G/A G/A      
Risk allele* G A      
WT/WT GG GG GG/GG 2 825 
Het/Het AG AG AG/AG 2 10 
Homo/Homo AA AA AA/AA 2 0 
WT/Homo GG AA GG/AA 4 27 
Homo/WT AA GG AA/GG 0 9 
Het/WT AG GG AG/GG 1 154 
WT/Het GG AG GG/AG 3 290 
Het/Homo AG AA AG/AA 3 1 





* Allele linked to low iron status from previously-published studies; bolded letters indicates risk 
alleles 
 
Supplemental Table S3. A list of all the 94 genotype combinations generated from 
the 6 TMPRSS6 SNPs 
 
Genotype group N TMPRSS6 SNP ARS 
GG/GG/GG/AA/AA/GG 18 0 
GG/GG/GG/AA/AG/GG 16 1 
GG/GG/GG/GA/AA/GG 10 1 
GG/GG/GA/AA/AG/GG  26 2 
GG/GG/GG/GA/AG/GG 20 2 
AG/GG/GG/AA/AG/GG 4 2 
AG/GG/GG/GA/AA/GG 4 2 
GG/AG/GG/AA/AA/CG 3 2 
GG/GG/GG/GG/AA/GG 3 2 
GG/GG/GG/GG/AA/GG 2 2 
GG/GG/GG/AA/GG/GG 1 2 
GG/GG/GG/GA/AA/CG  1 2 
AG/GG/GA/AA/AG/GG 72 3 
GG/GG/GA/AA/AG/CG 16 3 
GG/GG/GA/AA/GG/GG 16 3 
GG/GG/GA/GA/AG/GG 12 3 
AA/GG/GG/AA/AG/GG 1 3 
AG/GG/GA/NA/AG/NA 1 3 
AG/GG/GG/GA/AG/GG 1 3 
GG/AG/GA/AA/AG/GG 1 3 
GG/AG/GG/GA/AA/CG 1 3 
AG/GG/GA/GA/AG/GG 81 4 
GG/GG/GA/GA/AG/CG 52 4 
 AG/GG/GA/AA/GG/GG 29 4 
GG/AG/GA/GA/AG/GG 20 4 
GG/GG/AA/AA/GG/GG 14 4 
GG/GG/GA/GA/GG/GG 9 4 
GG/GG/GA/AA/GG/CG 6 4 
AG/AG/GG/AA/AG/CG 2 4 
AG/GG/GG/GA/GG/GG 2 4 
GG/GG/GA/GG/AG/GG 2 4 
GG/GG/GG/GG/GG/GG 2 4 
AA/GG/GA/AA/AG/GG 1 4 








Supplemental Table S3 cont. 
 
Genotype group N TMPRSS6 SNP ARS 
AG/GG/AA/AA/GG/GG 42 5 
AG/GG/GA/GA/GG/GG 42 5 
GG/GG/GA/GA/GG/CG 25 5 
AG/GG/GA/GG/AG/GG 16 5 
GG/GG/GA/GG/AG/CG 8 5 
GG/GG/AA/GA/GG/GG 7 5 
AA/GG/GA/AA/GG/GG  5 5 
 AG/AG/GA/AA/AG/CG 5 5 
GG/AG/GA/GA/AG/CG 5 5 
GG/GG/AA/AA/GG/CG 5 5 
GG/AG/GA/GA/GG/GG 4 5 
AA/GG/GA/GA/AG/GG 3 5 
AG/GG/GA/AA/GG/CG 3 5 
GG/GG/GA/GG/GG/GG 2 5 
AG/AG/GA/GA/AG/GG 1 5 
AG/GG/GA/GA/AG/CG 1 5 
GG/AG/AA/AA/GG/GG 1 5 
GG/AG/GA/AA/AG/CC 1 5 
NA/GG/AA/GA/GG/GG 1 5 
AA/GG/AA/AA/GG/GG 75 6 
AG/GG/AA/GA/GG/GG 56 6 
AG/GG/AA/AA/GG/CG 24 6 
GG/GG/AA/GA/GG/CG  20 6 
GG/AG/AA/GA/GG/GG 19 6 
AG/GG/GA/GG/GG/GG  16 6 
AA/GG/GA/GA/GG/GG 12 6 
GG/GG/GA/GG/GG/CG 7 6 
GG/AG/GA/GG/GG/GG 5 6 
AA/GG/GA/GG/AG/GG 4 6 
AG/AG/GA/GA/AG/CG 3 6 
AG/GG/GA/GA/GG/CG 2 6 
GG/AG/GA/GA/GG/CG 2 6 
GG/GG/AA/AA/GG/CC 2 6 
AG/AG/GA/GA/GG/GG  1 6 







Supplemental Table S3 cont. 
 
Genotype group N TMPRSS6 SNP ARS 
GG/AG/GA/GA/AG/CC  1 6 
GG/GG/AA/GG/GG/GG 1 6 
NA/GG/AA/GA/GG/CG 1 6 
AA/GG/AA/GA/GG/GG 123 7 
AG/GG/AA/GA/GG/CG 62 7 
AG/AG/AA/GA/GG/GG  32 7 
AG/GG/AA/GG/GG/GG 19 7 
GG/GG/AA/GA/GG/CC 8 7 
GG/GG/AA/GG/GG/CG 6 7 
GG/AG/AA/GA/GG/CG 4 7 
GG/AG/AA/GG/GG/GG 2 7 
AG/GG/AA/GG/GG/CG 50 8 
AA/GG/AA/GG/GG/GG 46 8 
AG/AG/AA/GG/GG/GG 30 8 
GG/GG/AA/GG/GG/CC 14 8 
GG/AG/AA/GG/GG/CG 13 8 
 AG/AG/AA/GA/GG/CG 6 8 
GG/AG/GA/GG/AG/GG 6 8 
GG/AA/AA/GG/GG/GG 1 8 
GG/AG/AA/GG/GG/CC 6 9 
AG/AG/AA/GG/GG/CG 2 9 
AG/GG/AA/GG/GG/CC  2 9 
AA/GG/AA/GG/GG/CG 1 9 
GG/AA/AA/GG/GG/CG 1 9 
GG/AA/AA/GG/GG/CC  3 10 
 
Abbreviations: ARS, allele risk score 
Legend: NA, genotypes that were not available for that particular SNP in the 
combination. 
















Supplemental Table S4. The effects of TMPRSS6 allele risk score on hepcidin, 






Std. error Beta P-value 
0 18 13.4 3.66 Reference group 
1 26 8.6 4.48 -4.80 0.285 
2 61 10.8 3.89 -2.64 0.498 
3 123 11.7 3.66 -1.68 0.645 
4 221 10.9 3.55 -2.49 0.483 
5 185 9.0 3.58 -4.39 0.220 
6 253 9.2 3.54 -4.26 0.229 
7 254 10.4 3.54 -3.04 0.390 
8 160 9.8 3.61 -3.61 0.317 
9 12 13.6 5.41 0.16 0.977 
10 3 3.5 9.04 -9.96 0.270 
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Background: The role of genetic determinants in mediating iron status in Africans is 
not fully understood. Genome-wide association studies in non-African populations 
have revealed genetic variants in the TMPRSS6 gene that are associated with the risk 
of anemia.  
Objectives: To investigated the effects of risk alleles for low iron status from 
TMPRSS6 rs2235321, rs855791 and rs4820268, on responses to oral iron in healthy 
Gambian adults.  
Methods: Using a recall-by-genotype design, participants were selected from a pre-
genotype cohort of 3000 individuals in the Keneba Biobank (MRCG at LSHTM). 
Participants were invited to participate in the study based on nine genotype 
combinations obtained from three TMPRSS6 SNPs (rs2235321, rs855791 and 
rs4820268). The participants fasted overnight and then ingested a single oral dose of 
ferrous sulfate (130 mg elemental iron). Blood samples were collected prior to iron 
ingestion and at 2 and 5 hours after the oral iron dose. The effects of genotype on 
hepcidin and plasma iron parameters were assessed.  
Results: A total of 251 individuals were enrolled. Homozygous carriers of the major 
TMPRSS6 alleles at each of the SNPs had higher plasma hepcidin at baseline 
(rs2235321: GG vs AA 9.50 vs 6.60ng/ml, p = 0.035; rs855791: GG vs AG = 9.50 vs 
4.96ng/mL, p=0.015; rs4820268: AA vs GG = 9.50 vs 3.27ng/mL, p=0.002) and at 
subsequent timepoints. There were no differences in delta plasma iron (a proxy for 
iron absorption) between genotypes. In most subjects, hepcidin levels increased 
following iron ingestion (overall group mean = 4.98±0.98ng/ml at 5h, p<0.001), but 
double heterozygotes at rs2235321 and rs855791 showed no increase 




Conclusions: This study revealed that common TMPRSS6 variants influence 
hepcidin concentrations, but not iron status indicators either at baseline or following a 
large oral dose of iron. These results suggest that genetic variations in the TMPRSS6 
gene are unlikely to be important contributors to variations in iron status in Africans. 
This study was registered at ClinicalTrials.gov # NCT03341338. 
 























Iron supplementation remains the dominant strategy for the prevention and treatment 
of anemia (1,2). However, despite decades of implementing this measure together 
with food-based approaches, the prevalence of anemia remains high particularly 
among children and women of reproductive age living in low- and middle-income 
countries (LMICs) (3). 
Matriptase-2 protein encoded by the transmembrane protease serine 6 (TMPRSS6) 
gene is a negetive regulator of hepcidin, the regulator of iron metabolism (4). Hepcidin 
blocks the release of intracellular iron by downregulating ferroportin, the only known 
mammalian cellular iron transporter (5). These effects are especially pronounced in 
enterocytes and in macrophages and thus elevated hepcidin is associated with 
impaired duodenal iron absorption and impaired recycling of aged red blood cells (5). 
Single nucleotide polymorphisms (SNPs) in TMPRSS6 can lead to decreased function 
or inactivation of matriptase-2, thus impairing its suppression of hepcidin (HAMP) gene 
expression (6). This leads to inappropriately elevated hepcidin which, by blocking iron 
absoption and recycling, promotes the risk of iron deficiency and anemia (7). Genome-
wide association studies (GWAS) have revealed numerous common SNPs in 
TMPRSS6 that are linked to an increased risk of iron deficiency anemia (IDA) (8).  
Three single nucleotide polymorphims (rs855791, rs2235321 and rs4820268) have 
been reported to be associated with low iron status, but mainly in non-African 
populations (9–12). However, the effects of these SNPs on the response to iron 
supplementation have not previously been described in Africans. The minor allele 
frequency (MAF) of these SNPs in Africans in the 1000 Genomes project are 10%, 




TMPRSS6 rs855791 is a non-synonymous SNP that alters matriptase 2 protein (14), 
but rs2235321 and rs4820268 are synonymous variants whose direct effect are not 
clear (15). Although synonymous changes were previously not though to directly affect 
phenotype, recent findings show that they can affect protein folding and splicing (16). 
In Caucasians, rs855791 is reported to be in high linkage disequilibrium (LD) with 
rs4820268 and rs2235321 (9,11), and is in high LD with rs4820268 in Asians (17). 
However, low LD has been observed between these SNPs in the Africans included in 
the 1000 Genomes project and in Gambians (18). 
In this study, we sought to assess the effects of the three common TMPRSS6 SNPs, 
either individually or combined, on the response to a high dose of oral iron in healthy 
Gambian adults. 
 
6.3. Materials and Methods 
Study Design 
The full details of the study design were published in the study protocol (19), and the 
study was registered at ClinicalTrials.gov (NCT03341338). Using a recall-by-genotype 
approach, participants were enrolled based on their TMPRSS6 rs2235321 
(MAF=43%), rs855791 (MAF=7%) and rs4820248 (MAF=27%) genotypes. We 
selected participants from the Keneba BioBank at MRCG@LSHTM, which contained 
3116 pre-genotyped participants. Out of these 3116 individuals, n=1695 met the 
criteria for for inclusion in the present study, Figure 1. 
 
Genotyping 
BioBank participants were previously genotyped using the Infinium 240k Human 




data-driven clustering (Genome Studio, Illumina, CA, USA). The TMPRSS6 
rs2235321, rs855791 and rs4820268 SNPs were selected based on their previously 
published associations with measures of iron status.  
 
Genotype combinations 
We constructed genotype combinations for each participant from the three candidate 
TMPRSS6 SNPs. This generated a total of 17 genotype combinations, Table 1. Only 
nine of these combinations had a sufficient number of individuals to perform grouped 
analysis. We focused on genotype groups that contained more than 95 individuals.  
 
Participant selection 
Participants were selected based on the combinations obtained from combining the 3 
possible genotypes for each of the three TMPRSS6 SNPs studied (Figure 1). 
Individuals were invited to participate if they were between 18 and 50 years of age. 
Women were excluded if they were breastfeeding or pregnant. Also, individuals who 
reported to be unwell and those with severe anemia (Hb<7g/dl) were excluded. 
Individuals that tested positive for malaria were to be excluded but there were none.  
 
Study procedures 
Contact details for the potential participants were retrieved from the Kiang West 
Demographic Database (20). A field worker initially contacted each participant in 
person or by telephone. Individuals who agreed to participate provided written 
informed consent (see below) and were invited to the study sites at MRCG Keneba or 




A baseline blood sample (3mL, 2.5mL in lithium heparin and 0.5mL in EDTA tubes) 
was taken following an overnight fast. Thereafter, a single dose of 400mg (2x 200mg) 
ferrous sulphate oral iron, containing 130mg elemental iron, was given by a study 
nurse. The choice of 400 mg ferrous sulphate was based on the studies by Hwang et 
al., 2011 23 which assessed the effects of a high dose of oral iron (650 mg ferrous 
sulphate) on hepcidin and Nai et al. 2011 18 which examined the effects of TMPRSS6 
rs855791 on the response to an oral iron dose. However, we reduced the 650 mg 
ferrous dose to 400 mg, to minimise the iron overload. The high dose was used to 
elicit a transient plasma iron overload.  
Participants were observed to ensure that the supplements were taken and the time 
of ingestion was recorded. Participants were asked to stay at the study site, and blood 
samples (2.5mL lithium heparin tubes, at each timepoint) were taken at 2- and 5-hours 
following iron supplementation. In addition, the weight and height of each participant 
to enable calculation of body mass index (BMI), and body temperature to assess 
possible fever, were measured. Plasma iron at the five hour post iron ingestion sample 
was used as the primary outcome variable and as a proxy for iron absorption. 
Differences in hepcidin concentration between genotypes was a secondary outcome. 
 
Laboratory procedures 
Full blood count (FBC) (Medonic M-Series, Boule Medical, Sweden), malaria rapid test 
(SD BioLine Malaria Antigen Pf, Standard Diagnostics Inc., Republic of Korea), 
sickling test (sodium metabisulphide method and Hb electrophoresis for confirmation 
of Hb genotype for positive samples) and G6PD screening (G6PD Hb+ R&D 
Diagnostics) were performed on the EDTA sample. The lithium heparin samples were 




unsaturated iron binding capacity (UIBC), soluble transferrin receptor (sTfR), C-
reactive protein (CRP) and alpha-1-glycoprotein (AGP) were measured using an 
automated biochemistry analyser (Cobas Integra 400 Plus, Roche Diagnostics). Total 
iron binding capacity (TIBC) and transferrin saturation (TSAT) were calculated from 
UIBC and iron (TIBC = UIBC+iron and TSAT = [iron/TIBC]*100). For all the 
biochemistry analysis, the analyser was calibrated using commercial calibrators and 
controls were analysed for each parameter.  
Hepcidin was quantified using a commercial enzyme-linked immunosorbent assay 
(ELISA) (DRG Instruments GmbH, Germany) according to manufacturer’s protocol. 
To ensure quality of the results, two manufacturer-supplied controls (high and low 
controls) were analysed alongside the samples in each ELISA plate.  
 
Statistical analysis 
Student’s t-test and the Wilcoxon test were used to determine the differences in iron 
biomarkers between sexes for non-skewed and skewed data respectively. Chi-square 
was used to test the differences between categorical data. Linear regression models 
were used to assess the effects of genetic variants (individual SNPs or genotype 
combination) on iron markers at each timepoint. The control group (group with 
individuals homozygous for the major allele at each SNP) was set as the reference in 
the model. Sex and inflammation status (CRP) were included as covariates to account 
for their known influence on iron status (21,22).  Also, G6PD and sickle cell anemia 
were accounted for. Furthermore, account for the influence of baseline iron on the 
response to the oral iron dose, baseline ferritin was included as a covariate in the 








This study was approved by the Medical Research Council Unit The Gambia (MRCG) 
Scientific Coordinating Committee and the MRCG at London School of Hygiene & 
Tropical Medicine (LSHTM)/Gambia Government Joint Ethics committee (SCC1429), 
and the LSHTM Ethics Committee (11679). A fieldworker administered a copy of the 
study information sheet to each participant. Individuals who could not read had it 
translated to a language they understood in the presence of an independent witness. 
Each participant provided a written informed consent prior to enrolling into the study, 
and those who cannot write provided a thumbprint. To ensure confidentiality of the 
participants, all the samples and forms were anonymized by allocating study numbers. 
 
6.4. Results 
A total of 251 individuals were enrolled in the study, and the number of individuals 
enrolled in each genotype group is shown in Table 2. Due mostly to outward migration 
of males we had more females (76%). The World Health Organisation  (WHO) 
hemoglobin (Hb) cut-offs (<12.0 g/dL and <13.0 g/dL, non-pregnant women and men, 
respectively) was applied to determine anemia in the study population. Eighty (31.9%) 
of the participants were anemic, and 54 (64%) of these were females. From the 80 
anemic individuals, 30 (37.5%) were iron deficient (had IDA) (ferritin <15 µg/L and 
CRP <5.0 g/L), with an overall 11.9% of the study population iron deficient. Twenty-
six (86.7%) of the iron deficient individuals were female. The study was conducted in 




the Capital City (Banjul). Due to the low economic activities in this area, it is common 
for men to leave for the urban areas in search of employment. The baseline 
characteristics of the study participants are presented in Table 3. 
 
The effects of genotype on plasma iron concentrations pre- and post-iron 
ingestion 
Plasma iron increased significantly in all the genotype groups after the iron dose 
(Figure 2). No significant differences were observed between the genotypes of 
individual SNPs (Figure 3A) and between double heterozygotes and the reference 
group, in plasma iron both before and after the iron dose (Figure 3B).  
 
The effects of genotype on hepcidin concentrations pre- and post-iron ingestion 
There were significant differences between genotypes of individual SNPs on hepcidin 
(Figure 4A). For each of the SNPs, carriers of the homozygous major alleles 
(rs2235321 GG, rs855791 GG and rs4820268 AA, Figure 4A) had higher hepcidin 
concentrations than individuals with the minor alleles, both before and after the iron 
dose. In addition, when comparing double heterozygotes and the reference group, the 
latter had the highest hepcidin concentrations at all the timepoints, and this 
significantly differed from the genotype group AG/AG/AA (Figure 4B). The genotype 
group AG/AG/AA had the lowest hepcidin concentration both before and after the iron 
dose (Figure 4B).  
There was an increase in hepcidin concentration in all the genotype groups, following 
the iron dose (Figure 5A), except in one group (AG/AG/AA: double heterozygotes at 
rs2235321 and rs855791) (Figure 5B). The individuals in the genotype group 




unchanged five hours after iron ingestion (Figure 5B).  Also, carriers of the genotype 
rs2235321 AA increased their hepcidin concentrations after the iron dose, but the 
difference between the baseline and five hours was not statistically significant  
(P=0.060) (Figure 5A).  
 
The efffects of genotype on TSAT, TIBC, UIBC, ferritin, sTfR, transferrin and  
hematology traits 
There were significant differences between genotypes of each of the SNPs in TIBC 
and UIBC at baseline, but these differences were not detected at 2- and 5-hours after 
the iron dose (Supplemental Table 1). There were no significant differences between 
the genotypes for any of the SNPs in TSAT, transferrin, ferritin or sTfR either before 
or after iron ingestion (Supplemental Table 1). Furthermore, there were no 
differences between genotypes for any of the SNPs on any of the hematological traits 
(Supplemental Table 2). There were no significant differences between the double 
heterozygotes and the reference group in TSAT, TIBC and UIBC.  
 
6.5. Discussion 
We used a candidate genotype approach to recall individuals with variant alleles of 
three TMPRSS6 SNPs previously associated with iron imbalances. We hypothesised 
that carriers of risk alleles previously reported to be associated with low iron status 
would have inappropriately elevated hepcidin levels and thus impair response to oral 
iron.  
Our study participants were healthy individuals, and we used the increase in plasma 
iron at five hours after ingestion of the iron dose as a proxy to measure response to 




TSAT levels at five hours, but there were no differences between genotypes 
individually or in combination. Therefore, we could not establish that carriage of low-
iron risk alleles from any one of these SNPs impairs the response to oral iron.  
The TMPRSS6 rs855791 A allele has been widely associated with IRIDA in 
Caucasians and Asians (25–28). Similarly, the rs2235321 A and rs4820268 G alleles 
have been linked to the risk of iron deficiency, including in African populations 
(10,29,30). In a meta-analysis, Gichohi-Wainaina and colleagues (8) reported the 
rs855791 A allele to be associated with decreased Hb and ferritin concentrations 
across all the populations they studied. Therefore, we expected these SNPs to have 
an effect on plasma iron biomarkers either at baseline or on the response to the iron 
dose. However, as with the plasma iron, we did not find any effects of these SNPs on 
ferritin, TSAT or any other iron biomarker either before or after iron ingestion. Also, 
there were no differences in hematological traits in our study.  
In most subjects plasma hepcidin showed the anticipated acute rise in response to the 
administered iron dose. For rs855791, we observed an unexpected result where, at 
baseline, GG carriers had higher hepcidin concentrations compared to AG. The same 
trend was observed at five hours post iron ingestion. This contradicts what has been 
reported about this SNP in other populations. The rs855791 AA (homozygous for the 
minor allele) has been associated with elevated hepcidin concentrations accompanied 
by decreased TSAT and serum iron in Europeans (9). In the study conducted by Nai 
and colleagues (9), hepcidin decreased in a dose-dependent manner with rs855791 
AA having higher hepcidin concentrations than AG and GG carriers. Our results 
contradict this finding, as we observed carriers of rs855791 GG to have higher 
hepcidin concentration than AG. However, due to its low MAF, we were unable to 




obtained from studies of non-African populations. Hence, our results suggest that 
rs855791 may have a different effect on hepcidin levels against the different genetic 
background of West Africans.  
There have been a number of recent studies on the effects of TMPRSS6 variants on 
iron status in different populations. A study of Pakistani women of reproductive age 
found that rs855791 T allele (A on the reverse strand) is associated with the risk of 
IDA (31). However, in the present study, we did not have individuals with the T allele. 
In a study of South African chronic kidney disease patients, Nalado and colleagues 
(32) found that the rs855791 C alleles do not predispose to IDA. This finding is similar 
to our results on this SNP, as we did not find any effects of the major allele (G, opposite 
strang of C) on iron status indices. Also, in an iron absorption study on Taiwanese 
women using stable iron isotopes, Buerkli et al., (33) reported that the TMPRSS6 
rs855791 alters iron absorption, and that the carriers of the C alleles absorbed iron 
better than T allele carriers. Our study was short (5 hours) and we did not use stable 
isotopes, and hence may not be sensitive for assessing iron absorption. 
From the analysis of genotype combinations, we did not find any group that differed 
significantly from the reference (GG/GG/AA: rs2235321 GG, rs855791 GG and 
rs4820268 AA) in plasma iron concentrations or TSAT levels.  However, we observed 
that carriers of the genotype combination AG/AG/AA (simultaneous carriage of 
rs2235321 AG rs855791 AG and rs4820268 AA)  maintained a low mean hepcidin 
concentration up to five hours, despite exposure to a high iron dose. The plasma iron 
levels of this group rose significanly by five hours post iron ingestion, while the 
hepcidin levels remained constant. This is in contradiction to the clear rises in hepcidin 
levels shown for most subjects in this study, and widely reported in the literature 




mechanism to halt further iron absorption when optimal levels are reached (36). In 
IDA, low levels of hepcidin promote iron absorption, but this is still accompanied by 
acute elevation of hepcidin concentration (5). Further studies of why this group lacks 
the acute hepcidin response, so clearly evident in the other subjects, warrants further 
investigation and might provide insights into the response of hepcidin. 
A strength of this study is that, using a recall-by-genotype strategy, we concentrated 
on informative individuals by focusing on known carriers of our genotypes of interest. 
This is an efficient method to identify genotype-phenotype relationship with improved 
statistical power and to eliminate the effects of confounders (37). A major limitation of 
our study was the low MAF of the variant most widely decribed in the literature 
(rs855791), and this prevented us from studying homozygotes for the minor allele.  
Other limitations include the use of high iron dose, which is double the routine dosage, 
and may be less sensitive for assessing iron absorption. Also, subjects were relatively 
iron replete with high hepcidin levels which might inhibit iron absorption (36). We 
therefore cannot exclude the possibility that the gene variants studied may have 
differential effects under conditions of iron deficiency. Likewise it is possible that 
responses to a lower (more physiological) dose of iron might differ to the results 
reported here. Using the post-prandial change in plasma iron as the primary outcome 
has strengeths and weaknesses. It permitted large numbers of measurements to be 
made and is a relevant measure of the acute response to iron administration but is 
only a proxy measure of intestinal iron absorbption (38). As in any study of this type 
the ability to detect genotype effects will be blunted by natural variance caused by 
differences in diet, nutritional status of other micronutrients potentially affecting iron 
status, and potential effects of inflammation. Also, epistatic influences of other genes 




From this study, we conclude that common TMPRSS6 variants influence hepcidin, but 
not post-prandial iron status (a proxy for oral iron absorption). It therefore seems 
unlikely that genetic variations in the TMPRSS6 gene are important contributors to 
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Table 1. The description of the configuration of the genotype combinations that formed 


















G/A G/A A/G    
GG/GG/AA G/G G/G A/A 117 0.066 
AA/GG/AA A/A G/G A/A 336 0.190 
AG/GG/GA A/G G/G G/A 391 0.229 
GG/GG/GA G/G G/G G/A 211 0.129 
GG/GG/GG G/G G/G G/G 92 0.054 
AG/AG/AA A/G A/G A/A 60 0.044 
AG/GG/AA A/G G/G A/A 361 0.211 
GG/AG/AA G/G A/G A/A 67 0.035 
GG/AG/GA G/G A/G G/A 60 0.033 
 
Bolded alleles indicate major alleles. The genotype combination GG/GG/AA consists of 
homozygotes for the major alleles at all the three SNPs. We used this group as the 
reference group. 
1The frequency of each genotype combination in the population with genotype data in The 
Keneba Biobank (n=3116) 



























Table 2. The number of individuals enrolled into each genotype group. 
 
Genotype group n Number of minor 
alleles 
Reference group (GG/GG/AA) 39 0 
rs2235321, A/A (AA/GG/AA) 35 2 
rs2235321, A/G (AG/GG/AA) 21 1 
rs855791, A/G (GG/AG/AA) 28 1 
rs4820268, G/A (GG/GG/GA) 28 1 
rs4820268, G/G (GG/GG/GG) 29 2 
Double heterozygote (AG/AG/AA: 
rs2235231 A/G & rs855791 A/G) 
13 2 
Double heterozygote (AG/GG/GA: 
rs2235321 A/G & rs4820268 G/A) 
38 2 
Double heterozygote (GG/AG/GA: 
rs855791 A/G & rs4820268 G/A) 
20 2 
Total number of study participants (N) 251   
 

























Table 3. Baseline characteristics of the study population 
Variable All (n=251) F (n=191) M (n=60) p-value 
(F vs M) 
Age, yrs1  29.0 (18.0, 50.0) 33.0 (18.0, 50.0) 22.0 (18.0, 40.0) <0.001 
Plasma iron 
(µmol/L)1 
13.5 (0.4, 57.1) 12.3 (0.4, 57.1) 15.6 (4.4, 36.2) 0.012 
Hepcidin (ng/mL)1 2.89 (0.05, 71.70) 2.46 (0.05, 34.60) 3.86 (0.09, 71.71) 0.009 
TSAT (%)1 21.6 (0.6, 100.0) 20.8 (0.6, 100) 26.0 (6.0, 57.8) 0.001 
Transferrin (g/L)2 2.82 (0.58) 2.91 (0.55) 2.55 (0.61) <0.001 
UIBC (µmol/L)1 46.9 (21.1, 105.1) 48.2 (21.1, 105.1) 41.7 (22.2, 86.2) <0.001 
TIBC (µmol/L)1 61.4 (10.3, 112.2) 62.2 (10.3, 112.2) 57.0 (35.9, 94.7) 0.002 
Ferritin (µg/L)1 31.0 (0.0, 237.7) 25.5 (0.0, 237.7) 50.0 (7.8, 160.4) <0.001 
sTfR (mg/L)1 4.00 (1.90, 11.32) 4.11 (1.90 11.32) 3.54 (2.01 7.62) 0.011 
CRP (mg/L)1 0.80 (0.03, 26.95) 0.91 (0.03, 26.95) 0.63 (0.05, 13.40) 0.175 
Hb (g/dL)2 12.3 (1.5) 12.0 (1.3) 13.3 (1.6) <0.001 
RBC (x10^12)2 4.4 (0.6) 4.3 (0.5) 4.8 (0.6) <0.001 
MCV (fL)2 81.1 (6.1) 81.1 (6.0) 80.0 (6.2) 0.882 
Haematocrit (%)2 35.9 (4.5) 35.0 (3.8) 38.8 (5.0) <0.001 
RDW (%)2 12.2 (1.2) 12.2 (1.2) 12.3 (1.0) 0.615 
MCH (pg)2 27.9 (2.5) 28.0 (2.5) 27.8 (2.5) 0.675 
MCHC (g/dl)2 34.4 (1.2) 34.5 (1.2) 34.3 (1.1) 0.424 
BMI (Kg/m2)1 21.3 (14.4, 39.1) 22.0 (14.4, 39.1) 19.5 (16.3, 25.8) <0.001 
Sickle cell trait 
(AS/AA)3 




4/177 0/133 4/44 0.003 
 
1Skewed data listed as medians (ranges)  
2Normally distributed data presented as means (SD)  
3Categorical data presented as proportions  
Student t-test was used to determine the differences between parametric data, and Wilcoxon 
test was used for non-parametric data. Chi-square was used to test the differences between 
categorical data. 
4Individuals not tested for G6PD deficiency (n=74).  
 
TSAT, transferrin saturation; UIBC, unsaturated iron binding capacity; TIBC, total iron binding capacity; 
sTfR, soluble transferrin receptor; CRP, C-reactive protein; Hb, haemoglobin; RBC, red blood cell 
number; MCV, mean corpuscular volume; RDW, red cell distribution width; MCH, mean corpuscular 
haemoglobin; MCHC, mean corpuscular haemoglobin concentration; BMI, body mass index; G6PD, 
glucose-6-phosphase dehydrogenase 
 
TSAT, transferrin saturation; UIBC, unsaturated iron binding capacity; TIBC, total iron binding 




6.9. Figure Legends 
Figure 1. A flow chart illustrating how the study participants were selected into nine 
groups based on the three candidate TMPRSS6 SNPs. The reference group consisted 
of individuals who were homozygous for the major alleles at all the three SNPs. The 
configuration of the genotype combinations is presented in Supplemental Table 1. 
 
Figure 2. Plasma iron concentrations in each genotype group before and after iron 
ingestion. Plasma iron significantly increased in all the genotype groups after the iron 
dose. The reference is the genotype group with individuals that carries two major 
allele at all the three SNPs. The configuration of the genotype groups is presented in 
Table 1.  
The horizontal lines showing the P values indicates the difference between the two-
extreme bar. 
 
Figure 3. The differences between genotypes of individual SNPs (rs2235321, 
rs85579 and rs4820268) (A), and between the double heterozygotes and the 
reference group (B), on iron concentration before and after iron ingestion.  
The reference group consisted of individuals who are homozygotes for the major 
allele at all the three SNPs (rs2235321 GG, rs855791 GG and rs4820268 AA), see 
Tables 1 and 2. There was no significant differences between the genotype groups 
in iron concentration both before and after the iron dose.  
 
Figure 4. Hepcidin concentrations before and after the iron dose, within the genotypes 
of individual SNPs (A) and in the double heterozygotes and the reference group (B). 
Hepcidin increased in all the genotype groups except in the genotype group 




The horizontal lines showing the P values indicates the difference between the two 
extreme bar. 
 
Figure 5. Differences in hepcidin concentrations between genotypes of individual 
SNPs (A), and between double heterozygotes and the reference group (B), before 
and after iron ingestion.  
The horizontal lines showing the P values in Figure A indicates the differences 
between the two extreme bar for each SNP. 
For each SNP, carriage of the homozygous major alleles is associated with elevated 
hepcidin concentrations. The genotype group AG/AG/AA had the lowest hepcidin 
concentration both before and after the iron dose (B). The reference group consist of 
individuals without any minor allele from the three SNPs (rs2235321 GG, rs855791 
GG and rs4820268 AA), see Tables 1 and 2. The group AG/AG/AA (consisting of 
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6.11. Supplemental information 
Common variants in the transmembrane protease serine 6 (TMPRSS6) gene alter 
hepcidin but not oral iron absorption in healthy Gambian adults: a recall-by-genotype 
study 
Authors: 
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Supplemental Table 1. The effects of individuals SNPs on iron markers, before and after iron ingestion 
Genotype Baseline 2 Hours 5 Hours 
Serum iron (umol/L) 
  Mean SE Beta p-value Mean SE Beta p-value Mean SE Beta p-value 
Reference 14.53 1.32 Reference 40.66 2.69 Reference 41.78 2.67 Reference 
rs855791 (A/G) 14.46 2.04 -0.07 0.972 42.26 4.05 1.60 0.755 42.82 4.05 1.037 0.939 
rs2235321 (A/G) 16.04 2.25 1.51 0.473 43.01 4.22 2.35 0.810 51.68 4.35 9.90 0.048 
rs2235321 (A/A) 14.38 1.94 -0.15 0.738 37.33 3.64 -3.34 0.620 40.29 3.77 -1.49 0.607 
rs4820268 (G/A) 12.86 2.09 -1.67 0.503 36.71 3.63 -3.95 0.490 40.11 4.14 -1.67 0.506 
rs4820268 (G/G) 15.24 2.07 0.72 0.589 40.27 3.60 -0.39 0.984 46.13 4.14 4.35 0.450 
 
 
Effects of double heterozygotes on plasma iron before and after iron ingestion  
Genotype Baseline 2 Hours 5 Hours 
Serum iron (umol/L) 
  Mean SE Beta p-value Mean SE Beta p-value Mean SE Beta p-value 
Reference 14.53 1.12 Reference 40.66 2.67 Reference 41.78 2.67 Reference 
AG/AG/AA 12.62 2.30 -1.91 0.409 41.69 5.30 1.03 0.846 52.18 5.33 10.41 0.054 
AG/GG/GA 14.09 1.59 -0.44 0.782 37.81 3.78 -2.86 0.452 41.57 3.79 -0.21 0.955 
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Supplemental Table 1 Continued 
 
Genotypes Baseline 2 Hours 5 Hours 
Transferrin saturation (%) 
  Mean SE Beta p-value Mean SE Beta p-value Mean SE Beta p-value 
Reference 2.90 0.10 Reference 4.06 0.07 Reference 4.16 0.06 Reference 
rs2235321 (A/G) 3.11 0.17 0.20 0.224 4.09 0.12 0.04 0.759 4.35 0.11 0.19 0.084 
rs2235321 (A/A) 3.10 0.14 0.20 0.173 4.08 0.10 0.02 0.814 4.17 0.09 0.01 0.957 
rs855791 (A/G) 3.13 0.16 0.22 0.160 4.14 0.10 0.08 0.442 4.16 0.10 0.00 0.961 
rs4820268 (G/A) 2.88 0.16 -0.02 0.884 4.17 0.11 -0.05 0.884 4.06 0.11 -0.11 0.307 
rs4820268 (G/G) 3.13 0.15 0.23 0.143 4.16 0.11 0.14 0.629 4.32 0.11 0.15 0.153 
Transferrin (g/L) 
Reference 2.86 0.08 Reference 2.79 0.09 Reference 2.64 0.08 Reference 
rs2235321 (A/G) 2.83 0.14 -0.03 0.842 2.90 0.15 0.11 0.456 2.82 0.14 0.18 0.206 
rs2235321 (A/A) 2.68 0.12 -0.18 0.133 2.81 0.13 0.01 0.924 2.73 0.12 0.09 0.468 
rs855791 (A/G) 2.81 0.14 -0.04 0.752 2.80 0.15 0.01 0.971 2.76 0.14 0.12 0.414 
rs4820268 (G/A) 3.08 0.14 0.22 0.118 3.12 0.16 0.33 0.040 3.11 0.15 0.46 0.227 













Supplemental Table 1 Continued 
 
Genotypes Baseline 2 Hours 5 Hours 
Total iron binding capacity (µmol/L) 
  Mean SE Beta p-value Mean SE Beta p-value Mean SE Beta p-value 
Reference 68.29 1.81 Reference 65.16 1.88 Reference 60.93 1.62 Reference 
rs2235321 (A/G) 61.63 3.06 -6.66 0.032 64.15 3.15 -1.01 0.750 63.54 2.74 2.61 0.344 
rs2235321 (A/A) 58.78 2.63 -9.51 0.000 60.21 2.71 -4.94 0.072 57.81 2.37 -3.12 0.192 
rs855791 (A/G) 60.79 3.50 -7.50 0.036 62.36 3.07 -2.80 0.365 60.82 2.53 -0.12 0.963 
rs4820268 (G/A) 63.33 2.89 -4.96 0.089 64.43 3.15 -2.22 0.482 63.82 2.81 1.97 0.483 
rs4820268 (G/G) 58.76 2.86 -9.54 0.001 61.92 3.12 -8.18 0.010 59.57 2.81 -3.20 0.258 
Unsaturated iron binding capacity (µmol/L) 
Reference group 53.76 2.27 Reference 24.49 2.52 Reference 19.15 2.31 Reference 
rs2235321 (A/G) 45.59 3.83 -8.17 0.036 21.14 4.22 -3.35 0.429 11.86 3.91 -7.29 0.065 
rs2235321 (A/A) 44.40 3.30 -9.36 0.006 22.89 3.64 -1.60 0.660 17.52 3.39 -1.64 0.630 
rs855791 (A/G) 48.05 3.91 -5.71 0.15 20.11 3.70 -4.38 0.240 18.32 3.49 -0.84 0.811 
rs4820268 (G/A) 50.47 3.64 -3.29 0.368 26.22 3.53 1.73 0.626 22.79 3.46 3.64 0.296 
rs4820268 (G/G) 43.51 3.61 -10.25 0.005 16.71 3.50 -7.79 0.028 11.99 3.42 -7.16 0.039 
 
For transferrin saturation, statistical analysis was done on log-transformed data, but transferrin TIBC and UIBC values were not log-
transformed as these values were normally distributed. For each of the SNPs, the bolded letters are the major allele. The reference group 
consists of individuals with homozygotes for the major alleles at all the three SNPs. The participants were selected in such a way that the 
reference genotype for each SNP do not have individual carrying the minor alleles at the other two SNPs. 
 
SE, standard error; TIBC, total iron binding capacity; TSAT, transferrin saturation; UIBC, unsaturated iron binding capacity.
Supplemental Table 2. The effects of individuals SNPS (rs855791, rs2235321 and 
rs4820268) on haematology traits 
 
rs2235321 (MAF=0.43) 
Trait Genotype Mean Std. Error Beta P-value 
Hb (g/dL) G/G 11.6 0.33 Reference 
  A/G 11.9 0.46 0.27 0.551 
  A/A 12.1 0.38 0.43 0.262 
RBC (x10^12) G/G 4.4 0.12 Reference 
  A/G 4.4 0.17 -0.05 0.749 
  A/A 4.2 0.14 -0.26 0.072 
MCV (fL) G/G 77.8 1.54 Reference 
  A/G 79.5 2.13 1.63 0.445 
  A/A 83.7 1.79 5.81 0.002 
HCT (%) G/G 34.4 1.03 Reference 
  A/G 34.8 1.42 0.34 0.814 
  A/A 34.9 1.20 0.49 0.685 
RDW (%) G/G 13.1 0.29 Reference 
  A/G 12.7 0.40 -0.38 0.342 
  A/A 12.2 0.33 -0.88 0.010 
MCH (pg) G/G 26.4 0.60 Reference 
  A/G 27.3 0.83 0.88 0.292 
  A/A 29.0 0.70 2.55 0.000 
MCHC (g/dL) G/G 33.9 0.25 Reference 
  A/G 34.3 0.34 0.34 0.321 
  A/A 34.6 0.29 0.69 0.019 
rs855791 (MAF=0.07) 
Hb (g/dL) G/G 11.9 0.44  Reference 
  A/G 12.0 0.46 0.07 0.882 
RBC (x10^12) G/G 4.5 0.14  Reference 
  A/G 4.5 0.17 -0.04 0.832 
MCV (fL) G/G 78.8 1.56  Reference 
  A/G 81.0 1.97 2.29 0.251 
HCT (%) G/G 35.2 1.18  Reference 
  A/G 35.9 1.49 0.70 0.641 
RDW (%) G/G 12.8 0.28  Reference 
  A/G 12.5 0.36 -0.36 0.311 
MCH (pg) G/G 26.7 0.61  Reference 
  A/G 27.1 0.77 0.39 0.617 
MCHC (g/dL) G/G 33.8 0.30  Reference 
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Supplemental Table 2. Continued 
 
rs4820268 (MAF=0.27) 
Trait Genotype Mean SE Beta P-value 
Hb (g/dL) A/A 12.09 0.23 Reference 
  G/A 11.69 0.32 -0.40 0.213 
  G/G 11.82 0.31 0.13 0.687 
RBC (x10^12) A/A 4.46 0.09 Reference 
  G/A 4.27 0.12 -0.19 0.125 
  G/G 4.38 0.12 -0.07 0.539 
MCV (fL) A/A 81.37 0.98 Reference 
  G/A 78.67 1.50 -2.70 0.076 
  G/G 79.80 1.49 -1.57 0.294 
HCT (%) A/A 35.94 0.71 Reference 
  G/A 33.38 1.00 -2.56 0.012 
  G/G 34.66 0.98 -1.28 0.192 
RDW (%) A/A 12.29 0.21 Reference 
  G/A 12.54 0.32 0.25 0.449 
  G/G 12.18 0.32 -0.12 0.709 
MCH (pg) A/A 27.46 0.39 Reference 
  G/A 27.57 0.60 0.11 0.861 
  G/G 28.15 0.59 0.69 0.249 
MCHC (g/dL) A/A 33.73 0.18 Reference  
G/A 34.99 0.28 1.26 0.000 





























Figure S1. The relationship between baseline ferritin and delta plasma iron. Delta 
plasma iron was calculated by subtracting the baseline plasma iron from the 5 hours 
plasma iron post iron ingestion.  
 
 
6.12. A summary of the pilot study 
In order to decide the optimal time points for the recall-by-genotype study, we 
conducted a pilot study. In this pilot stud, we selected participants from five genotype 
groups based on TMPRSS6 rs22235321 and rs4820268, while ensuring that no one 
carries the variant allele at rs855791, see Table 1.  
We included individuals if they were 18 years and above, although there is no 
maximum age limit, individual considered too old or frail were excluded. Individuals 
were excluded if they reported being unwell or when they were found to be unwell 
upon examination by a study nurse. Also, pregnant or lactating women, and individuals 
with severe anaemia (Hb <7g/dl) where excluded. 
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Iron supplementation and sample collection 
Each individual received 400mg ferrous sulfate (130 mg of elemental iron) orally (after 
an overnight fast) on Day 1, and then daily supplementation with 200mg of ferrous 
sulfate (65 mg of elemental iron) from day 2 for 14 days. At day one, each individual 
was bled at baseline following an overnight fast (before receiving the supplement) and 
at 1h, 2h, 5h, 24h. Thereafter, a blood sample was taken at (day 15), after iron 
completing the daily iron dose.  
 
Laboratory measurements 
FBC was analysed using a 3-part haematology analyser Medonic M-series (Boule 
Medical, Sweden). Malaria rapid diagnostic test (SD BioLine Malaria Antigen Pf, 
Standard Diagnostics Inc. Republic of Korea), sickle (Sodium metabisulphide method) 
and quantitative assessment of G6PD enzyme in RBCs (G6PD Hb+ R&D Diagnostics) 
were done on the same day.  
Iron biomarkers (serum iron, ferritin, serum transferrin, unsaturated iron binding 
capacity [UIBC]) and CRP were measured on frozen plasma samples by Cobas 
Integra 400Plus biochemistry analyser (Roche Diagnostics). Transferrin saturation 
(TSAT) and total iron binding capacity (TIBC) were calculated from UIBC and serum 
iron; TIBC= serum iron +UIBC; TSAT= (Serum iron/TIBC)*100. Hepcidin was 
measured by Bachem competitive ELISA (enzyme-linked immunosorbent assay) kit. 
 
Data analysis 
Data was analysed using the R statistical software version 3.2.3 26. Initially, a linear 
model with each biomarker as the outcome, genotype as response variable and age 
and sex as covariates was fitted. A more complex linear model was fitted to determine 
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the changes in biomarker across time points (using the baseline as a reference time 
group) and genotype as response variables. Where there was evidence of significant 
time or genotype effects, interactions between them was assessed using a log-
likelihood ratio test. 
 
Results 
A total of 44 individuals were enrolled in 5 genotype groups (Table 1) using the 
TMPRSS6 rs2235321 and rs4820248 as the basis for creating the genotype groups. 
From the 44 participants enrolled, 65.9% were females. The details of participant 





Table 1. Description of genotype combinations recruited for the pilot study, N=44 
  rs2235321 rs4820268 N (%) 
Major allele 
/minor allele 
G/A A/G   
AA/AA AA AA 8 (18.2) 
AG/GA AG GA 10(22.7) 
GG/AA GG AA 11(25.0) 
GG/GA GG GA 3(6.8) 
GG/GG GG GG 12(27.3) 
 
Everyone in these genotype combinations are GG (homozygous for the major allele) at 
rs855791.  
AA/AA, Homozygous for the variant of rs2235321, wildtype at rs4820268; AG/GA, Double 
heterozygotes, for both rs2235321 and rs4820268; GG/AA, Wildtype for rs2235321 and rs4820268 
this is the control group; GG/GA, Heterozygous at rs4820268, wildtype at rs2235321; Homozygous 
for the variant allele of rs4820268, wildtype at rs2235321. 
 







Table 2. Population characteristics of individuals enrolled in the pilot study 
Variable Male Female Total 
N (%) 15 (34.1) 29 (65.9) 44 
Age (yrs), mean (SD) 24.8 (5.5) 29.7 (8.5) - 
Sickle (n=44)       
AA (n=41, 93.2%)) 14 27 41 
AS (n=3, 6.8%) 1 2 3 
G6PD (n=41)       
Non-deficient (n=38, 
92.6%) 
11 27 38 
Deficient (n=3, 7.4%) 3 0 3 





Assessing the change in iron biomarkers over time  
Each iron biomarker was tested over six time-points [baseline and after iron 
supplementation [(1hr, 2hr, 5hr, 24hr and Day 15)]. The significant differences 
between time points in relation to the baseline occurred at 1hr, 2hr and 5hrs, in TSAT, 
hepcidin, serum iron and UIBC, see Figure 1. No significant changes in relation to the 
baseline were observed at 24hr and Day 15. Furthermore, no significant changes 
occurred in ferritin, transferrin, TIBC and CRP.  
 
 






Figure 1. Assessment of important time-points for inclusion in the main study, N=44. 
Significant differences in relation to the baseline were observed in TSAT (1hr, p=0.007; 2hr, 
p<0.0001; 5hr, p<0.001), hepcidin (5hr, p=0.0032), serum iron (1hr, p=0.0325; 2hr, p<0.001; 
5hr, p<0.001), UIBC (2hr, p<0.001; 5hr, p<0.001).  
 





Optimisation of follow-up bleeds 
Based on the response data from the pilot study, we selected time points 2 and 5 
hours for post iron ingestion sampling. The 24 hours and Day 15 time points were 
dropped, as they do not provide additional information, and substantial change in iron 
status occurred within the first day, see Figure 2. This will reduce the burden on study 
participants, by shortening the study duration, while enabling us to achieve the aim of 
the study. Also, the 1hour bleeding was dropped as it is not expected to additional 
information.  
Therefore, the selection of the time points for the main study (baseline, 2 and 5 hours) 





















Chapter 7:  
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7.1. General discussion  
This PhD thesis aimed to investigate whether common genetic variants within the 
hepcidin and iron regulatory genes, previously identified in non-African population, 
predispose healthy Gambians to anaemia and/or modulate response to oral iron 
supplementation. The work presented here was aimed at contributing to the 
understanding of genetic determinants of anaemia and oral iron absorption in Africans.  
In this chapter, I discuss the main findings of the studies constituting the thesis. Also, 
I highlight the limitations and presented suggestions future studies to follow-up this 
work. 
7.2. Main findings 
Highlights of main findings: 
1. There is significant lack of data on the genetic determinants of iron status on 
African populations. 
2. Wide disparity exists in allele frequencies of single nucleotide polymorphisms 
(SNPs) associated with iron status between Africans and non-African 
populations 
3. The linkage disequilibrium patterns between common TMPRSS6 SNPs 
reported in Europeans differ from that of Africans.  
4. Previously reported functional effects of TF rs3811647 on transferrin and iron 
binding capacity replicates in Gambians. 
5. TMPRSS6 rs2235321 influence hepcidin concentrations. 
6. We observed reverse trend on the effects of TMPRSS6 variant alleles on 
hepcidin, contradicting previous reports.  
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7.3. Discussion of main findings 
In chapter 3, a total of 64 studies were retrieved from the literature search, but only 
five were conducted in Africa. This finding highlights a significant gap in the availability 
of data on the genetic determinants of iron imbalance in Africa (Chapter 3, Fig 1). 
This demonstrates a critical need to conduct human genetic research in Africa to 
understand the contribution of genetic risk factors on the high burden of anaemia in 
African populations. Also, one of the key findings in this study was the wide disparity 
in allele frequency for most of the SNPs associated with iron status across global 
populations (Chapter 3, Supplemental Table 1). For example, TMPRSS6 rs855791, 
the most widely reported SNP that is associated with iron-refractory iron deficiency 
anaemia and impaired iron status indicators, has an average global minor allele 
frequency (MAF) of 40%. However, the MAF of TMPRSS6 rs855791 in Africans and 
Gambians is 10% and 7% respectively in the 1000 Genomes Project.  
Another significant finding from this study was the differences in linkage equilibrium 
(LD) observed between the common TMPRSS6 SNPs (rs855791 and rs2235321 or 
rs4820268) in different populations. TMPRSS6 rs855791 and rs2235321 were 
previously reported to be in high LD in Europeans (D’= 1.0, r2=0.44)1. Similarly, 
rs4820268 was reported to be in high LD with rs855791 in Italians (r2=0.81) 2. 
However, we found that rs855791 is in low LD with rs2235321 and rs4820268 both in 
the pan-African data in the 1000 Genomes project and in the Gambian population we 
studied (Chapter 3, Figure 4). The differences in LD between SNPs in different 
populations demonstrates that genetic results from one population may not be 
transferrable to others 3.  
In Chapter 4, we sought to investigate the whether the common TMPRSS6 and TF 
SNPs will have an effect on iron status indicators. We did not detect any effect 
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of TMPRSS6 genotype combinations or allele risk scores with any iron biomarker. 
This result indicated that these TMPRSS6 SNPs might not have an impact on iron 
status in Africans, unlike the previously reported associations in non-African 
populations 4–8. However, we found TMPRSS6 rs2235321 to have an effect on plasma 
hepcidin concentration with a stronger impact on individuals with lower haemoglobin 
(Hb) and ferritin levels. This suggest that despite being a synonymous variant, 
TMPRSS6 rs2235321 may influence hepcidin regulation of iron homeostasis.  
Also, we found TF rs3811647 to have a strong association with transferrin and 
transferrin binding (TSAT and UIBC). TF rs3811647 homozygotes (AA) had a 20% 
higher transferrin than the GG carriers. Our results indicate that this SNP is associated 
with transferrin binding of iron but not iron itself. This finding is in agreement with 
previous studies in both Europeans 9,10 and Africans 11, on the association between 
TF rs3811647 and iron status. Further research could assess how the TF rs3811647 
influences the functionality of transferrin and how this impact on the risk of iron 
deficiency in Africans.  
In Chapter 6, we conducted a recall-by-genotype (RbG) study to test the hypothesis 
that individuals carrying the variant alleles at the common TMPRSS6 SNPs might have 
less effective response to oral iron supplementation compared to the carriers of the 
major alleles. However, we failed to detect any effect of variants alleles on the 
response to oral iron ingestion in this population. Unexpectedly, for each of the three 
SNPs studies, individuals who are homozygotes for the minor alleles (rs2235321 AA, 
rs855791 AA and rs4820268 GG) had lower hepcidin concentrations compared to the 
homozygous major allele carriers (Chapter 6, Figure 6). These results are at variance 
with the previous reports on these SNPs, and they contradict what we expected to 
find. We expected that the carriage of minor alleles at TMPRSS6 rs2235321, rs855791 
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and rs4820268 would lead to elevated hepcidin, due to impaired TMPRSS6 function 
caused by these variants 12,13. TMPRSS6 rs855791 A allele is associated with 
elevated hepcidin accompanied by low TSAT and serum in Europeans 7. TMPRSS6 
rs2235321 A and rs4820628 G alleles are associated with the risk of low iron status 
including in Africans 4,14–16. However, we did not find previous reports on the effects of 
rs2235321 or rs4820268 on hepcidin concentration or response to iron 
supplementation. 
One significant finding from the RbG study is that we replicated the effects of 
rs2235321 on hepcidin we observed in the cross-sectional study (Chapter 4). In both 
studies, the carriers of the homozygous A allele have lower hepcidin levels than the 
GG carriers (Chapter 4 Figure 2 and Chapter 6 Figure 5A). These results 
demonstrate a possible effect of TMPRSS6 rs2235321 on hepcidin, which requires 
further investigation, particularly given the high MAF of this SNP in Africans (41%) and 
43% in Gambians. 
Another significant finding from this study is the identification of a genotype group with 
individuals that had a static hepcidin concentration despite ingesting a bolus dose of 
oral iron. The hepcidin level in all the genotype groups rose after the oral iron dose, 
except the group consisting of individuals with rs2235321 AG and rs855791 AG 
simultaneously (Chapter 6, Figure 5). The hepcidin concentration in this group 
remained unchanged whilst the plasma iron concentration rose after iron ingestion. 
These results may suggest that there might be an alternate pathway that is responsible 
for iron regulation at the enterocytes or that highly bioavailable iron evaded the 
hepcidin-mediated iron regulation at the enterocytes. Further research with larger 
sample size involving carriers of this genotype, and in different population groups 
might provide more insight into these results.  
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7.4. Limitations implications 
The candidate gene approach and the recall-by-genotype study design was made 
possible by the recent surge in GWAS to search for genetic variants that influence iron 
status. As mentioned in the methods of the different chapters, we chose the candidate 
SNPs based on the previous associations between these variants and various iron 
status indicators. However, as we note in the study presented in Chapter 3, the bulk 
of these studies were conducted in Europeans and a few on Asians, and we found 
only five studies that were conducted in Africa.  
The primary purpose of employing the recall-by-genotype study (RbG) design was to 
ensure that we focus on individuals with the SNPs of interest rather than using the 
standard case-control study design. Although we ensured that each genotype group 
was unique, we could not account for the presence of variants in other genes that 
influence iron status. For example, TF rs3811647 has a strong effect on transferrin 
and its ability to bind iron, as identified in previous research and our study in Chapter 
5. Unfortunately, we could not account for the confounding effects of TF rs3811647 in 
our RbG study. To eliminate the possible confounding effects of other genetic variants 
would require a larger pre-genotyped and traceable population. Larger sample size 
would require additional resources and time, which is beyond the scope of this PhD. 
Another limitation of this study design arises when it is applied to study low-frequency 
variants. The low minor allele frequency (MAF) of TMPRSS6 rs855791 in our study 
population and Africans impacted our study. We could not study homozygotes for the 
minor allele rs855791 (AA). We only had heterozygotes (AG) and homozygotes for 
the major allele (GG) to include. Therefore, the lack of individuals with rs855791 AA 
only was a notable limitation.  
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7.5. Public health implications and recommendations 
 
In this thesis, I attempted to assess whether common genetic variants previously 
identified in Europeans and Asians could increase the risk of anaemia and predispose 
to inadequate response to oral iron supplementation in Africans. This aim was 
conceived based on previous research findings linking genetic variants within 
the TMPRSS6 gene to the risk of iron refractory iron deficiency anaemia (IRIDA) 17,18. 
The key features of IRIDA include inappropriately elevated hepcidin for the degree of 
anaemia and inability to absorb oral iron 18,19. IRIDA patients usually present with 
varying degrees of anaemia, ranging from moderate to severe microcytosis with low 
serum iron and low-normal ferritin 17,20–22.   
Given that hepcidin elevation is a classic finding in patients with IRIDA, hepcidin 
suppression could be identified as a mechanism for enhancing iron absorption. 
Administration of a hepcidin antagonist could facilitate hepcidin suppression and 
thereby promote effective iron absorption. Currently, there are several candidate 
hepcidin antagonists at different stages of clinical development for potential use in the 
treatment of anaemias characterised with excess hepcidin levels 23–25. 
If our hypothesis had been confirmed, carriers of these genetic variants would have 
potentially been candidates for interventions utilising hepcidin suppression 
mechanisms. This approach could open the avenue for personalised medicine 
approaches to anaemia therapy. At the public health level, similar approaches might 
potentially be useful in settings where the frequency of the genetic variants associated 
with excess hepcidin is high. Given the high minor allele frequency (MAF) of some of 
the SNPs studied, we anticipated that identifying sub-population groups carrying these 
risk alleles might have facilitated population stratification approaches to anaemia 
control policies. However, we could not confirm that these TMPRSS6 variants 
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modulate oral iron absorption or predispose to anaemia in Africans. Thus, at this point, 
we cannot propose any personalised or public health intervention for the genetic 
defects in the hepcidin-iron axis.  
7.6. Potential future studies 
The studies presented in this thesis did not reveal substantial evidence on the effects 
of common TMPRSS6 and TF SNPs on the risk of anaemia and inadequate oral iron 
absorption in Africans. However, the results in Chapter 3 demonstrated that there are 
several other variants in the hepcidin and iron regulatory genes that are identified as 
risk factors for low iron status, whose effects on oral iron absorption have not been 
investigated in Africans. Also, SNPs linked to elevated iron status in Europeans have 
been reported, but their impact on low iron status have not been thoroughly 
investigated in Africans either. These include SNPs in the HFE, SLC40A1 and HAMP 
(the hepcidin gene), BMP6 and TFR2 (encoding transferrin receptor 2).  
Follow-up research could focus on comprehensively assessing the combine effects 
risk alleles at all these SNPs on the risk of anaemia. Such studies may be done by 
expanding our work in Chapter 5, where we aggregated the alleles at six TMPRSS6 
SNPs to develop allele risk scores for anaemia. Further studies may enable the 
development of allele risk scores for anaemia based on all the known SNPs linked to 
the low iron status from the different iron-related genes. Consequently, the effects of 
these allele risk scores on various iron status indicators or anaemia and iron deficiency 
may be validated in different population groups. Such allele scores, also referred to as 
genetic risk scores, may provide the basis for predicting the occurrence of anaemia 
and iron deficiency in Africans.  
Developing genetic risk scores for complex phenotypes such as BMI 26, blood 
pressure 27 and type 2 diabetes28 has been described. Therefore, identifying genetic 
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risk scores for anaemia and inadequate response to iron supplementation may be 
useful for improving iron supplementation strategies in different population groups.  
Given our finding on the association between TMPRSS6 rs2235321 and hepcidin, with 
the effects more pronounced in individuals with low ferritin or haemoglobin (Chapter 
4), follow-up studies could investigate the effect of this SNP on hepcidin in different 
population groups with diverse physiological risk factors for impaired iron status. Also, 
longer-term studies assessing the effect of common genetic variants on iron 
absorption throughout the routine iron supplementation duration (usually 12 weeks) 
may provide a better understanding on the role of these variants on the response to 
oral iron therapy.  
Moreover, gene fine-mapping studies may be conducted to determine the exact 
location of functional variants. Gene fine-mapping refers to the identification of the 
exact genomic location of functional variants and to precisely determine the causal 
variant 6181,1829,70.  Similarly, gene expression studies such as expression quantitative 
trait loci (eQTL) analysis may be conducted to identify new functional variants in the 
different hepcidin-iron regulatory genes. eQTL refers to the analysis of gene 
expression in cells or tissues to identify functional variants associated with a 
phenotype 32. These types of human genetic research done in Africans may help to 
provide a clearer insight into the molecular mechanisms underlying iron regulation in 
African populations.  
 
7.6.1 Specific immediate future research 
Based on our findings, I propose follow-up research as follows: 
1. To conduct a genome-wide association study (GWAS) on iron status indicators 
and iron deficiency. This project would use the new H3Africa chip to do a whole-
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genome sequencing on the available 8,000 individuals within the Keneba 
biobank at the MRCG at LSHTM. The H3Africa chip contains novel variants 
relevant for African populations which were not part of the previous Illumina 
arrays 33. Furthermore, the project would use the SNPs identified from the 
proposed GWAS, and those previously reported from other GWASs to develop 
genetic risk scores for iron deficiency, using the phenotype data available from 
the population in the Keneba Biobank. In addition to the SNPs in TMPRSS6 
and TF, these genetic risk scores would include variants in other iron regulatory 
genes such as HFE, DMT1 (SLC11A2), TFR2, BMP6, SLC40A1, HAMP, and 
any new loci that may be identified from the Africa-specific discovery GWAS. 
 
2. To use the recall-by-genotype approach to investigate the effects of TMPRSS6 
rs2235321, rs855791, rs4820268 and TF rs3811647, and any functional 
(putative functional) SNP discovered in the GWAS proposed above, on 
absorption of a more physiological form of iron in anaemic subjects. The studies 
proposed here may help to elucidate the effects of the common genetic variants 
in the iron and hepcidin regulatory genes on iron absorption in Africans. 
 
7.7. Conclusions 
Finally, the studies presented in this thesis attempted to examine the role of genetic 
risk factors on impaired iron status response to oral iron supplementation in Africans. 
We identified an association between TMPRSS6 2235321 and hepcidin 
concentrations, and we replicated the previously reported association 
between TF rs3811647 and transferrin. However, we found a discrepancy between 
our results and previous observations on the relationship 
between TMPRSS6 rs855791 and hepcidin. Therefore, we recommend that more 
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research is done to examine the reasons for this disparity and to map out whether host 
genetics risk factors play a role in predisposing Africans to low iron status or hindering 
the success of iron supplementation strategies. Understanding of the genetic risk 
factors for anaemia and iron deficiency may facilitate the formulation of population-
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8.1. Candidate’s contribution to  research papers 
While I was enrolled in this PhD, I contributed in ongoing research projects conducted 
by the Nutrition Theme at the MRCG at LSHTM. I have been working with this 
Research Group prior to starting the PhD and I continue to contribute significantly to 
research projects outside of my PhD, which resulted in publication of findings in high 
impact journals. Some of these works involved collaborations with external scientists. 
Below, I present a listed of the papers I contributed. 
1. Prentice S, Jallow AT, Sinjanka E, Jallow MW, Sise EA, Kessler NJ, et al. 
Hepcidin mediates hypoferremia and reduces the growth potential of bacteria 
in the immediate post-natal period in human neonates. Sci Rep. 2019 
Dec;9(1):16596. 
 
2. Armitage AE, Agbla SC, Betts M, Sise EA, Jallow MW, Sambou E, et al. Rapid 
growth is a dominant predictor of hepcidin suppression and declining ferritin in 
Gambian infants. Haematologica. 2019 Aug;104(8):1542–53. 
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Respiratory infections drive hepcidin-mediated blockade of iron absorption 
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recall by genotype as an efficient approach to detailed phenotyping and causal 
inference. Nat Commun. 2018 Dec;9(1):711. Available at: 
http://www.nature.com/articles/s41467-018-03109-y. 
 
5. Bah A, Pasricha S-R, Jallow MW, Sise EA, Wegmuller R, Armitage AE, et al. 
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